Cosmos Health (COSM) S-1/A10 Dec 24IPO registration (amended)Financial data

Company Profile

Cover

Cover	9 Months Ended
Cover	Sep. 30, 2024
Cover [Abstract]
Entity Registrant Name	COSMOS HEALTH INC.
Entity Central Index Key	0001474167
Document Type	S-1/A
Amendment Flag	true
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Filer Category	Non-accelerated Filer
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	27-0611758
Entity Address Address Line 1	5 AGIOU GEORGIOU
Entity Address Address Line 2	PILEA
Entity Address City Or Town	THESSALONIKI
Entity Address Postal Zip Code	55438
City Area Code	312
Amendment Description	This Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.
Local Phone Number	536-3102

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 3,314,845	$ 3,833,195	$ 20,749,683
Accounts receivable, net	17,484,240	19,759,254	23,691,997
Accounts receivable - related party	1,285,743	1,099,098	2,710,301
Marketable securities	22,808	20,075	14,881
Inventory	4,885,015	4,789,054	3,451,868
Loans receivable	491,897	411,858	377,038
Loans receivable - related party	445,800	442,480	427,920
Prepaid expenses and other current assets	1,914,881	1,811,911	1,546,225
Prepaid expenses and other current assets - related party	6,393,642	4,440,855	3,397,000
TOTAL CURRENT ASSETS	36,238,871	36,607,780	56,366,913
Property and equipment, net	10,575,928	10,455,499	1,817,025
Goodwill and intangible assets, net	7,746,761	7,684,183	706,914
Loans receivable - long term portion	3,225,879	3,509,200	3,792,034
Loans receivable - related party - long term	3,234,604	3,539,840	3,851,280
Operating lease right-of-use asset	710,711	1,131,552	1,069,747
Financing lease right-of-use asset	22,343	28,790	43,084
Advances for building's acquisition	2,000,020	2,000,020	0
Other assets	764,865	1,057,947	391,624
TOTAL ASSETS	64,519,982	66,014,811	68,038,621
CURRENT LIABILITIES:
Accounts payable and accrued expenses	11,605,255	11,911,978	10,134,146
Accounts payable and accrued expenses - related party	1,027,327	231,564	205,360
Accrued interest	185,561	166,348	275,547
Lines of credit	5,989,425	6,630,273	5,758,737
Notes payable	1,622,349	1,570,886	2,158,417
Notes payable - related party	11,368	11,283	10,912
Loans payable - related party	21,158	13,257	12,821
Operating lease liability, current portion	241,422	285,563	239,899
Derivative liability - convertible note		0	54,293
Convertible notes payable, net of unamortized discount of $0 and $258,938, respectively		0	100,000
Financing lease liability, current portion	18,888	27,222	24,576
Other current liabilities	4,488,465	3,474,096	2,647,291
TOTAL CURRENT LIABILITIES	25,211,218	24,322,470	21,748,854
Taxes payable		0	126,855
Share settled debt obligation	0	0	1,554,590
Notes payable - long term portion	2,645,623	3,035,341	2,859,570
Operating lease liability, net of current portion	468,157	844,866	828,762
Financing lease liability, net of current portion	5,845	5,261	31,333
Other liabilities	1,212,540	1,763,845	1,358,803
TOTAL LIABILITIES	29,543,383	29,971,783	28,381,912
Commitments and Contingencies (see Note 14)	0	0	0
MEZZANINE EQUITY
Preferred stock, $0.001 par value; 100,000,000 shares authorized: Series A preferred stock, stated value $1.000 per share, 6,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2023 and 2022; liquidation preference of $0 and $372,414 as of December 31, 2023 and 2022		0	372,414
STOCKHOLDERS' EQUITY:
Common stock, $0.001 par value; 300,000,000 shares authorized; 23,346,023 and 15,982,472 shares issued and 23,259,526 and 15,895,975 outstanding as of September 30, 2024 and December 31, 2023, respectively	23,346	15,983	10,606
Additional paid-in capital	140,797,456	129,008,301	112,205,952
Subscription receivable	(20)	(20)	(4,750,108)
Treasury stock, at cost, 86,497 and 15,497 shares as of and December 31, 2023 and 2022, respectively	(917,159)	(917,159)	(816,707)
Accumulated deficit	(104,479,192)	(91,644,233)	(66,232,813)
Accumulated other comprehensive loss	(447,832)	(419,844)	(1,132,635)
TOTAL STOCKHOLDERS' EQUITY	34,976,599	36,043,028	39,284,295
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY	$ 64,519,982	$ 66,014,811	$ 68,038,621

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Convertible notes payable, net of unamortized discount		$ 0	$ 258,938
Common stock, shares par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000	300,000,000
Common stock, shares issued	23,346,023	15,982,472	10,605,412
Common stock, shares outstanding	23,259,526	15,895,975	10,589,915
Preferred stock, shares par value		$ 0.001	$ 0.001
Preferred stock, shares authorized	100,000,000	100,000,000	100,000,000
Treasury stock	86,497	86,497	15,497
Preferred Stock, Share Issued		0	0
Preferred Stock,Shares Outstanding		0	0
Series A Preferred Stock [Member]
Preferred stock, shares par value		$ 1	$ 0.001
Preferred stock, shares authorized		6,000,000	6,000,000
Preferred Stock, Share Issued		0	0
Preferred Stock,Shares Outstanding		0	0
Preferred Stock, liquidation preference		$ 0	$ 372,414

UNAUDITED CONDENSED CONSOLIDATE

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
REVENUE	$ 12,411,048	$ 12,823,797	$ 40,202,238	$ 37,537,003	$ 53,376,874	$ 50,347,652
COST OF GOODS SOLD	11,204,186	11,609,039	36,894,502	34,418,334	49,027,305	44,390,695
GROSS PROFIT	1,206,862	1,214,758	3,307,736	3,118,669	4,349,569	5,956,957
OPERATING EXPENSES
General and administrative expenses	1,782,957	2,573,414	4,591,620	6,662,579	19,642,005	10,183,025
Salaries and wages	1,317,782	1,252,680	4,030,823	3,279,803	4,719,768	2,429,021
Sales and marketing expenses	41,848	157,435	326,291	942,759	1,204,636	630,057
Depreciation and amortization expense	304,139	248,530	937,000	478,466	614,377	188,890
TOTAL OPERATING EXPENSES	3,446,726	4,232,059	9,885,734	11,363,607	26,180,786	13,430,993
LOSS FROM OPERATIONS	(2,239,864)	(3,017,301)	(6,577,998)	(8,244,938)	(21,831,217)	(7,474,036)
OTHER INCOME (EXPENSE)
Other expense, net	(1,921)	14,404	160,598	(14,330)	(65,867)	(2,424,649)
Interest expense	(181,429)	(151,274)	(692,547)	(529,782)	(866,476)	(2,345,410)
Interest income	101,236	110,596	309,031	555,281	662,859	236,349
Gain on equity investments, net	428	(1,093)	2,518	2,876	4,584	1,676
Gain on extinguishment of debt	0	706	0	1,911,476	1,910,967	1,004,124
Change in fair value of derivative liability	0	0	0	3,384	3,384	(20,257)
Bargain purchase gain	0	0	0	1,633,842	1,440,249	0
Foreign currency transaction, net	139,016	(371,115)	158,463	(108,406)	198,863	(413,279)
Non-cash interest expense					0	(1,619,838)
TOTAL OTHER INCOME (EXPENSE), NET	57,330	(397,776)	(61,937)	3,454,341	3,288,563	(5,581,284)
LOSS BEFORE INCOME TAXES	(2,182,534)	(3,415,077)	(6,639,935)	(4,790,597)	(18,542,654)	(13,055,320)
INCOME TAX EXPENSE	0	65,873	0	0	0	(775,051)
NET LOSS	(2,182,534)	(3,349,204)	(6,639,935)	(4,790,597)	(18,542,654)	(13,830,371)
Deemed dividend on issuance of warrants	6,185,231	0	6,185,231		0	32,004,730
Deemed dividend on downround of warrants	0	(15,053)	0	(15,053)	(22,695)	(8,480,379)
Deemed dividend on warrant exchange/modification	(9,793)	0	(9,793)		(7,218,485)	(1,067,876)
Deemed dividend on downround of preferred stock					0	(8,189,515)
Deemed dividend on preferred stock					0	(372,414)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	(8,377,558)	(3,364,257)	(12,834,959)	(4,805,650)	(25,783,834)	(63,945,285)
OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation adjustment, net	747,879	(890,645)	(27,988)	(470,994)	712,791	(981,014)
TOTAL COMPREHENSIVE LOSS	$ (7,629,679)	$ (4,254,902)	$ (12,862,947)	$ (5,276,644)	$ (25,071,043)	$ (64,926,299)
BASIC NET LOSS PER SHARE	$ (0.45)	$ (0.27)	$ (0.72)	$ (0.42)	$ (2.15)	$ (33.16)
DILUTED NET LOSS PER SHARE	$ (0.45)	$ (0.27)	$ (0.72)	$ (0.42)	$ (2.15)	$ (33.16)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING
Basic	18,418,287	12,585,479	17,724,305	11,346,071	11,968,665	1,928,172
Diluted	18,418,287	12,585,479	17,724,305	11,346,071	11,968,665	1,928,172

UNAUDITED CONDENSED CONSOLIDA_2

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY AND MEZZANINE EQUITY - USD ($)	Total	Preferred Stock	Common Stock	Additional Paid-In Capital	Subscription Receivable	Retained Earnings (Accumulated Deficit)	Accumulated other comprehensive loss	Treasurys Stocks
Balance, shares at Dec. 31, 2021			701,780					15,497
Balance, amount at Dec. 31, 2021		$ 0	$ 702	$ 39,692,595	$ 0	$ (34,345,506)	$ (151,621)	$ (816,707)
Foreign currency translation adjustment, net	$ (981,014)	0	0	0	0	0	(981,014)	0
Adoption of ASU 2020-06	(240,752)	$ 0	0	(294,000)	0	53,248	0	0
Issuance of Series A preferred stock, net of issuance costs of $547,700, shares		6,000
Foreign currency translation adjustment, net	(981,014)
Issuance of Series A preferred stock, net of issuance costs of $547,700, amount	0	$ 5,452,300	0	0	0	0	0	0
Net loss	(13,830,371)	$ 0	$ 0	0	0	(13,830,371)	0	0
Conversion of Series A preferred stock, shares		(6,000)	386,588
Conversion of Series A preferred stock, amount	5,452,300	$ (5,452,300)	$ 387	5,451,913	0	0	0	0
Sale of common stock, shares			5,314,987
Sale of common stock, amount	6,622,924	0	$ 5,315	11,367,717	(4,750,108)	0	0	0
Sale of warrants bundled with common stock	26,216,237	0	$ 0	26,216,237	0	0	0	0
Exercise of warrants, shares			3,608,667
Exercise of warrants, amount	10,826,000	0	$ 3,609	10,822,391	0	0	0	0
Conversion of notes payable into shares of common stock, shares			9,520
Conversion of notes payable into shares of common stock, amount	973,420	0	$ 9	973,411	0	0	0	0
Conversion of convertible debt, shares			1,574
Conversion of convertible debt, amount	38,144	0	$ 1	38,143	0	0	0	0
Cashless exercise of warrants, shares			526,112
Cashless exercise of warrants, amount	0	0	$ 526	(526)	0	0	0	0
Shares issued in lieu of cash, shares			40,600
Shares issued in lieu of cash, amount	175,941	0	$ 41	175,900	0	0	0	0
Fair value of warrants issued in lieu of cash	24,401	0	0	24,401	0	0	0	0
Deemed dividend upon downround of preferred stock and warrants	0	0	0	16,669,894	0	(16,669,894)	0	0
Deemed dividend on preferred stock	(372,414)	372,414	0	0	0	(372,414)	0	0
Deemed dividend on warrant exchange	0	0	$ 0	1,067,876	0	(1,067,876)	0	0
Rounding upon reverse stock split of 1 for 25 common shares, shares			15,584
Rounding upon reverse stock split of 1 for 25 common shares, amount	16	0	$ 16	0	0	0	0	$ 0
Balance, shares at Dec. 31, 2022			10,605,412					15,497
Balance, amount at Dec. 31, 2022	39,284,295	372,414	$ 10,606	112,205,952	(4,750,108)	(66,232,813)	(1,132,635)	$ (816,707)
Foreign currency translation adjustment, net	336,463						336,463
Proceeds from sale of common stock	4,750,000				4,750,000
Shares issued in lieu of cash, shares			15,258
Shares issued in lieu of cash, amount	96,888		$ 15	96,873
Net loss	(459,863)					(459,863)
Balance, shares at Mar. 31, 2023			10,620,670					15,497
Balance, amount at Mar. 31, 2023	44,007,783	372,414	$ 10,621	112,302,825	(108)	(66,692,676)	(796,172)	$ (816,707)
Balance, shares at Dec. 31, 2022			10,605,412					15,497
Balance, amount at Dec. 31, 2022	39,284,295	372,414	$ 10,606	112,205,952	(4,750,108)	(66,232,813)	(1,132,635)	$ (816,707)
Foreign currency translation adjustment, net	(470,994)
Net loss	(4,790,597)
Balance, shares at Sep. 30, 2023			13,068,693					86,497
Balance, amount at Sep. 30, 2023	44,195,740	372,414	$ 13,069	117,791,721	(50,000)	(71,038,463)	(1,603,629)	$ (916,958)
Balance, shares at Dec. 31, 2022			10,605,412					15,497
Balance, amount at Dec. 31, 2022	39,284,295	372,414	$ 10,606	112,205,952	(4,750,108)	(66,232,813)	(1,132,635)	$ (816,707)
Foreign currency translation adjustment, net	712,791	0	0	0	0	0	712,791	0
Foreign currency translation adjustment, net	712,791
Proceeds from sale of common stock	4,750,088	0	0	0	4,750,088	0	0	0
Net loss	(18,542,654)	0	$ 0	0	0	(18,542,654)	0	0
Shares issued for purchase of customer base, shares			99,710
Shares issued for purchase of customer base, amount	316,081	0	$ 100	315,981	0	0	0	0
Shares issued for purchase of Cana, shares			46,377
Shares issued for purchase of Cana, amount	138,667	0	$ 46	138,621	0	0	0	0
Shares issued in lieu of cash, shares			15,258
Shares issued in lieu of cash, amount	96,888	0	$ 15	96,873	0	0	0	0
Deemed dividend on preferred stock	0
Proceeds from sale of common stock, net of financing fees of $19,467, shares			2,116,936
Proceeds from sale of common stock, net of financing fees of $19,467, amount	4,807,038	0	$ 2,117	4,804,921	0	0	0	0
Proceeds from the exercise of warrants, net of financing fees of $275,000, shares			1,487,000
Proceeds from the exercise of warrants, net of financing fees of $275,000, amount	3,258,741	0	$ 1,487	3,257,254
Shares issued for purchase of Cloudscreen, shares			280,000
Shares issued for purchase of Cloudscreen, amount	319,200	0	$ 280	318,920
Shares issued upon exchange of related party debt, shares			51,485
Shares issued upon exchange of related party debt, amount	52,000	0	$ 52	51,948
Stock-based compensation, shares			1,280,294
Stock-based compensation, amount	577,931	0	$ 1,280	576,651	0	0	0	$ 0
Repurchase of treasury stock, shares								71,000
Repurchase of treasury stock, amount	(100,452)	0	0	0	0			$ (100,452)
Deemed dividend upon issunace and downround of warrants	0	0	$ 0	7,241,180	0	(7,241,180)	0	$ 0
Deemed dividend reclassified upon elimination of its redemption provision	372,414	(372,414)				372,414
Balance, shares at Dec. 31, 2023			15,982,472					86,497
Balance, amount at Dec. 31, 2023	36,043,028	0	$ 15,983	129,008,301	(20)	(91,644,233)	(419,844)	$ (917,159)
Balance, shares at Mar. 31, 2023			10,620,670					15,497
Balance, amount at Mar. 31, 2023	44,007,783	372,414	$ 10,621	112,302,825	(108)	(66,692,676)	(796,172)	$ (816,707)
Foreign currency translation adjustment, net	83,188						83,188
Net loss	(981,530)					(981,530)
Shares issued for purchase of customer base, shares			99,710
Shares issued for purchase of customer base, amount	316,081		$ 100	315,981
Shares issued for purchase of Cana, shares			46,377
Shares issued for purchase of Cana, amount	138,667		$ 46	138,621
Stock-based compensation, shares			185,000
Stock-based compensation, amount	104,869		$ 185	104,684
Balance, shares at Jun. 30, 2023			10,951,757					15,497
Balance, amount at Jun. 30, 2023	43,669,058	372,414	$ 10,952	112,862,111	(108)	(67,674,206)	(712,984)	$ (816,707)
Foreign currency translation adjustment, net	(890,645)						(890,645)
Net loss	(3,349,204)					(3,349,204)
Stock-based compensation, amount	109,636			109,636
Proceeds from sale of common stock, net of financing fees of $442,870, shares			2,116,936
Proceeds from sale of common stock, net of financing fees of $442,870, amount	4,757,146		$ 2,117	4,804,921	(49,892)
Repurchase of treasury stock, shares								71,000
Repurchase of treasury stock, amount	100,251							$ 100,251
Deemed dividend				15,053		(15,053)
Balance, shares at Sep. 30, 2023			13,068,693					86,497
Balance, amount at Sep. 30, 2023	44,195,740	372,414	$ 13,069	117,791,721	(50,000)	(71,038,463)	(1,603,629)	$ (916,958)
Balance, shares at Jun. 30, 2023			10,951,757					15,497
Balance, amount at Jun. 30, 2023	43,669,058	372,414	$ 10,952	112,862,111	(108)	(67,674,206)	(712,984)	$ (816,707)
Balance, shares at Dec. 31, 2023			15,982,472					86,497
Balance, amount at Dec. 31, 2023	36,043,028	0	$ 15,983	129,008,301	(20)	(91,644,233)	(419,844)	$ (917,159)
Foreign currency translation adjustment, net	(599,276)						(599,276)
Shares issued in lieu of cash, amount	108,297			108,297
Net loss	(1,866,690)					(1,866,690)
Stock-based compensation, amount	231,897			231,897
Proceeds from sale of common stock, net of financing fees of $19,467, shares			901,488
Proceeds from sale of common stock, net of financing fees of $19,467, amount	629,426		$ 901	628,525
Shares issued pursuant to warrant exchange agreement, shares			950,063
Shares issued pursuant to warrant exchange agreement, amount			$ 950	(950)
Balance, shares at Mar. 31, 2024			17,834,023					86,497
Balance, amount at Mar. 31, 2024	34,546,682		$ 17,834	129,976,070	(20)	(93,510,923)	(1,019,120)	$ (917,159)
Balance, shares at Dec. 31, 2023			15,982,472					86,497
Balance, amount at Dec. 31, 2023	36,043,028	$ 0	$ 15,983	129,008,301	(20)	(91,644,233)	(419,844)	$ (917,159)
Foreign currency translation adjustment, net	(27,988)
Net loss	(6,639,935)
Balance, shares at Sep. 30, 2024			23,346,023					86,497
Balance, amount at Sep. 30, 2024	34,976,599		$ 23,346	140,797,456	(20)	(104,479,192)	(447,832)	$ (917,159)
Balance, shares at Mar. 31, 2024			17,834,023					86,497
Balance, amount at Mar. 31, 2024	34,546,682		$ 17,834	129,976,070	(20)	(93,510,923)	(1,019,120)	$ (917,159)
Foreign currency translation adjustment, net	(176,591)						(176,591)
Shares issued in lieu of cash, amount	108,444			108,444
Net loss	(2,590,711)					(2,590,711)
Stock-based compensation, amount	231,750			231,750
Balance, shares at Jun. 30, 2024			17,834,023					86,497
Balance, amount at Jun. 30, 2024	32,119,574		$ 17,834	130,316,264	(20)	(96,101,634)	(1,195,711)	$ (917,159)
Foreign currency translation adjustment, net	747,879						747,879
Shares issued in lieu of cash, shares			2,500,000
Shares issued in lieu of cash, amount	158,061		$ 2,500	155,561
Net loss	(2,182,534)					(2,182,534)
Stock-based compensation, shares			680,000
Stock-based compensation, amount	264,750		$ 680	264,070
Proceeds from exercise of warrants, net of financing fees of $372,109, shares			2,332,000
Proceeds from exercise of warrants, net of financing fees of $372,109, amount	3,868,869		$ 2,332	3,866,537
Deemed dividend on warrant inducement				6,195,024		(6,195,024)
Balance, shares at Sep. 30, 2024			23,346,023					86,497
Balance, amount at Sep. 30, 2024	$ 34,976,599		$ 23,346	$ 140,797,456	$ (20)	$ (104,479,192)	$ (447,832)	$ (917,159)

UNAUDITED CONDENSED CONSOLIDA_3

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$ (6,639,935)	$ (4,790,597)	$ (18,542,654)	$ (13,830,371)
Adjustments to Reconcile Net Loss to Net Cash Used In Operating Activities:
Depreciation and amortization expense	914,493	375,918	590,691	103,194
Amortization of right-of-use assets	22,507	102,549	23,686	85,696
Bad debt expense	(31,287)	836,300	11,850,788	5,621,938
Provision for extraordinary tax charges	0	579,387	(578,425)	0
Shares issued in lieu of cash	0	96,888	96,888	175,941
Lease expense	235,659	178,893	365,639	210,463
Interest on finance leases	1,765	20,629	2,903	16,467
Stock-based compensation	1,103,200	214,505	577,931	24,401
Deferred income taxes	0	(1,923)	78,553	780,099
Gain on extinguishment of debt	0	(1,911,476)	(1,910,967)	(876,894)
Bargain purchase gain	0	1,633,842	(1,440,249)	0
Change in fair value of the derivative liability	0	(3,384)	(3,384)	20,257
Gain on net change in fair value of equity investments	(2,518)	(2,876)	(4,584)	(1,676)
Other income	0	(928)	(928)	0
Amortization of debt discounts and accretion of debt			0	1,619,838
Gain on forgiveness of accrued interest			0	(127,230)
Changes in assets and liabilities:
Accounts receivable	(2,392,104)	1,960,236	(5,484,213)	(3,073,366)
Accounts receivable - related party	176,512	416,814	1,457,845	(170,815)
Inventory	46,301	2,299,829	(890,903)	(485,469)
Prepaid expenses and other assets	283,932	1,856,642
Prepaid expenses and other current assets - related party	1,873,513	2,312,324	(913,574)	(375,311)
Loan receivable - related party	0	0	0	4,213,728
Prepaid expenses and other assets			(579,467)	(894,893)
Accounts payable and accrued expenses	(437,391)	206,746	644,838	2,092,104
Accounts payable and accrued expenses - related party	795,471	(112,233)	71,777	(357,681)
Accrued interest	17,531	(194,361)	(115,668)	(913,280)
Lease liabilities	(234,834)	(179,081)	(373,816)	(210,781)
Taxes payable	0	307,357	(128,801)	(1,107,135)
Other current liabilities	910,885	(783,174)	(1,359,180)	(320,420)
Other liabilities	(550,606)	(1,047,178)	(227,575)	1,338,013
NET CASH USED IN OPERATING ACTIVITIES	(3,883,215)	(16,587,726)	(15,635,999)	(14,870,639)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from loan receivable	550,565	609,455	806,464	351,474
Cash paid for the acquisition of Cana	0	5,230,593	5,230,593	0
Loan receivable - related party	0	168,469	168,469	0
Sale of intangible assets	1,999	0
Advances for building's acquisition	0	1,665,000	1,665,000	0
Purchase of intangible assets	0	(2,678,167)	(6,189,564)	(308,866)
Sale of fixed assets			0	12,736
Purchase of property and equipment	(345,593)	(1,266,490)	(1,313,195)	(74,207)
Purchase of marketable securities			0	(2,634)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	206,971	(10,399,264)	(13,760,357)	(21,497)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payment of convertible note payable	0	(100,000)	(100,000)	(525,000)
Payment of related party note payable			0	(421,373)
Payment of note payable	(814,267)	(1,494,867)	(1,611,774)	(12,479,735)
Proceeds from note payable	434,797	1,059,300	1,057,540	487,098
Payment of related party loan	(7,609)	0	0	(4,824,035)
Proceeds from related party loan	15,218	0	0	3,625,007
Payment of lines of credit	(19,504,594)	(14,569,517)	(19,532,735)	(20,975,110)
Proceeds from lines of credit	18,831,043	14,218,787	20,193,343	22,354,567
Proceeds from issuance of Series A Preferred Stock	0	0	0	6,000,000
Proceeds from the issuance of common stock	649,039	9,950,037	10,000,017	35,275,573
Proceeds from the exercise of warrants	4,240,977	0	3,533,741	10,826,000
Payment of loans payable			0	(1,065,000)
Payments of finance lease liability	(26,408)	(118,847)	(27,786)	(99,906)
Proceeds from loans payable			0	65,000
Payments for purchase of treasury stock	0	(100,251)	(100,452)	0
Payments of financing fees	(391,575)	(442,892)	(717,888)	(3,194,798)
NET CASH PROVIDED BY FINANCING ACTIVITIES	3,426,621	8,401,750	12,694,007	35,048,288
Effect of exchange rate changes on cash	(268,727)	196,161	(214,139)	307,044
NET CHANGE IN CASH	(518,350)	(18,389,079)	(16,916,488)	20,463,196
CASH AT BEGINNING OF YEAR	3,833,195	20,749,683	20,749,683	286,487
CASH AT END OF YEAR	3,314,845	2,360,604	3,833,195	20,749,683
Cash paid during the year:
Interest	198,194	317,449	406,885	588,051
Income tax	0	0	0	0
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Conversion of notes payable to common stock			0	973,420
Deemed dividend upon warrant exchange	6,195,024	0
Closing of acquisition of Cloudscreen	637,080	0
Common shares issued for acquisition of customer base	0	316,081	316,081
Common stock issued to employees	372,303	0
Common shares issued for acquisition of Cana	0	138,667	138,667	$ 0
Common stock issued to consultants	$ 727,570	$ 0
Deemed dividend reclassified upon elimination of its redemption provision			$ 372,414
Conversion of convertible notes payable to common stock			15,000	386,588
Deemed dividend on warrants upon conversion of convertible debt			$ 7,218,485	$ 32,004,730
Deemed dividend on preferred stock and warrants upon trigger of downround feature			0	16,669,894
Deemed dividend upon cumulative dividend on preferred stock			0	372,414
Conversion of Series A preferred stock			0	5,452,300
Conversion of convertible debt			$ 0	$ 38,144

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
BASIS OF PRESENTATION	Sep. 30, 2024
BASIS OF PRESENTATION
BASIS OF PRESENTATION	NOTE 1 – BASIS OF PRESENTATION The terms “COSM,” “we,” the “Company,” the “Group” and “us” as used in this report refer to Cosmos Health Inc. The accompanying unaudited condensed consolidated balance sheet as of September 30, 2024 and unaudited condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of the management of COSM, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2024, are not necessarily indicative of the results that may be expected for the year ending December 31, 2024, or any other period. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2023, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (“Form 10-K”). The accompanying condensed consolidated balance sheet as of December 31, 2023 has been derived from the audited financial statements filed in our Form 10-K and is included for comparison purposes on the accompanying balance sheet. Going Concern The Company’s unaudited condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplates the continuation of the Company as a going concern. For the nine months ended September 30, 2024, the Company had revenue of $40,202,238, net loss of $6,639,935 and net cash used in operations of $3,883,215. Additionally, as of September 30, 2024, the Company had positive working capital of $11,027,653, an accumulated deficit of $104,479,192, and stockholders’ equity of $34,976,599. It is the management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the date of this filing. The Company’s revenues are not able to sustain its operations, and concerns exist regarding the Company’s ability to meet its obligations as they become due. The Company is subject to a number of risks to those of smaller commercial companies, including dependence on key individuals and products, the difficulties inherent in the development of a commercial market, the need to obtain additional capital, competition from larger companies, and other pharmaceutical and health care companies. Management evaluated the above conditions which raise substantial doubt about the Company’s ability to continue as a going concern to determine if it can meet its obligations for the subsequent twelve months from the date of this filing. Management considered its ability to access future capital, curtail expenses if needed, expand product lines, and acquire new products. Management’s plans include expansion of brand name products to the market, expanding the current product portfolio, and evaluating acquisition targets to expand distribution. Furthermore, the Company intends to vertically integrate the supply chain distribution network. During the period up to the issuance of this report the Company has signed multiple distribution agreements for its SPL products in Europe and Asia and a variety of contract manufacturing agreements though its subsidiary, Cana Laboratories Holdings (Cyprus) Limited. Finally, the Company plans to further access the capital markets in order to raise additional funds through equity offerings. More specifically, up to the issuance of its consolidated financial statements for the nine months ended September 30, 2024, the Company has sold 901,488 shares of common stock for net proceeds of $629,426 through two Prospectus Supplements to its Registration Statement on Form S-3 (No. 333-267550) filed with the SEC on February 29 and March 7, 2024. Management will also consider postponing the repayment of its outstanding Trade Facility ($1,588,163 balance as of September 30, 2024), intends to make substantial efforts to receive additional debt financing through its subsidiary, Cosmofarm SA, and plans to raise additional equity funds through utilizing its outstanding warrants. Following such efforts, on September 26, 2024, the Company entered into a Warrant Inducement Letter with an investor pursuant to which the Company issued 9,748,252 new warrants and reduced the exercise price of 4,874,126 warrant shares from $1.45 to $0.8701 to induce exercise and receive gross cash proceeds of $4,240,977. On July 29, 2024 the Company’s subsidiary Cosmofarm SA entered into an agreement with a third-party lender in the principal amount of €400,000 ($432,760). Moreover, the Company’s management is considering postponing certain repayments of suppliers and creditors. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described herein and eventually secure other sources of financing and attain profitable operations. Considering the above, management is of the view that substantial doubt exists about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty.

ORGANIZATION AND NATURE OF BUSI

ORGANIZATION AND NATURE OF BUSINESS	9 Months Ended	12 Months Ended
ORGANIZATION AND NATURE OF BUSINESS	Sep. 30, 2024	Dec. 31, 2023
ORGANIZATION AND NATURE OF BUSINESS
ORGANIZATION AND NATURE OF THE BUSINESS	NOTE 2 – ORGANIZATION AND NATURE OF BUSINESS Cosmos Health Inc. and its subsidiaries (Nasdaq: COSM), (“us”, “we”, the “Group”, or the “Company”) are an international healthcare group headquartered in Thessaloniki, Greece. The group is engaged in the nutraceuticals sector through its own proprietary lines of products “Sky Premium Life” and “Mediterranation”. The Company is operating in the pharmaceutical sector as well, through the provision of a broad line of branded generics and OTC medications. In addition, the group is involved in the healthcare distribution sector through its subsidiaries in Greece and the UK, serving retail pharmacies and wholesale distributors. The Company is strategically focusing on the research and development (“R&D”) of novel patented nutraceuticals (Intellectual Property) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. The Company has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. The Company has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. The Company was incorporated in the State of Nevada under the name Prime Estates and Developments, Inc. on July 21, 2009. On November 14, 2013, we changed our name to Cosmos Holdings Inc., and on November 29, 2022, we changed our name to Cosmos Health Inc. Through its acquisition of Amplerissimo Ltd, on September 27, 2013, the Company changed its principal activities into trading of products, providing representation, and provision of consulting services to various sectors. On August 1, 2014, the Company formed SkyPharm S.A., a Greek Company (“SkyPharm”), a subsidiary that used to focus on the trading, sourcing and export of nutraceutical and pharmaceutical products. In February 2017, the Company acquired Decahedron Ltd., a UK Company (“Decahedron”) which is a fully licensed second-generation wholesaler specializing in imports and exports of generics and OTC pharmaceutical products within the EEA and distributor of Sky Premium Life nutraceutical products in the UK. On December 19, 2018, the Company acquired Cosmofarm, a pharmaceutical wholesaler specializing in the distribution and export of pharmaceutical products through its extensive pharmacies network. On April 3, 2023, the Company completed the acquisition of ZipDoctor Inc. (“ZipDoctor”), a telehealth company, a direct-to-consumer subscription-based telemedicine platform. On June 30, 2023, the Company acquired Cana Laboratories Holdings (Cyprus) Limited (“Cana”), which wholly owned an operating subsidiary, Pharmaceutical Laboratories Cana S.A. (“Cana SA”), a Greek pharmaceutical company that manufactures, sells, distributes, and markets original branded products researched and developed by leading global pharmaceutical and healthcare companies. Acquisition Accounting Cloudscreen On January 23, 2024, the Company completed the acquisition of Cloudscreen, a cutting-edge Artificial Intelligence (AI) powered platform. The acquisition is pursuant to the purchase agreement announced on October 11, 2023. Cloudscreen is a multimodal platform specialized in drug repurposing, a process that involves uncovering new target proteins or indications for existing drugs for use in treating different diseases. The total purchase price amounted to $637,080 and consisted of 280,000 shares of common stock with a fair value of $319,200 and an amount of $317,880 to be settled in cash during 2024 based on the Promissory Note signed on October 10, 2023. The Company accounted for the acquisition as an asset acquisition in accordance with Accounting Standards Codification (“ASC”) Topic 805, Business Combinations, (“ASC 805”) and recorded $637,080 as an intangible asset related to the technology platform acquired. ZipDoctor On April 3, 2023, the Company completed the acquisition of ZipDoctor Inc. (“ZipDoctor”), a telehealth company for a total sum of $150,000 in cash and $8,788 in fees. The Company accounted for the acquisition as an asset acquisition in accordance with Accounting Standards Codification (“ASC”) Topic 805, Business Combinations Bikas On June 15, 2023, Cosmos Health Inc. entered into an Assignment and Assumption Agreement (the “Agreement”) with Ioannis Bikas O.E., a Greek Company (“Bikas”). Bikas is owner of a pharmaceutical distribution network in Greece and agreed to sell to the Company their distribution network and customer base. The purchase price of the network was €100,000 ($109,330) in cash, and €300,000 ($316,081) in the Company’s common stock. The Company issued 99,710 shares of common stock related to the acquisition of the customer base, based on the fair value of the stock on the acquisition date. The Company accounted for the acquisition as an asset acquisition in accordance with ASC 805 and recorded $425,411 as an intangible asset related to the customer base acquired. Buildings Acquisitions On April 24, 2023, the Company purchased a building for a total sum of $1,054,872 in cash. The Company accounted for the acquisition as an asset acquisition in accordance with ASC 805 and recorded the cost of the building as “Property, plant and equipment” on the consolidated balance sheets. On January 6, 2023, the Company agreed to purchase land and building located in Montreal, Canada from a third-party vendor. The total purchase price amounts to $3,950,000 and the closing date of the agreement based on the amendment signed on July 19, 2023, is December 31, 2023. As of September 30, 2024, the Company has made no additional prepayments concerning this building. The closing date of the agreement has been extended to December 31, 2024. Cana On June 30, 2023, the Company acquired Cana Laboratories Holdings (Cyprus) Limited (“Cana”), which wholly owned an operating subsidiary, Pharmaceutical Laboratories Cana S.A. (“Cana SA”) for €800,000 ($873,600) in cash and 46,377 shares of common stock, with fair value of $138,667 as of the date of acquisition. Moreover, on February 28, Consideration Cash $ 5,331,120 Fair value of common stock issued 138,667 Fair value of total consideration transferred $ 5,469,787 Recognized amounts of identifiable assets acquired Financial assets $ 1,796,911 Inventory 297,340 Property, plant and equipment 7,488,818 Identifiable intangible assets 562,200 Financial liabilities (3,235,233 ) Total identifiable net assets $ 6,910,036 Bargain purchase gain $ 1,440,249 Revenue for the 9 - month period ended September 30, 2024 $ 549,567 Loss for the 9 - month period ended September 30, 2024 $ (1,674,785 ) During the prior year period, Cana had minimal operations as it was in financial difficulties and seeking for an investor. Basis of Financial Statement Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. Principles of Consolidation Our consolidated accounts include our accounts and the accounts of our wholly owned subsidiaries, SkyPharm S.A., Decahedron Ltd., Cosmofarm S.A., Cana Laboratories Holdings (Cyprus) Limited and ZipDoctor Inc. The Group’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). The consolidated financial statements reflect the consolidation of all entities in which the Company has control, as determined by the ability to direct the activities that significantly affect the entities’ economic performance. All significant intercompany balances and transactions have been eliminated. Transactions in and Translations of Foreign Currency The functional currency for the Greek subsidiaries of the Company (CANA Laboratories, Cosmofarm S.A. and SkyPharm SA) is Euro (€) and for the UK subsidiary (Decahedron Ltd) is GBP (£). ZipDoctor Inc. is a U.S. based entity. As a result, the financial statements of the subsidiaries (except for ZipDoctor Inc.) have been translated from the local currency into U.S. dollars using (i) year-end exchange rates for balance sheet accounts, and (ii) average exchange rates for the reporting period for all income statements accounts. Foreign currency translations gains and losses are reported as a separate component of the condensed consolidated statements of changes in stockholders’ equity and mezzanine equity. Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Effects of War in the Ukraine On February 24, 2022, Russian forces launched significant military action against Ukraine. There continues to be sustained conflict and disruption in the region, which is expected to endure for the foreseeable future. We do not conduct any commercial transactions with either Ukraine or Russia and the Company and, as such, is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. Such political issues and conflicts could have a material adverse effect on our results of operations and financial condition if they escalate in areas in which we do business. In addition, changes in and adverse actions by governments in foreign markets in which we do business could have a material adverse effect on our results of operations and financial condition. Credit Losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments, which amends the requirement on the measurement and recognition of expected credit losses for financial assets held. Furthermore, amendments ASU 2019-10 and ASU 2019-11 provided additional clarification for implementing ASU 2016-13. ASU 2016-13 is effective for the Company beginning January 1, 2023, with early adoption permitted. The Company adopted the standard on January 1, 2023, and the standard did not have a material impact on the Company’s consolidated financial statements and related disclosures. The Company is exposed to credit losses primarily through sales to its customers and the loans that it has provided. The Company assesses each customer’s/ borrower’s ability to pay, and a credit loss estimate by conducting a credit review which includes consideration of established credit rating, or an internal assessment of the customer’s creditworthiness based on an analysis of their payment history when a credit rating is not available. The Company monitors credit exposure through active review of customer balances. The Company’s expected loss methodology for accounts receivable is developed through consideration of factors including, but not limited to, historical collection experience, current customer credit ratings, current customer financial condition, current and future economic and market conditions, and age of the receivables. More specifically, the Company assesses a number of customers with significant long outstanding balances on an individual basis, applying different credit loss percentages to them, and subsequently summarizes the ones not included in the individual analysis, groups them based on their rating (decided based on the factors described above) and applies specific credit loss percentages to each group. The Company has elected to follow the simplified ECL approach. The charges related to credit losses are included in “General and administrative expenses” and are recorded in the period that the outstanding receivables are determined to be doubtful. Account balances are written-off against the allowance when they are deemed uncollectible. Cash and Cash Equivalents For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company maintains bank accounts in the United States denominated in U.S. Dollars, in Greece denominated in Euros, U.S. Dollars and Great Britain Pounds (British Pounds Sterling), and in Bulgaria denominated in Euros. The Company also maintains bank accounts in the United Kingdom, denominated in Euros and Great Britain Pounds (British Pounds Sterling). Accounts Receivable, net Accounts receivable are stated at their net realizable value. The allowance for doubtful accounts against gross accounts receivable, prepaid expenses and other current assets and other assets reflects the best estimate of probable losses inherent in the receivables’ portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. As of September 30, 2024 and December 31, 2023, the Company’s allowance for doubtful accounts was $19,905,776 and $19,686,091, respectively. Below is the summary of changes in the allowance for doubtful accounts: September 30, 2024 Balance as of January 1st, 2024 $ 19,686,091 Provisions for credit losses - Write-offs 250,971 Foreign exchange adjustments Other adjustments (31,286 ) Balance as of September 30, 2024 $ 19,905,776 Tax Receivables The Company pays Value Added Tax (“VAT”) or similar taxes (“input VAT”), income taxes, and other taxes within the normal course of its business in most of the countries in which it operates related to the procurement of merchandise and/or services it acquires and/or on sales and taxable income. The Company also collects VAT or similar taxes on behalf of the government (“output VAT”) for merchandise and/or services it sells. If the output VAT exceeds the input VAT, this creates a VAT payable to the government. If the input VAT exceeds the output VAT, this creates a VAT receivable from the government. The VAT tax return is filed on a monthly basis offsetting the payables against the receivables. In observance of EU regulations for intra-EU cross-border sales, our subsidiaries in Greece, SkyPharm and Cosmofarm, do not charge VAT for sales to wholesale drug distributors registered in other European Union member states. As of September 30, 2024 and December 31, 2023, the Company had a VAT net receivable balance of $322,576 and $187,512 respectively, recorded in the consolidated balance sheet as prepaid expenses and other current assets and accounts payable and accrued expenses, respectively. Inventory Inventory is stated at the lower-of-cost or net realizable value using the weighted average method. Inventory consists primarily of finished goods and packaging materials, i.e., packaged pharmaceutical products and the wrappers and containers they are sold in. A periodic inventory system is maintained by 100% count. Inventory is replaced periodically to maintain the optimum stock on hand available for immediate shipment. The Company writes down inventories to net realizable value based on physical condition, expiration date, and current market conditions, as well as forecasted demand. The Company’s inventories are not highly susceptible to obsolescence. Many of the Company’s inventory items are eligible for return to our suppliers when pre-agreed product requirements, including, but not limited to, physical condition and expiration date, are not met. No significant judgments have been applied in estimating the selling price of our inventory. Property and Equipment, net Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated on a straight-line basis over the useful lives (except for leasehold improvements which are depreciated over the lesser of the lease term or the useful life) of the assets as follows: Estimated Useful Life Leasehold improvements and technical works Lesser of lease term or 25 years Buildings 25-30 years Vehicles 6 years Machinery 20 years Furniture, fixtures and equipment 5–10 years Computers and software 3-5 years Depreciation expense was $89,694 and $124,910 for the three months ended September 30, 2024 and 2023, respectively and $306,126 and $237,479 for the nine months ended September 30, 2024 and 2023, respectively. Property and Equipment additions Property and Equipment additions are recognized as assets when it is probable that future economic benefits associated with the asset will flow to the entity and the cost of the asset can be measured reliably. Additions are initially measured at cost, which includes all costs directly attributable to bringing the asset to its working condition and location for its intended use. This may include purchase price, freight, installation, and any directly attributable professional fees. They are capitalized if their cost exceeds a certain threshold. The threshold is determined based on materiality considerations. Costs below the threshold are typically expensed as incurred. After initial recognition, additions are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is calculated systematically over the estimated useful life of the asset. They are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If the carrying amount exceeds the recoverable amount, an impairment loss is recognized, and the carrying amount of the asset is adjusted accordingly. Borrowing costs directly attributable to the acquisition, construction, or production of qualifying assets, including Property and Equipment additions, are capitalized as part of the cost of those assets. Goodwill and Intangibles, net The Company periodically reviews the carrying value of intangible assets not subject to amortization, including goodwill, to determine whether impairment may exist. Goodwill and certain intangible assets are assessed annually, or when certain triggering events occur, for impairment using fair value measurement techniques. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. First, under step 0, we determine whether it is more likely than not that the fair value of the reporting unit is less than the carrying amount. Following, if step 0 fails, goodwill impairment is determined using a two-step process. The first step of the goodwill impairment test is used to identify potential impairment by comparing the fair value of a reporting unit with its carrying amount, including goodwill. The Company uses level 3 inputs and a discounted cash flow methodology to estimate the fair value of a reporting unit. A discounted cash flow analysis requires one to make various judgmental assumptions including assumptions about future cash flows, growth rates, and discount rates. The assumptions about future cash flows and growth rates are based on the Company’s budget and long-term plans. Discount rate assumptions are based on an assessment of the risk inherent in the respective reporting units. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired and the second step of the impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit. On December 19, 2018, as a result of the acquisition of Cosmofarm, the Company recorded $49,697 of goodwill. Intangible assets with definite useful lives are recorded on the basis of cost and are amortized on a straight-line basis over their estimated useful lives. The Company uses a useful life of 5 years for an import/export license and a useful life of 10 years for the pharmaceutical and nutraceutical products licenses included in Note 4 as “Licenses”. A useful life of 10 years is also used for the platforms included in Note 4 as “Software” and the customer bases. The Company evaluates the remaining useful life of intangible assets annually to determine whether events and circumstances warrant a revision to the remaining amortization period. If the estimate of the intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over that revised remaining useful life. As of September 30, 2024 and December 31, 2023, no revision to the remaining amortization period of the intangible assets was made. Amortization expense was $196,183 and $88,168 for the three months ended September 30, 2024 and 2023, respectively and $579,556 and $138,438 for the nine months ended September 30, 2024 and 2023, respectively. Impairment of Long-Lived Assets In accordance with ASC 360-10, Long-lived Assets, property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Equity Method Investment For those investments in common stock or in-substance common stock in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee, the investment is accounted for under the equity method. The Company records its share in the earnings of the investee and is included in “Equity earnings of affiliate” in the consolidated statement of operations. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognizes an impairment loss to adjust the investment to its then current fair value. Investments in Equity Securities Investments in equity securities are accounted for at fair value with changes in fair value recognized in net income (loss). Equity securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Equity securities that are readily available for sale in current operations are reported as a component of current assets on the accompanying consolidated balance sheets. Equity securities that are not considered available for use in current operations would be reported as a component of long-term assets on the accompanying consolidated balance sheets. For equity securities with no readily determinable fair value, the Company elects a measurement alternative to fair value. Under this alternative, the Company measures the investments at cost, less any impairment, and adjusted for changes resulting from observable price changes in transactions for identical or similar investments of the investee. The election to use the measurement alternative is made for each eligible investment. As of September 30, 2024, investments consisted of 16,666 shares which traded at a closing price of $0.75 per share or value of $12,416 of National Bank of Greece. Additionally, the Company has $7,665 in equity securities of Pancreta Bank, which are revalued annually. Fair Value Measurement The Company applies ASC 820, Fair Value Measurements and Disclosures, (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements establishes a framework for measuring fair value and expands disclosure about such fair value measurements. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. In addition, ASC 825-10-25, Fair Value Option, (“ASC 825-10-25”), expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments. Our financials also included the following financial instruments as of September 30, 2024 and December 31, 2023: cash, accounts receivable, inventory, prepaid expenses, loans receivable, accounts payable, notes payable and lines of credit. Except for the loans receivable which carry fixed interest rates, the carrying value of the remaining instruments, approximates fair value due to their short-term nature. Customer Advances The Company receives prepayments from certain customers for pharmaceutical products prior to those customers taking possession of the Company’s products. The Company records these receipts as current liabilities until it has met all the criteria for recognition of revenue including passing control of the products to its customer, at such point, the Company will reduce the customer advances balance and credit the Company’s revenues. Revenue Recognition In accordance with ASC Topic 606, Revenue from Contracts with Customers 1) Identification of the Contract: The Company identifies a contract with a customer when it enters into an agreement that creates enforceable rights and obligations. 2) Identification of Performance Obligations: The Company identifies distinct performance obligations within each contract, which represent promises to transfer goods or services to the customer. 3) Determination of Transaction Price: The Company determines the transaction price, which represents the amount of consideration to which it expects to be entitled in exchange for transferring promised goods or services to the customer, excluding any amounts collected on behalf of third parties. 4) Allocation of Transaction Price: The Company allocates the transaction price to each distinct performance obligation based on its standalone selling price. If the standalone selling price is not observable, the Company estimates it using an appropriate method. 5) Recognition of Revenue: Revenue is recognized when (or as) the Company satisfies a performance obligation by transferring a promised good or service to the customer. This typically occurs at a point in time or over time, depending on the nature of the performance obligation. Wholesale revenue and sales of own branded nutraceutical and pharmaceutical products The Company has contracts or signed partnership forms (usual in the wholesale sector of the pharma industry) with its customers, stipulating enforceable rights and obligations. The Company is responsible for transferring the goods to the customer’s location, which represents its sole performance obligation. Thus, the transaction price, which is predetermined in most of the products sold, is exclusively allocated to this performance obligation. Revenue is recognized at a single point in time, which is upon issuance of the corresponding sales invoice. The Company has assessed the impact of the items invoiced but not delivered to the customer’s location as of December 31, 2023 and September 30, 2024, and deemed that it had no material effect. Pharma manufacturing The Company has active contracts with its customers, stipulating enforceable rights and obligations. The Company is responsible for the manufacturing and the packaging of specific products assigned by its customers, which represents its performance obligations to which the Company allocates the transaction price determined. The customers are responsible for providing the raw materials to the Company. Revenue is recognized over a period of time, which is during the production and packaging period of the respective products. As of September 30, 2024, there were no products or batches of products for which the production or packaging phase was in progress. Medihelm SA Commencing from January 1, 2023, and pursuant to the agreement with Medihelm, the exclusive distributor of the Company’s own proprietary line of nutraceuticals, the Company considers the transaction price to be variable and records an estimate of the transaction price, subject to the constraint for variable consideration. The Company is basing the change in transaction price with the exclusive distributor through assessment of significant overdue receivables from the exclusive distributor, which the Company reassesses each reporting period. Through this assessment, the Company applied the “expected value” model under ASC 606-10-32-5 and had applied specific constraints to revenue due from the customer at the end of each reporting period. Following the application of the “expected value” model, the Company had deferred an amount of $397,000 and recorded it against the sales to Medihelm for the twelve months ended December 31, 2023. However, the Company assessed once more the trading relationship with Medihelm SA at year end and since no significant receipts had taken place up to the issuance of the report, the Company recorded an allowance for the total receivable amount not received up to the issuance date. More specifically a cumulative reserve of $12,655,615 was applied, leaving a receivable of $532,704 due from Medihelm SA, as of December 31, 2023. The Company does not consider that new sales to Medihelm SA or sales to any other customer include a variable component as of September 30, 2024 and has limited such sales to the minimum required. Stock-based Compensation The Company records stock-based compensation in accordance with ASC 718, Stock Compensation (“ASC 718”) and Staff Accounting Bulletin No. 107 (“SAB 107”) regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock-based compensation at fair value using the Black-Scholes Option Pricing Model. The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASU 2018-07, “Compensation-Stock Compensation-Improvements to Nonemployee Share-Based Payment Accounting.” Income Taxes The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statemen	NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS Cosmos Health Inc. and its subsidiaries (Nasdaq: COSM), (“us”, “we”, the “Group”, or the “Company”) are an international healthcare group headquartered in Chicago, Illinois. The Group is engaged in the nutraceuticals sector through its own proprietary lines of products “Sky Premium Life” and “Mediterranation”. The Company is operating in the pharmaceutical sector as well, through the provision of a broad line of branded generics and OTC medications. In addition, the Group is involved in the healthcare distribution sector through its subsidiaries in Greece and the UK, serving retail pharmacies and wholesale distributors. The Company is strategically focusing on the research and development (“R&D”) of novel patented nutraceuticals (Intellectual Property) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. The Company has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. The Company has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. The Company was incorporated in the State of Nevada under the name Prime Estates and Developments, Inc. on July 21, 2009. On November 14, 2013, we changed our name to Cosmos Holdings Inc., and on November 29, 2022, we changed our name to Cosmos Health Inc. Through its acquisition of Amplerissimo Ltd, on September 27, 2013, the Company changed its principal activities into trading of products, providing representation, and provision of consulting services to various sectors. On August 1, 2014, the Company formed SkyPharm S.A., a Greek Company (“SkyPharm”), a subsidiary that used to focus on the trading, sourcing and export of nutraceutical and pharmaceutical products. In February 2017, the Company acquired Decahedron Ltd., a UK Company (“Decahedron”) which is a fully licensed second-generation wholesaler specializing in imports and exports of generics and OTC pharmaceutical products within the EEA (European Economic Area) and distributor of Sky Premium Life nutraceutical products in the UK. On December 19, 2018, the Company acquired Cosmofarm S.A. (“Cosmofarm”), a pharmaceutical wholesaler specializing in the distribution and export of pharmaceutical products through its extensive pharmacies network. On April 3, 2023, the Company completed the acquisition of ZipDoctor Inc. (“ZipDoctor”), a telehealth company, a direct-to-consumer subscription-based telemedicine platform. On June 30, 2023, the Company acquired Laboratories Holdings (Cyprus) Limited (“Cana”), which wholly owned an operating subsidiary, Pharmaceutical Laboratories Cana S.A. (“Cana SA”), a Greek pharmaceutical company that manufactures, sells, distributes, and markets original branded products researched and developed by leading global pharmaceutical and healthcare companies. Acquisition Accounting Cloudscreen On January 23, 2024, the Company completed the acquisition of Cloudscreen, a cutting-edge Artificial Intelligence (AI) powered platform. The acquisition is pursuant to the purchase agreement announced on October 11, 2023. Cloudscreen is a multimodal platform specialized in drug repurposing, a process that involves uncovering new target proteins or indications for existing drugs for use in treating different diseases. The total purchase price amounted to $637,080 and consisted of 280,000 shares of common stock with a fair value of $319,200 and an amount of $317,880 to be settled in cash during 2024 based on the Promissory Note signed on October 10, 2023. The Company accounted for the acquisition as an asset acquisition in accordance with Accounting Standards Codification (“ASC”) Topic 805, Business Combinations, (“ASC 805”) and recorded $637,080 as another asset related to the technology platform acquired. The total amount was reclassified to “Goodwill and intangible assets, net” in January 2024 with the closing of the agreement (refer to Note 20). ZipDoctor On April 3, 2023, the Company completed the acquisition of ZipDoctor Inc. (“ZipDoctor”), a telehealth company for a total sum of $150,000 in cash and $8,788 in fees. The Company accounted for the acquisition as an asset acquisition in accordance with Accounting Standards Codification (“ASC”) Topic 805, Business Combinations Bikas On June 15, 2023, Cosmos Health Inc. entered into an Assignment and Assumption Agreement (the “Agreement”) with Ioannis Bikas O.E., a Greek Company (“Bikas”). Bikas is owner of a pharmaceutical distribution network in Greece and agreed to sell to the Company their distribution network and customer base. The purchase price of the network was €100,000 ($109,330) of cash, and €300,000 ($316,081) of the Company’s stock. The Company issued 99,710 shares of common stock related to the acquisition of the customer base, based on the fair value of the stock on acquisition date. The Company accounted for the acquisition as an asset acquisition in accordance with ASC 805 and recorded $425,411 as an intangible asset related to the customer base acquired. Buildings Acquisitions On April 24, 2023, the Company purchased a building for a total sum of $1,054,872 in cash. The Company accounted for the acquisition as an asset acquisition in accordance with ASC 805 and recorded the cost of the building as “Property, plant and equipment” on the consolidated balance sheets. On January 6, 2023, the Company agreed to purchase land and building located in Montreal, Canada from a third-party vendor. The total purchase price amounts to $3,950,000 and the closing date of the agreement based on the amendment signed on July 19, 2023, is December 31, 2023. As of December 31, 2023, the Company has made prepayments of $2,000,020 classified as “Advances for building’s acquisition” on the Company’s consolidated balance sheets. Cana On June 30, 2023, the Company acquired Cana Laboratories Holding (Cyprus) Limited (“Cana”), which wholly owned an operating subsidiary, Pharmaceutical Laboratories Cana S.A. (“Cana SA”) for €800,000 ($873,600) in cash and 46,377 shares of common stock, with fair value of $138,667 as of the date of acquisition. Moreover, on February 28, Consideration Cash $ 5,331,120 Fair value of common stock issued 138,667 Fair value of total consideration transferred $ 5,469,787 Recognized amounts of identifiable assets acquired Financial assets $ 1,796,911 Inventory 297,340 Property, plant and equipment 7,488,818 Identifiable intangible assets 562,200 Financial liabilities (3,235,233 ) Total identifiable net assets $ 6,910,036 Bargain purchase gain $ 1,440,249 Revenue for the 6- month period ended December 31, 2023 $ 344,708 Loss for the 6- month period ended December 31, 2023 $ (1,232,732 ) During the prior year period, Cana had minimal operations as it was in financial difficulties and seeking for an investor. Therefore, we consider that presenting prior period pro forma financial information pursuant to ASC 805 would not provide meaningful information. Going Concern The Company’s consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplates the continuation of the Company as a going concern. For the year ended period December 31, 2023, the Company had revenue of $53,376,874, net loss of $18,542,654 and net cash used in operations of $14,998,919. Additionally, as of December 31, 2023, the Company had positive working capital of $12,285,310, an accumulated deficit of $91,644,233, and stockholders’ equity of $36,043,028. It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months from the date of this filing. The Company’s revenues are not able to sustain its operations, and concerns exist regarding the Company’s ability to meet its obligations as they become due. The Company is subject to a number of risks to those of smaller commercial companies, including dependence on key individuals and products, the difficulties inherent in the development of a commercial market, the need to obtain additional capital, competition from larger companies, and other pharmaceutical and health care companies. Management evaluated the above conditions which raise substantial doubt about the Company’s ability to continue as a going concern to determine if it can meet its obligations for the subsequent 12 months from the date of this filing. Management considered its ability to access future capital, curtail expenses if needed, expand product lines, and acquire new products. Management’s plans include expansion of brand name products to the market, expanding the current product portfolio, and evaluating acquisition targets to expand distribution. Furthermore, the Company intends to vertically integrate the supply chain distribution network. Finally, the Company plans to access the capital markets further in order to raise additional funds through equity offerings. More specifically, management will consider postponing the repayment of its outstanding Trade Facility ($1,908,195 balance as of December 31, 2023), intends to make substantial efforts to receive additional debt financing in conjunction with utilizing potential equity proceeds by its outstanding warrants. Moreover, the Company’s management is considering of postponing certain repayments of suppliers and creditors. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described herein and eventually secure other sources of financing and attain profitable operations. Considering the above, management is of the view that substantial doubt exists for the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Dec. 31, 2023
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Financial Statement Presentation The accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP. Principles of Consolidation Our consolidated accounts include our accounts and the accounts of our wholly owned subsidiaries, SkyPharm S.A., Decahedron Ltd., Cosmofarm S.A., Cana Laboratories Holding (Cyprus) Limited and ZipDoctor Inc. The Group’s financial statements are prepared in accordance with U.S. GAAP. The consolidated financial statements reflect the consolidation of all entities in which the Company has control, as determined by the ability to direct the activities that significantly affect the entities’ economic performance. All significant intercompany balances and transactions have been eliminated. Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Effects of War in the Ukraine On February 24, 2022, Russian forces launched significant military action against Ukraine. There continues to be sustained conflict and disruption in the region, which is expected to endure for the foreseeable future. We do not conduct any commercial transactions with either Ukraine or Russia and the Company and, as such, is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Annual Report on Form 10-K. Such political issues and conflicts could have a material adverse effect on our results of operations and financial condition if they escalate in areas in which we do business. In addition, changes in and adverse actions by governments in foreign markets in which we do business could have a material adverse effect on our results of operations and financial condition. Credit Losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments, which amends the requirement on the measurement and recognition of expected credit losses for financial assets held. Furthermore, amendments ASU 2019-10 and ASU 2019-11 provided additional clarification for implementing ASU 2016-13. ASU 2016-13 is effective for the Company beginning January 1, 2023, with early adoption permitted. The Company adopted the standard on January 1, 2023, and the standard did not have a material impact on the Company’s consolidated financial statements and related disclosures. The Company is exposed to credit losses primarily through sales to its customers and the loans that it has provided. The Company assesses each customer’s/ borrower’s ability to pay, and a credit loss estimate by conducting a credit review which includes consideration of established credit rating, or an internal assessment of the customer’s creditworthiness based on an analysis of their payment history when a credit rating is not available. The Company monitors credit exposure through active review of customer balances. The Company’s expected credit loss (“ECL) methodology for accounts receivable is developed through consideration of factors including, but not limited to, historical collection experience, current customer credit ratings, current customer financial condition, current and future economic and market conditions, and age of the receivables. More specifically, the Company assesses a number of customers with significant long outstanding balances on an individual basis, applying different credit loss percentages to them, and subsequently summarizes the ones not included in the individual analysis, groups them based on their rating (decided based on the factors described above) and applies specific credit loss percentages to each group. The Company has elected to follow the simplified ECL approach and for the period ended December 31, 2023 applied a 5% loss rate to all balances outstanding for more than 90 days and 1% loss rate to the total outstanding balance. The charges related to credit losses are included in “General and administrative expenses” and are recorded in the period that the outstanding receivables are determined to be doubtful. Account balances are written-off against the allowance when they are deemed uncollectible. Foreign Currency Translation and Other Comprehensive Loss The functional currency of the Company’s subsidiaries is the Euro and British Pound. For financial reporting purposes, both the Euro (“EUR”) and British Pound (“GBP”) have been translated into United States dollars ($) and/or (“USD”) as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss)”. Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive loss as other comprehensive loss. There have been no significant fluctuations in the exchange rate for the conversion of EUR or GBP to USD after the balance sheet date. Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. As of December 31, 2023 and 2022, the exchange rates used to translate amounts in Euros into USD and British Pounds into USD for the purposes of preparing the consolidated financial statements were as follows: December 31, 2023 December 31, 2022 Exchange rate on balance sheet dates EUR: USD exchange rate 1.1062 1.0698 GBP: USD exchange rate 1.2743 1.2077 Average exchange rate for the period EUR: USD exchange rate 1.0817 1.0534 GBP: USD exchange rate 1.2440 1.2371 Cash and Cash Equivalents For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of December 31, 2023 and December 31, 2022, there were no cash equivalents. The Company maintains bank accounts in the United States denominated in U.S. Dollars, in Greece denominated in Euros, U.S. Dollars and Great Britain Pounds (British Pounds Sterling), and in Bulgaria denominated in Euros. The Company also maintains bank accounts in the United Kingdom, denominated in Euros and Great Britain Pounds (British Pounds Sterling). As of December 31, 2023 and 2022, the aggregate amount in these foreign accounts were $1,047,738 and $831,793, respectively. Additionally, as of December 31, 2023 and 2022, the Company had cash on hand in the amount of $48,590 and $15,690, respectively. Reclassifications to Prior Year Financial Statements and Adjustments Certain reclassifications have been made in the Company’s financial statements of the prior year to conform with current year presentation. As of December 31, 2022, $421,302, $322,010, $120,294 and $66,401 (an aggregate total of $930,006) was reclassified from “Prepaid expenses and other current assets,” “Other assets,” “Accounts receivable – related party,” and “Prepaid expenses and other current assets – related party,” respectively to “Accounts receivable, net”. Moreover, $248,678 was reclassified from “Financing lease right-of-use asset” to “Operating lease right-of-use asset” and $247,595 was reclassified from Financing Lease Liabilities to Operating Lease Liabilities as of the year ended, December 31, 2022. Finally, an amount of $1,784,751 was reclassified from “Accounts payable and accrued expenses” to “Other current liabilities” as of the year ended, December 31, 2022. These reclassifications had no impact on earnings or stockholders’ equity. Accounts Receivable & Allowance for Doubtful Accounts Accounts receivable are stated at their net realizable value. The allowance for credit losses against gross accounts receivable reflects the best estimate of probable losses inherent in the receivables’ portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. As of December 31, 2023 and 2022, the Company’s allowance for credit losses was $19,686,091 and $7,309,311, respectively. Below is the summary of changes in the allowance for doubtful accounts: December 31, 2023 Balance as of January 1, 2023 $ 7,309,311 Provisions for credit losses 11,850,788 Write-offs - Foreign exchange adjustments 525,992 Other adjustments - Balance as of December 31, 2023 $ 19,686,091 Tax Receivables The Company pays Value Added Tax (“VAT”) or similar taxes (“input VAT”), income taxes, and other taxes within the normal course of its business in most of the countries in which it operates related to the procurement of merchandise and/or services it acquires and/or on sales and taxable income. The Company also collects VAT or similar taxes on behalf of the government (“output VAT”) for merchandise and/or services it sells. If the output VAT exceeds the input VAT, this creates a VAT payable to the government. If the input VAT exceeds the output VAT, this creates a VAT receivable from the government. The VAT tax return is filed on a monthly basis offsetting the payables against the receivables. In observance of EU regulations for intra-EU cross-border sales, our subsidiaries in Greece, SkyPharm and Cosmofarm, do not charge VAT for sales to wholesale drug distributors registered in other European Union member states. As of December 31, 2023 and 2022, the Company had a VAT net receivable balance of $187,512 and a net receivable balance of $79,373 respectively, recorded in the consolidated balance sheet as prepaid expenses and other current assets and accounts payable and accrued expenses, respectively. Inventories Inventory is stated at the lower-of-cost or net realizable value using the weighted average method. Inventory consists primarily of finished goods and packaging materials, i.e., packaged pharmaceutical products and the wrappers and containers they are sold in. A periodic inventory system is maintained by 100% count. Inventory is replaced periodically to maintain the optimum stock on hand available for immediate shipment. The Company writes down inventories to net realizable value based on physical condition, expiration date, current market conditions, as well as forecasted demand. The Company’s inventories are not highly susceptible to obsolescence. Many of the Company’s inventory items are eligible for return to our suppliers when pre-agreed product requirements, including, but not limited to, physical condition and expiration date, are not met. No significant judgments have been applied in estimating the selling price of our inventory. Property and Equipment, net Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated on a straight-line basis over the useful lives (except for leasehold improvements which are depreciated over the lesser of the lease term or the useful life) of the assets as follows: Estimated Useful Life Leasehold improvements and technical works Lesser of lease term or 25 years Buildings 25-30 years Vehicles 6 years Machinery 20 years Furniture, fixtures and equipment 5–10 years Computers and software 3-5 years Depreciation expense was $353,043 and $70,109 for the years ended December 31, 2023 and 2022, respectively. Property and Equipment additions Property and Equipment additions are recognized as assets when it is probable that future economic benefits associated with the asset will flow to the entity and the cost of the asset can be measured reliably. Additions are initially measured at cost, which includes all costs directly attributable to bringing the asset to its working condition and location for its intended use. This may include purchase price, freight, installation, and any directly attributable professional fees. They are capitalized if their cost exceeds a certain threshold. The threshold is determined based on materiality considerations. Costs below the threshold are typically expensed as incurred. After initial recognition, additions are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is calculated systematically over the estimated useful life of the asset. They are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If the carrying amount exceeds the recoverable amount, an impairment loss is recognized, and the carrying amount of the asset is adjusted accordingly. Borrowing costs directly attributable to the acquisition, construction, or production of qualifying assets, including Property and Equipment additions, are capitalized as part of the cost of those assets. Impairment of Long-Lived Assets In accordance with ASC 360-10, Long-lived Assets, property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. For the years ended December 31, 2023 and 2022, the Company had no impairment of long-lived assets. Goodwill and Intangibles, net The Company periodically reviews the carrying value of intangible assets not subject to amortization, including goodwill, to determine whether impairment may exist. Goodwill and certain intangible assets are assessed annually, or when certain triggering events occur, for impairment using fair value measurement techniques. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. First, under step 0, we determine whether it is more likely than not that the fair value of the reporting unit is less than the carrying amount. Following, if step 0 fails, goodwill impairment is determined using a two-step process. The first step of the goodwill impairment test is used to identify potential impairment by comparing the fair value of a reporting unit with its carrying amount, including goodwill. The Company uses level 3 inputs and a discounted cash flow methodology to estimate the fair value of a reporting unit. A discounted cash flow analysis requires one to make various judgmental assumptions including assumptions about future cash flows, growth rates, and discount rates. The assumptions about future cash flows and growth rates are based on the Company’s budget and long-term plans. Discount rate assumptions are based on an assessment of the risk inherent in the respective reporting units. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired and the second step of the impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit. On December 19, 2018, as a result of the acquisition of Cosmofarm, the Company recorded $49,697 of goodwill. Intangible assets with definite useful lives are recorded on the basis of cost and are amortized on a straight-line basis over their estimated useful lives. The Company uses a useful life of 5 years for an import/export license and a useful life of ten years for the pharmaceutical and nutraceutical products licenses included in Note 4 as “Licenses”. A useful life of ten years is also used for the platforms included in Note 4 as “Software” and the customer bases. The Company evaluates the remaining useful life of intangible assets annually to determine whether events and circumstances warrant a revision to the remaining amortization period. If the estimate of the intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over that revised remaining useful life. As of December 31, 2023, no revision to the remaining amortization period of the intangible assets was made. Amortization expense was $239,841 and $33,085 for the years ended December 31, 2023 and 2022, respectively. Equity Method Investment For those investments in common stock or in-substance common stock in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee, the investment is accounted for under the equity method. The Company records its share in the earnings of the investee and is included in “Equity earnings of affiliate” in the consolidated statement of operations. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognizes an impairment loss to adjust the investment to its then current fair value. Investments in Equity Securities Investments in equity securities are accounted for at fair value with changes in fair value recognized in net income (loss). Equity securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Equity securities that are readily available for sale in current operations are reported as a component of current assets in the accompanying consolidated balance sheets. Equity securities that are not considered available for use in current operations would be reported as a component of long-term assets in the accompanying consolidated balance sheets. For equity securities with no readily determinable fair value, the Company elects a measurement alternative to fair value. Under this alternative, the Company measures the investments at cost, less any impairment, and adjusted for changes resulting from observable price changes in transactions for identical or similar investments of the investee. The election to use the measurement alternative is made for each eligible investment. As of December 31, 2023, investments consisted of (i) 3,000,000 shares, which traded at a closing price of $0 per share or a value of $0 of ICC International Cannabis Corp and (ii) 16,666 shares which traded at a closing price of $0.70 per share or value of $11,596 of National Bank of Greece. Additionally, the Company has $8,479 in equity securities of Pancreta Bank, which are revalued annually. As of December 31, 2022, investments consisted of (i) 3,000,000 shares, which traded at a closing price of $0 per share or a value of $0 of ICC International Cannabis Corp and (ii) 16,666 shares which traded at a closing price of $0.40 per share or value of $6,681 of National Bank of Greece. Additionally, the Company has $8,200 in equity securities of Pancreta Bank, which are revalued annually. See Note 2 for additional investments in equity securities. Fair Value Measurement The Company applies ASC 820, Fair Value Measurements and Disclosures, (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements establishes a framework for measuring fair value and expands disclosure about such fair value measurements. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. The following table presents assets that are measured and recognized at fair value as of December 31, 2023 and 2022, on a recurring basis: December 31, 2023 Total Carrying Level 1 Level 2 Level 3 Value Marketable securities – ICC International Cannabis Corp. $ - - - $ - Marketable securities – National Bank of Greece 11,596 - - 11,596 $ 11,596 $ 11,596 December 31, 2022 Total Carrying Level 1 Level 2 Level 3 Value Marketable securities – ICC International Cannabis Corp. $ - - - $ - Marketable securities – National Bank of Greece 6,681 - - 6,681 $ 6,681 $ 6,681 In addition, ASC 825-10-25, Fair Value Option, (“ASC 825-10-25”), expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments. Our financials also included the following financial instruments as of December 31, 2023: cash, accounts receivable, inventory, prepaid expenses, loans receivable, accounts payable, notes payable and lines of credit. Except for the loans receivable which carry fixed interest rates, the carrying value of the remaining instruments, approximates fair value due to their short-term nature. Derivative Instruments Derivative financial instruments are recorded in the accompanying consolidated balance sheets at fair value in accordance with ASC 815. When the Company enters into a financial instrument such as a debt or equity agreement (the “host contract”), the Company assesses whether the economic characteristics of any embedded features are clearly and closely related to the primary economic characteristics of the remainder of the host contract. When it is determined that (i) an embedded feature possesses economic characteristics that are not clearly and closely related to the primary economic characteristics of the host contract, and (ii) a separate, stand-alone instrument with the same terms would meet the definition of a financial derivative instrument, then the embedded feature is bifurcated from the host contract and accounted for as a derivative instrument. The estimated fair value of the derivative feature is recorded in the accompanying consolidated balance sheets separately from the carrying value of the host contract. Subsequent changes in the estimated fair value of derivatives are recorded as a gain or loss in the Company’s consolidated statements of operations. Customer Advances The Company receives prepayments from certain customers for pharmaceutical products prior to those customers taking possession of the Company’s products. The Company records these receipts as current liabilities until it has met all the criteria for recognition of revenue including passing control of the products to its customer, at such point, the Company will reduce the customer advances balance and credit the Company’s revenues. Revenue Recognition In accordance with ASC Topic 606, Revenue from Contracts with Customers 1) Identification of the Contract: The Company identifies a contract with a customer when it enters into an agreement that creates enforceable rights and obligations. 2) Identification of Performance Obligations: The Company identifies distinct performance obligations within each contract, which represent promises to transfer goods or services to the customer. 3) Determination of Transaction Price: The Company determines the transaction price, which represents the amount of consideration to which it expects to be entitled in exchange for transferring promised goods or services to the customer, excluding any amounts collected on behalf of third parties. 4) Allocation of Transaction Price: The Company allocates the transaction price to each distinct performance obligation based on its standalone selling price. If the standalone selling price is not observable, the Company estimates it using an appropriate method. 5) Recognition of Revenue: Revenue is recognized when (or as) the Company satisfies a performance obligation by transferring a promised good or service to the customer. This typically occurs at a point in time or over time, depending on the nature of the performance obligation. Wholesale revenue and sales of own branded nutraceutical and pharmaceutical products The Company has contracts or signed partnership forms (usual in the wholesale sector of the pharma industry) with its customers, stipulating the enforceable rights and obligations. The Company is responsible for transferring the goods to the customer’s location, which represents its sole performance obligation. Thus, the transaction price, which is predetermined in most of the products sold, is exclusively allocated to this performance obligation. Revenue is recognized at a single point in time, which is upon issuance of the corresponding sales invoice. The Company has assessed the impact of the items invoiced but not delivered to the customer’s location as of December 31, 2023, and deemed that it had no material effect. Pharma manufacturing The Company has active contracts with its customers, stipulating the enforceable rights and obligations. The Company is responsible for the manufacturing and the packaging of specific products assigned by its customers, which represents its performance obligations to which the Company allocates the transaction price determined. The customers are responsible for providing the raw materials to the Company. Revenue is recognized over a period of time, which is during the production and packaging period of the respective products. As of December 31, 2023 there were no products or batches of products for which the production or packaging phase was in progress. Medihelm SA Commencing from January 1, 2023, and pursuant to the agreement with Medihelm, the exclusive distributor of the Company’s own proprietary line of nutraceuticals, the Company considers the transaction price to be variable and records an estimate of the transaction price, subject to the constraint for variable consideration. The Company is basing the change in transaction price with the exclusive distributor through assessment of significant overdue receivables from the exclusive distributor, which the Company reassesses each reporting period. Through this assessment, the Company applied the “expected value” model under ASC 606-10-32-5 and had applied specific constraints to revenue due from the customer at the end of each reporting period. Following the application of the “expected value” model, the Company deferred an amount of $397,000 and recorded it against the sales to Medihelm for the year ended December 31, 2023. The Company does not consider that sales to any other customer include a variable component as of December 31, 2023. Stock-based Compensation The Company records stock-based compensation in accordance with ASC 718, Stock Compensation (“ASC 718”) and Staff Accounting Bulletin No. 107 (“SAB 107”) regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock-based compensation at fair value using the Black-Scholes Option Pricing Model. The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASU 2018-07, “Compensation-Stock Compensation-Improvements to Nonemployee Share-Based Payment Accounting.” Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash investments and accounts receivable. The Company had no clients which contributed 10% or more of revenue and accounts receivable, respectively for the year ended December 31, 2023. Income Taxes The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company is liable for income taxes in Greece and the United Kingdom. The corporate income tax rate is 22% in Greece and 25% in the United Kingdom. Losses may also be subject to limitation under certain rules regarding change of ownership. We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. At December 31, 2023, we believe our United Kingdom and Greece deferred tax assets will not be realized, as such, we did not record a reversal on the full valuation approach we followed during the period ended December 31, 2022. Leases The Company accounts for leases in accordance with ASC 842. For all leases, the Company recognizes a right-of-use (ROU) asset and a lease liability on the balance sheet. The ROU asset represents the Company’s right to use the underlying asset for the lease term, and the lease liability represents the obligation to make lease payments arising from the lease, both measured at the present value of future lease payments. Lease payments are recognized as an operating expense on a straight-line basis over the lease term. The interest on the lease liability and the amortization of the ROU asset are recognized separately in the income statement

EQUITY METHOD INVESTMENTS

EQUITY METHOD INVESTMENTS	9 Months Ended	12 Months Ended
EQUITY METHOD INVESTMENTS	Sep. 30, 2024	Dec. 31, 2023
EQUITY METHOD INVESTMENTS
EQUITY METHOD INVESTMENTS	NOTE 3 – EQUITY METHOD INVESTMENTS Distribution and Equity Agreement On March 19, 2018, the Company entered into a Distribution and Equity Acquisition Agreement with Marathon Global Inc. (“Marathon”), a company incorporated in the Province of Ontario, Canada. Marathon was formed to be a global supplier of cannabis, cannabidiol (CBD) and/or any cannabis extract products, extracts, ancillaries and derivatives (collectively, the “Products”). The Company was appointed the exclusive distributor of the Products initially throughout Europe and on a non-exclusive basis wherever else lawfully permitted. The Company has no present intention to distribute any Products under this Agreement in the United States or otherwise participate in cannabis operations in the United States. The Company intended to await further clarification from the U.S. government on cannabis regulation prior to determining whether to enter the domestic market. The above transaction closed on May 22, 2018 after the due diligence period, following which the Company received: (a) a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in common shares of the Company if it failed to meet certain performance milestones. The Company was entitled to receive an additional CAD $2,750,000 upon the Company’s receipt of gross sales of CAD $6,500,000 and an additional CAD $2,750,000 upon receipt of gross sales of CAD $13,000,000. The Company was also given the right to nominate one director to the Marathon board of directors. Since Marathon was a newly formed entity with no assets and no activity, the Company attributed no value to the 5 million shares in Marathon which was received as consideration for the distribution services. The Distribution and Equity Acquisition Agreement was to remain in effect indefinitely unless Marathon fails to provide Market Competitive (as defined) product pricing and Marathon has not become profitable within five (5) years of the agreement. On March 20, 2023, the Company sent a termination notice, to Marathon, which became effective on April 19, 2023 as a result of Marathon’s failure to satisfy these conditions. The Company had accounted for its obligation to issue a variable number of the Company’s Common Shares as Share-settled debt obligation in accordance with ASC Topic 480, Distinguishing Liabilities from Equity CosmoFarmacy LP In September 2019, the Company entered into an agreement with an unaffiliated third party to incorporate CosmoFarmacy L.P. for the purpose of providing strategic management consulting services and the retail trade of pharmaceutical products, and OTC to pharmacies. CosmoFarmacy was incorporated with a 30-year term through May 31, 2049. The unaffiliated third party is the general partner (the “GP”) of the limited partnership and is responsible for management and decision-making associated with CosmoFarmacy. The initial share capital was set to EUR 150,000 ($163,080) which was later increased to EUR 500,000 ($543,600). The GP contributed the pharmacy license (the “License”) valued at EUR 350,000 (30-year term) to operate the business of CosmoFarmacy in exchange for a 70% equity ownership. The Company is a limited partner and contributed cash of EUR 150,000 ($163,080) for the remaining 30% equity ownership. CosmoFarmacy is not publicly traded and the Company’s investment has been recorded using the equity method of accounting. The value of the investment as of September 30, 2024 and December 31, 2023, was $167,175 and $165,930, respectively, and is included in “Other assets” on the Company’s consolidated balance sheets.	NOTE 3 –EQUITY METHOD INVESTMENTS Distribution and Equity Agreement On March 19, 2018, the Company entered into a Distribution and Equity Acquisition Agreement with Marathon Global Inc. (“Marathon”), a company incorporated in the Province of Ontario, Canada. Marathon was formed to be a global supplier of cannabis, cannabidiol (CBD) and/or any cannabis extract products, extracts, ancillaries and derivatives (collectively, the “Products”). The Company was appointed the exclusive distributor of the Products initially throughout Europe and on a non-exclusive basis wherever else lawfully permitted. The Company has no present intention to distribute any Products under this Agreement in the United States or otherwise participate in cannabis operations in the United States. The Company intended to await further clarification from the U.S. Government on cannabis regulation prior to determining whether to enter the domestic market. The above transaction closed on May 22, 2018 after the due diligence period, following which the Company received: (a) a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in common shares of the Company if it failed to meet certain performance milestones. The Company was entitled to receive an additional CAD $2,750,000 upon the Company’s receipt of gross sales of CAD $6,500,000 and an additional CAD $2,750,000 upon receipt of gross sales of CAD $13,000,000. The Company was also given the right to nominate one director to the Marathon board of directors. Since Marathon was a newly formed entity with no assets and no activity, the Company attributed no value to the 5 million shares in Marathon which was received as consideration for the distribution services. The Distribution and Equity Acquisition Agreement was to remain in effect indefinitely unless Marathon fails to provide Market Competitive (as defined) product pricing and Marathon has not become profitable within five years of the agreement. On March 20, 2023, the Company sent a termination notice, to Marathon, which became effective on April 19, 2023 as a result of Marathon’s failure to satisfy these conditions. The Company had accounted for its obligation to issue a variable number of the Company’s Common Shares as Share-settled debt obligation in accordance with ASC Topic 480, Distinguishing Liabilities from Equity CosmoFarmacy LP In September 2019, the Company entered into an agreement with an unaffiliated third party to incorporate CosmoFarmacy L.P. for the purpose of providing strategic management consulting services and the retail trade of pharmaceutical products, and OTC to pharmacies. CosmoFarmacy was incorporated with a 30-year term through May 31, 2049. The unaffiliated third party is the general partner (the “GP”) of the limited partnership and is responsible for management and decision-making associated with CosmoFarmacy. The initial share capital was set to EUR 150,000 ($163,080) which was later increased to EUR 500,000 ($543,600). The GP contributed the pharmacy license (the “License”) valued at EUR 350,000 (30-year term) to operate the business of CosmoFarmacy in exchange for a 70% equity ownership. The Company is a limited partner and contributed cash of EUR 150,000 ($163,080) for the remaining 30% equity ownership. CosmoFarmacy is not publicly traded and the Company’s investment has been recorded using the equity method of accounting. The value of the investment as of December 31, 2023 and December 31, 2022, was $165,930 and $160,470, respectively, and is included in “Other assets” on the Company’s consolidated balance sheets.

PROPERTY AND EQUIPMENT, NET

PROPERTY AND EQUIPMENT, NET	9 Months Ended	12 Months Ended
PROPERTY AND EQUIPMENT, NET	Sep. 30, 2024	Dec. 31, 2023
PROPERTY AND EQUIPMENT, NET
PROPERTY AND EQUIPMENT, NET	NOTE 4 – PROPERTY AND EQUIPMENT, NET Property and equipment, net consists of the following at September 30, 2024 and December 31, 2023: September 30, 2024 December 31, 2023 Land $ 3,577,662 $ 3,551,020 Buildings and improvements 4,868,378 4,787,963 Leasehold improvements 3,667 3,639 Vehicles 285,609 285,388 Furniture, fixtures and equipment 3,014,683 2,707,442 Computers and software 203,215 168,173 11,953,214 11,503,625 Less: Accumulated depreciation and amortization (1,377,286 ) (1,048,126 ) Total $ 10,575,928 $ 10,455,499	NOTE 4 – PROPERTY AND EQUIPMENT, NET Property and equipment, net consists of the following at December 31, 2023 and 2022: 2023 2022 Land $ 3,551,020 $ - Buildings and improvements 4,787,963 - Leasehold improvements 3,639 502,882 Vehicles 285,388 107,976 Furniture, fixtures and equipment 2,707,442 1,945,207 Computers and software 168,173 138,783 11,503,625 2,694,848 Less: Accumulated depreciation and amortization (1,048,126 ) (877,823 ) Total $ 10,455,499 $ 1,817,025

INTANGIBLE ASSETS

INTANGIBLE ASSETS	9 Months Ended	12 Months Ended
INTANGIBLE ASSETS	Sep. 30, 2024	Dec. 31, 2023
INTANGIBLE ASSETS
INTANGIBLE ASSETS	NOTE 5 – INTANGIBLE ASSETS Goodwill and intangible, net assets consist of the following at September 30, 2024 and December 31, 2023: September 30, 2024 December 31, 2023 License $ 6,976,209 $ 6,876,169 Trade name / mark 390,188 392,197 Customer base 602,204 602,204 Software 795,867 158,787 8,764,468 8,029,357 Less: Accumulated amortization License (805,555 ) (235,925 ) Trade name / mark (36,997 ) (36,997 ) Customer base (157,333 ) (110,160 ) Software (67,520 ) (11,789 ) Subtotal 7,697,064 7,634,486 Goodwill 49,697 49,697 Total $ 7,746,761 $ 7,684,183 At September 30, 2024, the estimated aggregate amortization expense for intangible assets subject to amortization for each of the five succeeding fiscal years is as follows: Year Amount 2024 $ 208,530 2025 833,637 2026 834,846 2027 834,846 2028 783,423 Thereafter 3,846,582 Total $ 7,341,864	NOTE 5 – INTANGIBLE ASSETS Intangible assets consist of the following at December 31, 2023 and 2022: 2023 2022 License $ 6,876,169 $ 643,204 Trade name / mark 392,197 36,997 Customer base 602,204 176,793 Software 158,788 - 8,029,358 856,994 Less: Accumulated amortization License (235,925 ) (98,686 ) Trade name / mark (36,997 ) (29,881 ) Customer base (110,161 ) (71,210 ) Software (11,789 ) - Subtotal 7,634,486 657,217 Goodwill 49,697 49,697 Total $ 7,684,183 $ 706,914 At December 31, 2023, the estimated aggregate amortization expense for intangible assets subject to amortization for each of the five succeeding fiscal years is as follows: Year Amount 2024 $ 763,292 2025 763,026 2026 764,213 2027 764,213 2028 735,772 Thereafter 3,488,769 Sum $ 7,279,285

LOAN RECEIVABLE

LOAN RECEIVABLE	9 Months Ended	12 Months Ended
LOAN RECEIVABLE	Sep. 30, 2024	Dec. 31, 2023
LOAN RECEIVABLE
LOAN RECEIVABLE	NOTE 6 – LOAN RECEIVABLE On October 30, 2021, the Company entered into an agreement for a ten-year loan with Medihelm SA to memorialize €4,284,521 ($4,849,221) in prepayments the Company had made. The prepayments to Medihelm SA had been made in accordance with the parallel export business, through which Medihelm supplied and would supply SkyPharm SA with branded pharmaceuticals. This business is no longer in place for the Company and thus the Company entered into this agreement with Medihelm SA in order for the outstanding amount to be settled. Interest is calculated at a rate of 5.5% per annum on a 360-day basis. Under the terms of the agreement, the Company is to receive 120 equal payments over the term of the loan. During the year ended December 31, 2023, the Company received €352,438 ($389,867) in principal payments such that as of December 31, 2023, the Company had a short-term receivable balance of $411,858 and a long-term receivable balance of $3,509,200 under this loan. The Company also received €223,914 ($249,552) in principal payments and €107,144 ($119,411) in interest payments during the nine-month period ended September 30, 2024. The Note is considered fully recoverable.	NOTE 6 – LOAN RECEIVABLE On October 30, 2021, the Company entered into an agreement for a ten-year loan with Medihelm SA to memorialize €4,284,521 ($4,849,221) in prepayments the Company had made. The prepayments to Medihelm SA had been made in accordance with the parallel export business, through which Medihelm supplied and would supply SkyPharm SA with branded pharmaceuticals. This business is no longer in place for the Company and thus the Company entered into this agreement with Medihelm SA in order for the outstanding amount to be settled. Interest is calculated at a rate of 5.5% per annum on a 360-day basis. Under the terms of the agreement, the Company is to receive 120 equal payments over the term of the loan. As of December 31, 2022, the Company had a short-term receivable balance of $377,038 and a long-term receivable balance of $3,792,034 under this loan. During the year ended December 31, 2023, the Company received €352,438 ($389,867) in principal payments such that as of December 31, 2023, the Company had a short-term receivable balance of $411,858 and a long-term receivable balance of $3,509,200 under this loan. The Company also received €174,711 ($193,265) in interest payments during year ended December 31, 2023. The Note is considered fully recoverable and all capital and interest repayments due as of December 31, 2023 have been settled.

CAPITAL STRUCTURE

CAPITAL STRUCTURE	9 Months Ended	12 Months Ended
CAPITAL STRUCTURE	Sep. 30, 2024	Dec. 31, 2023
CAPITAL STRUCTURE
CAPITAL STRUCTURE	NOTE 8 – CAPITAL STRUCTURE Preferred Stock The Company is authorized to issue 100 million shares of preferred stock, of which 6,000,000 are designated as Series A convertible preferred stock. The preferred stock has a liquidation preference over the common stock and is non-voting. As of September 30, 2024 and December 31, 2023, no preferred shares were issued and outstanding. Major Rights & Preferences of Series A Preferred Stock On and effective October 4, 2021, the Company amended and restated its articles of incorporation (the “Amended and Restated Articles”) and filed a certificate of designation (the “COD”) for its Series A Preferred Stock (the “Series A Preferred Stock”) with the State of Nevada. The Amended and Restated Articles allow the Company’s Board of Directors the authority to authorize the issuance of preferred stock from time to time in one or more classes or series by resolution. On February 23, 2022, the Company filed Correction No. 1 to the COD. On July 28, 2022, the Company filed an Amendment to the COD with the State of Nevada to allow a holder to waive application of the Beneficial Ownership Limitation with respect to the conversion of Series A Preferred Stock. With respect to payment of dividends and distribution of assets upon liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary, all shares of the Series A Preferred Stock will rank: (i) senior to all of the Company’s Common Stock and any other equity securities that the Company may issue in the future, (ii) equal to any other equity securities that the Company may issue in the future, the terms of which specifically provide that such equity securities are on parity or senior to the Series A Preferred Stock (“Parity Securities”), (iii) junior to all other equity securities the Company issues, the terms of which specifically provide that such equity securities rank senior to the Series A Preferred Stock, and (iv) junior to all of the Company’s existing and future indebtedness; without the prior written consent of the Majority Holders. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company (a “Liquidation”), the Holders of shares of Series A Preferred Stock shall be first entitled to receive out of the assets of the Company available for distribution to its shareholders. Each Holder shall not be entitled to vote with holders of outstanding shares of Common Stock, voting together as a single class, with respect to any and all matters presented to the stockholders of the Company for their action or consideration, except as provided by law or as set forth in the COD. The holders of Series A Preferred Stock are entitled to receive dividends paid and distributions made to the holders of Common Stock to the same extent as if the holders of Series A Preferred Stock had converted such shares into shares of Common Stock. The Series A Preferred Stock was initially convertible into the Company’s Common Stock as determined by dividing the number of shares of Series A Preferred Stock to be converted by the lower of (i) $75.00 or (ii) 80% of the average volume weighted average price for the Company’s Common Stock for the five trading days immediately following the effectiveness of the registration statement concerning the shares (the “Conversion Price”). On June 14, 2022, the Conversion Price was reset to $15.54 per share. Each holder is entitled to receive dividends in shares of Series A Preferred Stock or cash determined based on the stated value of each Series A Preferred Stock at the dividend rate of 8.0% per year. For the year ended December 31, 2022, the Company recorded $372,414 as a deemed dividend in accordance with the Series A Preferred Stock cumulative dividend. As of December 31, 2022, the cumulative dividend has been recorded as mezzanine equity. Following, Mr. Siokas waiver of the right to receive the dividends on February 26, 2024, and the unanimous written consent of the Company’s Board of Directors on February 29, 2024, through which was resolved that the Company shall remove all accrued and unpaid dividends payable to the previous holders of Series A Preferred stock, the Company eliminated the total deemed dividend of $372,414 through retained earnings. Thus, the balance of mezzanine equity as of September 30, 2024, and December 31, 2023 is $0. The Series A Shares rank senior to all of the Company’s Common Stock and any other equity securities that the Company may issue in the future with respect to payment of dividends and distribution of assets upon liquidation, dissolution or winding up. While the Series A Shares are outstanding, the Company may not amend, alter or change adversely the powers, preferences or rights given to the Series A Shares, create, or authorize the creation of, any additional class or series of capital stock of the Company (or any security convertible into or exercisable for any class or series of capital stock of the Company), including any class or series of capital stock of the Company that ranks superior to or in parity with the Series A Shares, alter, amend, modify, or repeal its Articles of Incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series A Shares, increase or decrease the number of authorized shares of Series A Shares, any agreement, commitment or transaction that would result in a Change of Control, any sale or disposition of any material assets outside of the ordinary course of business of the Company, any material change in the principal business of the Company, including the entry into any new line of business or exit of any current line of business, and circumvent a right or preference of the Series A Shares. Any holder of the Series A Shares shall have the right by written election to the Company to convert all or any portion of the outstanding Series A Shares. Immediately upon effectiveness of a registration statement registering for resale all of the Registrable Securities (as defined in the Registration Rights Agreement), all outstanding Series A Shares shall automatically convert into Common Stock, subject to certain beneficial ownership limitations. Treasury stock As of September 30, 2024 and December 31, 2023, the Company held 86,497 and 86,497, respectively, shares of our common stock at a cost of $917,159 and $917,159, respectively. Shares of our common stock that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. Cosmos may repurchase shares from time to time through open market purchases in accordance with applicable securities laws and other restrictions. The Company repurchased no shares of our common stock during the nine months ended September 30, 2024. The Company repurchased 71,000 shares of our common stock for $100,452 during the year ended December 31, 2023. The Company repurchased no shares of our common stock during the nine months ended September 30, 2024. On January 24, 2023 the Company announced that its Board of Directors has approved a share repurchase program with authorization to purchase up to $3 million of its common stock. Cosmos may repurchase shares from time to time through open market purchases in accordance with applicable securities laws and other restrictions. Common Stock The Company is authorized to issue 300 million shares of common stock. As of September 30, 2024 and December 31, 2023, the Company had 17,834,023 and 15,982,472 shares of our common stock issued, respectively, and 21,346,023 and 15,895,975 shares outstanding, respectively. Issuance of Common Stock During the nine-month period ended September 30, 2023 the Company issued 15,258 shares to a consultant for services rendered. The shares were valued and expensed on the date of issuance and are separately presented in the condensed consolidated statement of changes in stockholders’ equity and mezzanine as “Shares issued in lieu of cash”. During the nine months ended September 30, 2024, the Company raised additional equity funds through two Prospectus Supplements to its Registration Statement on Form S-3 (No. 333-267550) filed with the SEC on February 29 and March 7, 2024. More specifically, the Company sold 901,488 shares of common stock for gross proceeds of $648,893. Placement agent’s fees and other commissions amounted to $19,467 and thus the total net proceeds for the period were $629,426. On December 29, 2023, the Company had entered into a warrant exchange agreement (the “Warrant Exchange”) with an investor to reduce the exercise price of 2,437,063 warrants from $2.75 per share to $1.45 per shares as an inducement to exercise. The Company issued 1,487,000 shares of common stock, held 950,063 shares in escrow until the investor’s beneficial ownership limitation allows for the transfer of the escrow shares, and received gross cash proceeds of 3,533,741. The 950,063 shares were issued within the nine-month period ended September 30, 2024 but were already valued in the year ended December 31, 2023. On September 26, 2024, the Company entered into a Warrant Inducement Letter (the “Letter”) with an investor pursuant to which the Company issued 9,748,252 new warrants (the “New Warrants”) and reduced the exercise price of 4,874,126 warrant shares from $1.45 to $0.8701 to induce exercise and receive gross cash proceeds of $4,240,977 (the “Original Warrants”). The Company issued 2,332,000 shares of common stock, held 2,532,126 shares in escrow until the investor’s beneficial ownership limitation allows for the transfer of the escrow shares. Exercise of Warrants During the nine months ended September 30, 2024, the Company issued 2,332,000 shares of common stock upon the exercise of 2,332,000 warrants. The Company received gross proceeds of $4,240,977 upon exercise. The net proceeds after deducting legal, agent and escrow fees of $372,109 amounted to $3,868,868. The warrants were exercised following the Warrant Inducement letter the Company signed on September 26, 2024, through which their exercise price was reduced from $1.45 to $0.8701. Warrant Classification The Company determines the classification of its warrants upon issuance by identifying the instrument issued to determine if it is debt or equity classified. The Company determined its warrants meet the scope exception in ASC 815-10 and are equity classified because, (a) the warrant is indexed to the Company’s own stock, (b) require settlement in equity shares, and (c) the Company has enough authorized and unissued shares.	NOTE 7 – CAPITAL STRUCTURE Preferred Stock The Company is authorized to issue 100 million shares of preferred stock, of which 6,000,000 are designated as Series A convertible preferred stock. The preferred stock has a liquidation preference over the common stock and is non-voting. As of December 31, 2023 and 2022, all Series A convertible preferred stock had been converted and no preferred shares were issued and outstanding. Major Rights & Preferences of Series A Preferred Stock On and effective October 4, 2021, the Company amended and restated its articles of incorporation (the “Amended and Restated Articles”) and filed a certificate of designation (the “COD”) for its Series A Preferred Stock (the “Series A Preferred Stock”) with the State of Nevada. The Amended and Restated Articles allow the Company’s Board of Directors the authority to authorize the issuance of preferred stock from time to time in one or more classes or series by resolution. On February 23, 2022, the Company filed Correction No. 1 to the COD. On July 28, 2022, the Company filed an Amendment to the COD with the State of Nevada to allow a holder to waive application of the Beneficial Ownership Limitation with respect to the conversion of Series A Preferred Stock. With respect to payment of dividends and distribution of assets upon liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary, all shares of the Series A Preferred Stock will rank: (i) senior to all of the Company’s Common Stock and any other equity securities that the Company may issue in the future, (ii) equal to any other equity securities that the Company may issue in the future, the terms of which specifically provide that such equity securities are on parity or senior to the Series A Preferred Stock (“Parity Securities”), (iii) junior to all other equity securities the Company issues, the terms of which specifically provide that such equity securities rank senior to the Series A Preferred Stock, and (iv) junior to all of the Company’s existing and future indebtedness; without the prior written consent of the Majority Holders. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company (a “Liquidation”), the Holders of shares of Series A Preferred Stock shall be first entitled to receive out of the assets of the Company available for distribution to its shareholders. Each Holder shall not be entitled to vote with holders of outstanding shares of Common Stock, voting together as a single class, with respect to any and all matters presented to the stockholders of the Company for their action or consideration, except as provided by law or as set forth in the COD. The holders of Series A Preferred Stock are entitled to receive dividends paid and distributions made to the holders of Common Stock to the same extent as if the holders of Series A Preferred Stock had converted such shares into shares of Common Stock. The Series A Preferred Stock was initially convertible into the Company’s Common Stock as determined by dividing the number of shares of Series A Preferred Stock to be converted by the lower of (i) $75.00 or (ii) 80% of the average volume weighted average price for the Company’s Common Stock for the five trading days immediately following the effectiveness of the registration statement concerning the shares (the “Conversion Price”). On June 14, 2022, the Conversion Price was reset to $15.54 per share. Each holder is entitled to receive dividends in shares of Series A Preferred Stock or cash determined based on the stated value of each Series A Preferred Stock at the dividend rate of 8.0% per year. For the year ended December 31, 2022, the Company recorded $372,414 as a deemed dividend in accordance with the Series A Preferred Stock cumulative dividend. As of December 31, 2022, the cumulative dividend has been recorded as mezzanine equity. Following, Mr. Siokas waiver of the right to receive the dividends on February 26, 2024 and the unanimous written consent of the Company’s Board of Directors on February 29, 2024, through which was resolved that the Company shall remove all accrued and unpaid dividends payable to the previous holders of Series A Preferred stock, the Company eliminated the total deemed dividend of $372,414 through retained earnings. Thus, the balance of mezzanine equity as of December 31, 2023 is $0. On February 28, 2022, the Company entered into a securities purchase agreement, or the Purchase Agreement, with certain investors and an insider for a private placement of the Company’s securities (the “Private Placement”). The Private Placement consisted of the sale of 6,000 shares of the Company’s Series A Convertible Preferred Stock, or the Series A Shares, at a price of $1,000 per share, and 80,000 warrants to purchase shares of common stock, or the Warrants, for aggregate gross proceeds of approximately $6 million. The Warrants were initially exercisable to purchase shares of common stock at $82.50 per share, or 110% of the Series A Shares initial conversion price and will expire five and one-half years following the initial exercise date of the Warrants. The Company determined that the 80,000 warrants are additional value being distributed to the preferred stockholders and presented the warrants’ fair value of $5,788,493 as a deemed dividend on issuance of warrants in the consolidated statements of operations and comprehensive loss. The warrants were valued using the Black-Scholes option pricing model with the following terms: a) exercise price of $82.50, b) common stock fair value of $85.50, c) volatility of 118%, d) discount rate of 1.71%, e) term of 5.50 years and f) dividend rate of 0%. The closing of the Private Placement occurred on February 28, 2022. As a condition to the closing of the sale, the Company’s common stock received conditional approval for listing and trading on the Nasdaq Capital Market and commenced trading on February 28, 2022, under the trading symbol COSM. Concurrent with the issuance of the Series A Shares, the Company executed a registration rights agreement (the “Registration Rights Agreement”) to register the resale of the shares of common stock issuable upon conversion of the Series A Shares and the shares of common stock issuable upon exercise of the warrants issued in connection with the Series A Shares. The Company was required to file its initial registration statement within 45 days following February 28, 2022. The Effectiveness Date was required to be 60 days after February 28, 2022, or 75 days following the SEC’s full review, and any additional registration statements that may be required are to be filed within 20 days following the date required by the SEC. If the Company fails to timely file its initial registration statement, or any additional registration statement, or otherwise comply with the requirements of the Registration Rights Agreement, the Company shall pay each holder 2% of the subscription amount in cash until cured, with an additional penalty of 18% if the cash payment is not made within seven days of the cash payable date. The Company filed its initial registration statement on May 25, 2022, and thus accrued for liquidated damages payable to the holders in the amount of $250,260, calculated as described above, for both the late filing of the registration statement (event) and the 1st anniversary (30 days following the event date) of the event, which, along with an additional lump sum amount of $2,000,000 agreed to be paid to the investors as additional damages, led to a total amount of $2,250,260 concerning liquidated damages related to the February Private Placement within the year ended December 31, 2022. Upon the effectiveness of the Company’s registration statement, the Series A Shares conversion price was adjusted to $15.54 and the warrant exercise price was adjusted to $15.54 per share. The Company recorded a deemed dividend in the amount of $8,189,515 upon reducing the conversion price from $75.00 to $15.54 which was recorded as an increase to additional paid-in capital and an increase to accumulated deficit. The Series A Shares rank senior to all of the Company’s Common Stock and any other equity securities that the Company may issue in the future with respect to payment of dividends and distribution of assets upon liquidation, dissolution or winding up. While the Series A Shares are outstanding, the Company may not amend, alter or change adversely the powers, preferences or rights given to the Series A Shares, create, or authorize the creation of, any additional class or series of capital stock of the Company (or any security convertible into or exercisable for any class or series of capital stock of the Company), including any class or series of capital stock of the Company that ranks superior to or in parity with the Series A Shares, alter, amend, modify, or repeal its Articles of Incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series A Shares, increase or decrease the number of authorized shares of Series A Shares, any agreement, commitment or transaction that would result in a Change of Control, any sale or disposition of any material assets outside of the ordinary course of business of the Company, any material change in the principal business of the Company, including the entry into any new line of business or exit of any current line of business, and circumvent a right or preference of the Series A Shares. Any holder of the Series A Shares shall have the right by written election to the Company to convert all or any portion of the outstanding Series A Shares. Immediately upon effectiveness of a registration statement registering for resale all of the Registrable Securities (as defined in the Registration Rights Agreement), all outstanding Series A Shares shall automatically convert into Common Stock, subject to certain beneficial ownership limitations. Treasury stock As of December 31, 2023 and 2022, the Company held 86,497 and 15,497, respectively, shares of its common stock at a cost of $917,159 and $816,707, respectively. Shares of common stock that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. Cosmos may repurchase shares from time to time through open market purchases in accordance with applicable securities laws and other restrictions. The Company repurchased 71,000 shares of its common stock for $100,452 during the year ended December 31, 2023. On January 24, 2023, the Company announced that its Board of Directors has approved a share repurchase program with authorization to purchase up to $3 million of its common stock. Cosmos may repurchase shares from time to time through open market purchases in accordance with applicable securities laws and other restrictions. Mezzanine Equity The Series A Shares are recorded as mezzanine equity in accordance with ASC 480 at its initial net carrying value in the amount of $5,452,300. The Series A Shares are recorded as mezzanine equity in accordance with ASC 480 as the Company may be obligated to issue a variable number of shares at a fixed price known at inception and there is no maximum number of shares that could potentially be issued upon conversion. In this instance, cash settlement would be presumed and the Series A Shares are classified as mezzanine equity in accordance with ASC 480-10-S99. Immediately upon effectiveness of the registration statement registering for resale of all the common stock issuable under the Series A Shares, all outstanding Series A Shares shall automatically convert into common stock. As of December 31, 2022, 6,000 of the Series A Shares had been converted into 386,588 shares of common stock in accordance with the terms of the agreements and thus an amount of $5,452,300 was reclassified from mezzanine equity to common stock and additional paid-in capital, in the aggregate. Common Stock The Company is authorized to issue 300 million shares of common stock. As of December 31, 2023 and 2022, the Company 15,982,472 and 10,605,412 shares of our common stock issued, respectively, and 15,895,975 and 10,589,915 shares outstanding, respectively. Issuance of Common Stock During the 12 months ended December 31, 2023, the Company issued 15,258 shares of common stock to a consultant for services rendered. The shares were valued and expensed in the amount of $96,888 on the date of issuance and are separately presented in the consolidated statement of changes in stockholders’ equity and mezzanine equity as “Shares issued in lieu of cash” for the year ended December 31, 2023. On April 3, 2023, the Company issued 185,000 shares of unvested common stock to employees, officers and directors under the Company’s Equity Incentive Plan. These shares vest in two tranches, 1) 50% vesting on October 2, 2023, and 2) 50% vesting on October 2, 2024. The Company valued these shares on April 3, 2023 in the amount of $653,050 which is being amortized over the vesting period. During the year ended December 31, 2023, the Company had recorded $323,957 of stock-based compensation expense related to the shares issued, which is included in “General and administrative expense” on the accompanying consolidated statements of operations and comprehensive loss. As of December 31, 2023, the unamortized stock-based compensation for the 185,000 shares of common stock was $329,093, which will be amortized through October 2, 2024. On June 15, 2023, the Company issued 99,710 shares of common stock related to the acquisition of the customer base of Bikas. The fair value of these shares at the acquisition date was $316,081, which was included in the purchase price. On June 30, 2023, the Company issued 46,377 shares of common stock related to the acquisition of the Cana. The fair value of these shares at the acquisition date was $138,667, which was included in the purchase price of Cana. On July 20, 2023, the Company entered into a Securities Purchase Agreement with three investors to issue and sell in the aggregate 1,401,163 shares of common stock, 715,773 pre-funded warrants at an exercise price of $0.01 per share in lieu of common stock and warrants to purchase 1,935,484 warrants at an exercise price of $2.75 per share of common stock. The 1,935,484 warrants expire on January 1, 2029. The common stock and warrants were sold together at the unit price of $2.75 per share, raised gross proceeds of approximately $5,250,000, and incurred financing fees of approximately $443,000. The Company issued 2,116,936 shares of common stock which were recorded in the amount of $4,807,038 on the Company’s consolidated statements of changes in stockholders’ equity and mezzanine equity. The July 20, 2023 Securities Purchase Agreement triggered a downround provision for 782,610 previously issued warrants. The Company recorded a deemed dividend in the amount of $15,385, which was calculated using the Black-Scholes option pricing model with the following assumptions: a) exercise prices of $11.50 before repricing and $2.75 after repricing, b) common stock fair value of $1.89, c) volatility of 253.1% before repricing and 234.7% after repricing, d) discount rate of 4.26% before repricing and 4.03% after repricing, e) terms of 4.42 years before repricing and 5.51 years after repricing and f) dividend rate of 0%. On October 9, 2023, the Company issued 280,000 shares for the acquisition of Cloudscreen. The fair value of these shares at the acquisition date was $319,200, which was included in the purchase price. On October 24, 2023, the Company issued 51,485 shares of common stock priced at $1.01, which is the fair market value of our stock on the date of the agreement, to George Terzis, the CFO of the Company, in exchange for $52,000 of debt. The debt related to unpaid salaries and bonuses, the Company had due to Mr. Terzis, as of December 31, 2023. This amount was recorded as equity. On November 21, 2023, the Company issued 970,000, in the aggregate, shares of common stock to multiple parties for services rendered. The fair value of these shares was $77,448, which was recorded as general and administrative expense. They were treated as Nonemployee share-based payment equity awards and measured at the grant-date fair value of the equity instruments, similar to employee share-based payment equity awards. On December 29, 2023, the Company issued 125,294 shares of common stock related to the acquisition of the customer base of Bikas. The fair value of these shares was $176,665, which was included in the purchase price. During the year ended December 31, 2022, the Company issued 300 shares of common stock for services rendered and recorded $3,120 of compensation expense in relations to the services. Reverse split On December 15, 2022 the Company announced a reverse stock split with a ratio of 1-for-25 (one-for-twenty five) effective at the opening of the business day on Friday, December 16, 2022. The CUSIP number of the Company after the split will change to 221413-305. The reverse stock split was authorized at the Company’s Annual General Meeting (“AGM”) on December 2, 2022 and was approved by the Company’s Board of Directors on December 15, 2022. The Company’s financial statements and supplementary data for all periods presented in this Annual Report on Form 10-K have been retrospectively adjusted to give effect to the reverse stock split. Debt Conversions During the year ended December 31, 2022, the Company issued 9,520 shares of common stock upon the conversion of $1,190,000 of notes payable. The Company recorded $973,420 as a capital contribution and an increase in equity related to the conversion of the $1,190,000 reduced by $216,580 recorded as a gain upon extinguishment of debt upon modification. The $216,580 gain upon extinguishment was determined using the fair value of the Company of $102.25 per share at the extinguishment commitment date. On May 1, 2022, the Company issued 1,574 shares of common stock to convert $26,515 principal and accrued interest. Following the conversion, the outstanding balance of the above Note was $0. Upon conversion, the 1,574 shares were issued at a fair value of $38,144 which was recorded as equity. Accordingly, upon conversion, the Company reduced its derivative liability by $11,629 (see Note 11). Exercise of Warrants During the year ended December 31, 2022, the Company issued 3,608,667 shares of common stock upon the exercise of 3,608,667 warrants. The Company received proceeds of $10,826,000 upon exercise. During the year ended December 31, 2022, the Company issued 526,112 shares of common stock upon the cashless exercise of 776,674 warrants. During the year ended December 31, 2023, the Company issued 2,437,063 shares of common stock upon the exercise of 2,437,063 warrants. The Company received proceeds of $3,533,741 upon exercise. Issuance of Common Stock and Warrants On December 29, 2023, the Company entered into a warrant exchange agreement (the “Warrant Exchange”) with an investor to reduce the exercise price of 2,437,063 warrants from $2.75 per share to $1.45 per shares as an inducement to exercise. The Company issued 1,487,000 shares of common stock, held 950,063 shares in escrow until the investor’s beneficial ownership limitation allows for the transfer of the escrow shares, and received gross cash proceeds of 3,533,741. The Company contingently granted 4,874,126 additional warrants to be issued upon shareholder approval, with an exercise price of $1.45 and a term of five years. For the year ending December 31, 2023, the Company recorded a deemed dividend of $7,642 for the inducement to exercise and $7,218,485 for the grant of new warrants. On May 25, 2022, the Company granted 1,333 warrants to a third party based on a settlement agreement signed on May 25, 2022, as compensation concerning the consulting services the third party provided for the Private Placement closed on February 28, 2022. The Company recorded stock-based compensation in the amount of $24,101 upon issuance of the warrants valued using the Black-Scholes option pricing model with the following assumptions: a) common stock fair value of $26.75, b) exercise price of $82.50, c) term of 5.51 years, d) volatility of 107.3%, e) dividend rate of 0%, and f) discount rate of 2.71%. On June 7, 2022, the Company issued 344,765 warrants upon triggering the down round protection feature in relation to the warrants issued in connection with the Series A shares with an exercise price of $15.54 and a term of approximately 5 years. Additionally, the Company lowered the exercise price of the 80,000 warrants then outstanding from $82.50 to $15.54 per common share upon triggering the down round protection. The Company recorded a deemed dividend in the amount of $8,480,379 in relation to the down round protection feature for the incremental value of the shares issued and lowered exercise price valued using the Black-Scholes option pricing model with the following assumptions: a) common stock fair value of $26.75, b) old exercise price of $82.50 and revised exercise price of $15.54, c) term of 5.24 years, d) volatility of 121.47%, e) dividend rate of 0%, and f) discount rate of 2.99%. On July 14, 2022, the Company issued 300 shares to a consultant for services rendered. For the year ended December 31, 2022, the Company recorded $3,120 as general and administrative expense related to the issuance. On October 20, 2022, the Company issued 2,486,667 shares of common stock and 5,000,000 warrants, in the aggregate, upon entering into a securities purchase agreement for an aggregate purchase price of $7,500,000. Of the 5,000,000 warrants, 2,500,000 were designated as Series A and 2,500,000 were designated as Series B. The Series A warrants have an exercise price of $3.00 per share and expire two years from the date of issuance. The Series B warrants have an exercise price of $3.00 per share and expire seven years from the date of issuance. The Company allocated the proceeds between the common stock and warrants issued and recorded a discount to the common stock associated with the warrants in the amount of $8,437,977, in the aggregate, which was recorded as additional paid-in capital and a deemed dividend. The warrants were valued using the Black-Scholes option pricing model with the following assumptions: a) fair value of common stock of $2.20, b) exercise price of $3.00, c) terms of two years and seven years, d) dividend rate of 0%, e) volatility of 135.05% and 129.02%, and f) risk free interest rate of 4.62% and 4.36%. On October 20, 2022, the Company cancelled 424,765 warrants in exchange for 849,530 additional warrants with existing warrant holders. The new warrants were issued with an exercise price of $3.00 per common share and a term of seven years. As a result, the Company recorded a deemed dividend as an increase to accumulated deficit and additional paid-in capital and reduced net income available to common shareholders by $1,067,876. The Company valued (a) the fair value of the 424,765 warrants immediately before exchange in the amount of $645,108, (b) the fair value of the warrants immediately after the exchange in the amount of $1,712,984, and (c) recorded the difference as a deemed dividend in the amount of $1,067,876. The warrants were valued using the Black-Scholes option pricing model using the following assumptions: a) fair value of common stock of $2.20, b) exercise prices of $15.54 pre-exchange and $3.00 post-exchange, c) terms of 4.87 years pre-exchange and seven years post-exchange, d) dividend rate of 0%, e) volatility of 132.3% pre-exchange and 131.9% post-exchange, and f) risk free interest rate of 4.45% pre-exchange and 4.36% post-exchange. On November 21, 2022, the Company entered into a settlement and general release pursuant to a letter agreement dated July 7, 2021 whereby a consultant claimed to be entitled to compensation with respect to a previous financing. As a result of the settlement, the Company issued 40,000 shares of common stock which was recorded as general and administrative expense for the year ended December 31, 2022 in the amount of $173,121. On December 19, 2022, the Company issued 2,828,320 shares of common stock and 2,828,320 warrants (of which 260,870 were cancelled subsequent to December 31, 2022), in the aggregate, upon entering into a securities purchase agreement for an aggregate purchase price of $32,525,680 and net proceeds of $30,600,319. The warrants have an exercise price of $11.50 per share and expire five years from the date of issuance. The Company allocated the proceeds between the common stock and net warrants issued and recorded a discount to the common stock associated with the warrants in the amount of $17,778,260 which was recorded as additional paid-in capital and a deemed dividend. The warrants were valued using the Black-Scholes option pricing model with the following assumptions: a) fair value of common stock of $11.50, b) exercise price of $7.59, c) terms of five years, d) dividend rate of 0%, e) volatility of 157.53%, and f) risk free interest rate of 3.70%. No options warrants or other potentially dilutive securities other than those disclosed above have been issued as of December 31, 2023. Warrant Classification The Company determines the classification of its warrants upon issuance by identifying the instrument issued to determine if it is debt or equity classified. The Company determined its warrants meet the scope exception in ASC 815-10 and are equity classified because, (a) the warrant is indexed to the Company’s own stock, (b) require settlement in equity shares, and (c) the Company has enough authorized and unissued shares.

INCOME TAXES

INCOME TAXES	9 Months Ended	12 Months Ended
INCOME TAXES	Sep. 30, 2024	Dec. 31, 2023
INCOME TAXES
INCOME TAXES	NOTE 7 – INCOME TAXES The Company is incorporated in the United States of America and is subject to United States federal taxation. No provisions for income taxes have been made as the Company had no U.S. taxable income for the nine months ended September 30, 2024, and 2023. The Company’s Greek subsidiaries are governed by the income tax laws of Greece. The corporate tax rate in Greece is 22% on income reported in the statutory financial statements after appropriate tax adjustments. The Company’s United Kingdom subsidiaries are governed by the income tax laws of the United Kingdom. The corporate tax rate in the United Kingdom is 25% on income reported in the statutory financial statements after appropriate tax adjustments. As of September 30, 2024, and 2023, the Company’s effective tax rate differs from the U.S. federal statutory tax rate primarily due to a valuation allowance recorded against net deferred tax assets in in the United States and the United Kingdom. We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. As of September 30, 2024, and December 31, 2023, the Company has maintained a valuation allowance against all net deferred tax assets in the United States, Greece, and the UK. For the three months ended September 30, 2024, and 2023, the Company has recorded tax benefit in any jurisdiction where it is subject to income tax, in the amount of $0 and $65,873, and respectively, on the Condensed Consolidated Statements of Operations and Comprehensive Loss. No tax loss or benefit was recorded for the equivalent nine month periods.	NOTE 8 – INCOME TAXES The Company provides for income taxes using an asset and liability approach under which deferred income taxes are provided for based upon enacted tax laws and rates applicable to periods in which the taxes become payable. The domestic and foreign components of income (loss) before (benefit from) provision for income taxes were as follows: December 31, 2023 December 31, 2022 Domestic $ (2,832,980 ) $ (7,093,161 ) Foreign (15,709,674 ) (5,962,159 ) $ (18,542,654 ) $ (13,055,320 ) The components of the (benefit from) provision for income taxes are as follows: December 31, 2023 December 31, 2022 Current tax provision Federal $ - $ - State - - Foreign - (75,724 ) Total current tax provision $ - $ (75,724 ) Deferred tax provision Domestic $ - $ - State - - Foreign - 850,775 Total deferred tax provision $ - $ 850,775 Total current provision $ - $ 775,051 The reconciliation of income tax expense computed at the U.S. federal statutory rate to the income tax provision for the years ended December 31, 2023 and 2022 is as follows: December 31, 2023 December 31, 2022 US Loss before income taxes $ (18,542,654 ) $ (13,055,320 ) Taxes under statutory US tax rates $ (3,893,957 ) $ (2,741,617 ) Increase (decrease) in taxes resulting from: Increase in valuation allowance $ 4,339,572 $ 3,989,786 Foreign tax rate differential $ 245,518 $ 34,601 Permanent differences $ (448,032 ) $ 128,705 Prior period adjustments $ (151,879 ) $ (186,143 ) State taxes $ (91,222 ) $ (450,280 ) Income tax expense $ - $ 775,052 Companies subject to the Global Intangible Low-Taxed Income provision (GILTI) have the option to account for the GILTI tax as a period cost if and when incurred, or to recognize deferred taxes for outside basis temporary differences expected to reverse as GILTI. We have elected to account for GILTI as a period cost. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities consist of the following: December 31, 2023 December 31, 2022 Net operating loss carryforward $ 7,621,277 $ 5,899,702 Capital loss carryforward 801,744 801,744 Section 163(j) carryforward 563,138 561,130 Foreign exchange 129,916 297,263 Allowance for doubtful accounts 4,404,277 1,616,926 Accrued expenses 261,466 352,025 Mark to market adjustment in securities 358,761 358,761 Lease liability 261,377 259,381 Capitalized research & development costs 52,261 - Depreciation (35,734 ) (22,914 ) Total deferred tax assets 14,418,483 10,124,018 Intangibles (15,845 ) (8,139 ) Inventory 4,853 (49,961 ) Right of use asset (258,770 ) (256,769 ) Goodwill (10,980 ) (10,979 ) Total deferred tax liabilities (280,742 ) (325,848 ) Valuation allowance (14,137,741 ) (9,798,170 ) Net deferred tax assets $ - $ - At December 31, 2023, the Company had U.S. net operating loss (“NOL”) carryforwards of approximately $21,516,941 that may be offset against future taxable income, subject to limitation under IRC Section 382. Of the $21.5 million Federal NOL carryforwards, $2.5 million are pre-2018 and begin to expire in 2031. The remaining balance of $19 million, are limited to utilization of 80% of taxable income but do not have an expiration. At December 31, 2023, the Company had Greek NOL carryforwards of $2,240,902 and had UK NOL carryforwards of $1,753,800. A valuation allowance exists for all operations, based on a more likely than not criterion and in consideration of all available positive and negative evidence. ASC 740 requires that the tax benefit of net operating losses (“NOLs”), temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is “more likely than not.” Realization of the future tax benefits is dependent on the Company’s ability to generate sufficient taxable income within the carryforward period. Because of the Company’s history of domestic operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance, on all our deferred tax asset. Management considered all available evidence to when evaluating the realizability of foreign deferred tax assets by jurisdiction and concluded primarily based upon a strong earnings history that these deferred tax assets were more-likely-than-not realizable. The Company applied the “more-likely-than-not” recognition threshold to all tax positions taken or expected to be taken in a tax return, which resulted in no unrecognized tax benefits as of December 31, 2023 and December 31, 2022, respectively. We recognize interest accrued related to unrecognized tax benefits and penalties as income tax expense. The Company files income tax returns in Illinois, United States, and in foreign jurisdictions including Greece and the United Kingdom. As of December 31, 2023, all domestic tax years are open to tax authority examination due the availability of net operating loss deductions, 2010 through 2023. In Greece, the statute of limitations is open for five years, 2018 through 2023. In the United Kingdom, the statute of limitations is open for four years, 2019 through 2023. Currently, there are no ongoing tax authority income tax examinations.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended	12 Months Ended
RELATED PARTY TRANSACTIONS	Sep. 30, 2024	Dec. 31, 2023
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS	NOTE 9 – RELATED PARTY TRANSACTIONS Doc Pharma S.A. Doc Pharma S.A is considered a related party to the Company due to the fact that the CEO of Doc Pharma is the wife of Grigorios Siokas, the Company’s CEO and principal shareholder, who also served as a principal of Doc Pharma S.A. in the past. Prepaid expenses and other current assets – related party As of September 30, 2024 and December 31, 2023, the Company had a prepaid balance of $6,393,642 and $4,347,184, respectively, to Doc Pharma related to purchases of inventory and pharmaceutical and nutraceutical licenses to be purchased. Accounts payable and accrued expenses - related party As of September 30, 2024 and December 31, 2023, the Company had an accounts payable balance to Doc Pharma of $72,968 and $34,217, respectively. Accounts receivable - related party The Company had a receivable balance of $2,448,517 and $2,386,721 from Doc Pharma S.A as of September 30, 2024, and December 31, 2023, respectively. Sales and Purchases During the three months ended September 30, 2024 and 2023, the Company purchased a total of $85,073 and $456,257 of products from Doc Pharma S.A., respectively. During the three months ended September 30, 2024, and 2023, the Company had $40,370 and $61,163 revenue from Doc Pharma, respectively. During the nine months ended September 30, 2024 and 2023, the Company purchased a total of $510,711 and $1,057,621 of products from Doc Pharma S.A., respectively. During the nine months ended September 30, 2024 and 2023, the Company had $581,862 and $43,107 revenue from Doc Pharma, respectively. Other Agreements On October 10, 2020, the Company entered into a contract manufacturer outsourcing (“CMO”) agreement with Doc Pharma whereby Doc Pharma is responsible for the development and manufacturing of pharmaceutical products and nutritional supplements according to the Company’s specifications based on strict pharmaceutical standards and good manufacturing practice (“GMP”) protocols as the National Organization for Medicines requires. The Company has the exclusive ownership rights for trading and distribution of its own branded nutritional supplements named “Sky Premium Life ® For the three months ended September 30, 2024 and 2023, the Company has purchased €34,350 ($38,096) and €418,577 ($455,586) respectively, in inventory related to this agreement. For the nine months ended September 30, 2024 and 2023, the Company has purchased €161,108 ($175,123) and €967,785 ($1,048,557) respectively, in inventory related to this agreement. On May 17, 2021, Doc Pharma and the Company entered into a Research and Development (“R&D”) agreement whereby Doc Pharma will be responsible for the research, development, design, registration, copy rights and licenses of 250 nutritional supplements for the final products called Sky Premium Life ® Purchase of branded pharmaceuticals On June 28, 2023, the Company approved the purchase of five proprietary and innovative branded pharmaceuticals with significant market presence and material profit contribution from Zakalia Ltd., the parent company of Doc Pharma, for €1,800,000 ($1,965,600). The transaction was settled on a non-cash basis through the reduction of an equivalent amount of prepaid expense balances the Company held with Doc Pharma. The purchased branded pharmaceuticals are presented in “Goodwill and intangible assets, net” on the accompanying consolidated balance sheets. On December 29, 2023, the Company approved the purchase of 19 additional licenses from DocPharma, of a total value of €3,200,000 ($3,539,840). This transaction was also settled on a non-cash basis through the reduction of an equivalent amount of prepaid expense balances the Company held with Doc Pharma. Loans receivable - related party The balance of prepaid expenses due Doc Pharma as of December 31, 2022, had increased to €7,103,706 ($7,599,545), which was mainly attributable to the prepayments SkyPharm S.A. made in accordance with the CMO agreement and the extensive orders and sales of the SPL products the Company expects to achieve within 2023, mainly through its Amazon channels in the UK, Singapore, Canada and other countries. However, as the benefit from a significant portion of the prepaid balance would not have been realized within a 12-month period, the Company opted to secure a portion of the outstanding prepaid balance through a loan agreement. SkyPharm S.A. (the “Lender”) entered into a loan agreement with Doc Pharma (the “Borrower”) for €4,000,000 ($4,279,200), all of which was financed through the outstanding prepaid balance. The duration of the loan is for a 10-year period up to December 31, 2032 (the “Maturity Date”). The loan bears a fixed interest rate of 5.5% payable on a monthly basis and will be repayable in 120 equal instalments of €33,333.33 ($37,150). The loan may be prepaid anytime during its duration in full or partially based on the Company’s product requirements and other factors, without Doc Pharma incurring any prepayment penalty. As of September 30, 2024 and December 31, 2023, the loan had a current portion of €400,000 ($445,800) and €400,000 ($442,480), and a non-current portion of €2,900,000 ($3,232,050), and €3,200,000 ($3,539,840), respectively, which is classified as "Loans receivable – related party" on the accompanying consolidated balance sheets. During the nine months ended September 30, 2024, the Company received €300,000 ($334,350) in principal repayments, and €121,550 ($135,467) of interest repayments. Additionally, during the nine months ended September 30, 2024, the Company recorded €143,000 ($155,440) as interest income relating to this loan. Cana Laboratories Holding Limited Cana was considered a related party as the Company had signed a binding letter of intent and an SPA for the acquisition of Cana. The acquisition was completed on June 30, 2023 according to the SPA signed on May 31, 2023. Thus, all balances between the Company and Cana were eliminated upon consolidation as of December 31, 2023. The Secured Promissory Note discussed below was included in consideration transferred upon acquisition. Loans receivable - Related Party - Long Term On February 28, Panagiotis Kozaris Panagiotis Kozaris is considered a related party due to the fact that he is a former General operational manager and current employee of Cosmofarm S.A. Prepaid Expenses and Other Current Assets - Related Party From time to time the Company purchases back shares that Panagiotis Kozaris owns and records them as treasury shares. The Company pays Panagiotis Kozaris in advance for the shares owned and obtains the shares upon execution of a cumulative stock-purchase agreement (“SPA”). During the three months ended September 30, 2024 and 2023, the Company paid Panagiotis Kozaris an additional sum of $0 and $51,159 respectively for shares owned, however, no SPA for these funds has been executed as of September 30, 2024. The Company intends to execute a cumulative SPA for these amounts during 2024. The total balances owed of $194,215 and $194,215 are included in “Prepaid expenses and other current assets - related party”, on the accompanying consolidated balance sheets as of September 30, 2024 and December 31, 2023, respectively. Basotho Investment Limited Basotho Investment Limited is considered a related party once Panagiotis Kozaris (former general operational manager and current employee of Cosmofarm SA) is one of its directors. General and administrative expenses On November 21, 2023, the Company issued 120,000 shares of common stock to Basotho Investment Limited for services rendered. The fair value of these shares for the period ended December 31, 2023 was $10,300, which was recorded as general and administrative expense. The fair value of the shares vested for the nine-month period ended September 30, 2024 was $92,700, which was recorded as general and administrative expense. Maria Kozari Maria Kozari is considered a related party to the Company due to the fact that she is the daughter of Panagiotis Kozaris, a former Operational General Manager and current employee of Cosmofarm S.A. Accounts Receivable - Related Party During 2021, the Company, through its subsidiary, Cosmofarm SA, commenced a partnership with a pharmacy called “Pharmacy & More”, owned by Maria Kozari. The transactions with the respective pharmacy were in Cosmofarm’s normal course of business, however, a more flexible credit policy was allowed as the pharmacy was new and needed to be established in the market. During the three and nine months ended September 30, 2024 and 2023 the Company’s net sales to Pharmacy & More amounted to $113,161 and $122,969 and $310,126 and $359,760 respectively. As of September 30, 2024 and December 31, 2023 the Company’s outstanding receivable balance due from the pharmacy amounted to $1,123,835 (€1,203,739) and $1,142,402 (€1,032,726), respectively, and are included in “Accounts receivable - related party”, on the accompanying consolidated balance sheets. The Company plans to acquire Pharmacy & More within fiscal year 2024. Upon acquisition, the Company intends to offset the outstanding receivable balance with the corresponding purchase price and additionally plans to make Pharmacy & More the first shop-in-shop of its own branded line of nutraceutical products, Sky Premium Life® (SPL). Other Related Parties The Company has the following balances as of September 30, 2024: a) a balance of $731,000 relating to unpaid salaries and bonuses due to Grigorios Siokas, the CEO of the Company and $188,000 due to George Terzis, the CFO of the Company, classified as "Accounts payable and accrued expenses - related party" in the Company’s condensed consolidated balance sheets, b) a net payable balance of $29,832 due to Konstantinos Gaston Kanaroglou, former manager and current employee of the Company’s wholly owned subsidiary Cana, classified as " Accounts payable and accrued expenses - related party" in the Company’s condensed consolidated balance sheets. Additionally, the Company had the following balances as of December 31, 2023: a) a balance of $98,000 relating to unpaid salaries and bonuses due to George Terzis, the CFO of the Company, classified as "Accounts payable and accrued expenses - related party" in the Company’s consolidated balance sheets, b) a net payable balance of $85,332 due to Konstantinos Gaston Kanaroglou, former manager and current employee of the Company’s wholly owned subsidiary Cana, classified as " Accounts payable and accrued expenses - related party" in the Company’s consolidated balance sheets. Notes Payable – Related Party A summary of the Company’s related party notes payable as of September 30, 2024 and December 31, 2023 is presented below: September 30, 2024 December 31, 2023 Beginning Balance $ 11,283 $ 10,912 Payments - - Foreign currency translation 85 371 Ending Balance $ 11,368 $ 11,283 Dimitrios Goulielmos Dimitris Goulielmos was the Company’s former CEO and a Director of the Company. On November 21, 2014, the Company entered into an agreement with Dimitrios Goulielmos, as amended on November 4, 2016. Pursuant to the amendment, this loan has no maturity date and is non-interest bearing. As of September 30, 2024 and December 31, 2023, the Company had a principal balance of €10,200 ($11,368) and €10,200 ($11,283), respectively. The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the nine months ended September 30, 2024, the Company recorded a foreign currency translation loss of $85. Loans Payable – Related Party A summary of the Company’s related party loans payable as of September 30, 2024 and December 31, 2023 is presented below: September 30, 2024 December 31, 2023 Beginning balance $ 13,257 $ 12,821 Proceeds 18,344 - Payments (8,918 ) - Foreign currency translation (1,525 ) 436 Ending balance $ 21,158 $ 13,257 Grigorios Siokas From time to time, Grigorios Siokas loans the Company funds in the form of non-interest bearing, no-term loans. As of September 30, 2024, the Company had an outstanding principal balance under these loans of $21,158 in loans payable to Grigorios Siokas. As of December 31, 2023, the Company had an outstanding principal balance of $13,257 related to this payable. The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the nine months ended September 30, 2024, the Company recorded a gain of $1,525. Except as set forth above, we have not entered into any material transactions with any director, executive officer, and promoter, beneficial owner of five percent or more of our common stock, or family members of such persons.	NOTE 9 – RELATED PARTY TRANSACTIONS Doc Pharma S.A. Doc Pharma S.A. is considered a related party to the Company due to the fact that the CEO of Doc Pharma is the wife of Grigorios Siokas, the Company’s CEO and principal shareholder, who also served as a principal of Doc Pharma S.A. in the past. Prepaid expenses and other current assets – related party As of December 31, 2023, and December 31, 2022, the Company had a prepaid balance of $4,347,184 and $3,320,345, respectively, to Doc Pharma related to purchases of inventory. Accounts payable and accrued expenses – related party As of December 31, 2023, and December 31, 2022, the Company had an accounts payable balance to Doc Pharma of $34,217 and $201,991, respectively. Accounts receivable – related party Additionally, the Company had a receivable balance of $2,386,721 and $2,070,570 from Doc Pharma S.A. as of December 31, 2023, and December 31, 2022, respectively. Sales and Purchases During the years ended December 31, 2023 and 2022, the Company purchased a total of $1,365,324 and $1,755,103 of products from Doc Pharma S.A., respectively. During the years ended December 31, 2023 and 2022, the Company had $619,637 and $1,058,780 revenue from Doc Pharma, respectively. Other Agreements On October 10, 2020, the Company entered into a contract manufacturer outsourcing (“CMO”) agreement with Doc Pharma whereby Doc Pharma is responsible for the development and manufacturing of pharmaceutical products and nutritional supplements according to the Company’s specifications based on strict pharmaceutical standards and good manufacturing practice (“GMP”) protocols as the National Organization for Medicines requires. The Company has the exclusive ownership rights for trading and distribution of its own branded nutritional supplements named “Sky Premium Life ® For the years ended December 31, 2023 and 2022, the Company has purchased €1,144,043 ($1,237,467) and €1,653,911 ($1,742,282), respectively, in inventory related to this agreement. On May 17, 2021, Doc Pharma and the Company entered into a Research and Development (“R&D”) agreement whereby Doc Pharma will be responsible for the research, development, design, registration, copy rights and licenses of 250 nutritional supplements for the final products called Sky Premium Life ® Purchase of branded pharmaceuticals On June 28, 2023, the Company approved the purchase of five proprietary and innovative branded pharmaceuticals with significant market presence and material profit contribution from Zakalia Ltd., the parent company of Doc Pharma, for €1,800,000 ($1,965,600). The transaction was settled on a non-cash basis through the reduction, of an equivalent amount, of prepaid expense balances the Company held with Doc Pharma. The purchased branded pharmaceuticals are presented in “Goodwill and intangible assets, net” on the accompanying consolidated balance sheets. On December 29, 2023, the Company approved the purchase of additional 19 licenses from Doc Pharma, of a total value of €3,200,000 ($3,539,840). This transaction was also settled on a non-cash basis through the reduction, of an equivalent amount, of prepaid expense balances the Company held with Doc Pharma. Loans receivable - related party The balance of prepaid expenses due Doc Pharma as of December 31, 2022, had increased to €7,103,706 ($7,599,545), which was mainly attributable to the prepayments SkyPharm S.A. made in accordance with the CMO agreement and the extensive orders and sales of the SPL products the Company expects to achieve within 2023, mainly through its Amazon channels in the UK, Singapore, Canada and other countries. However, as the benefit from a significant portion of the prepaid balance would not have been realized within a 12-month period, the Company opted to secure a portion of the outstanding prepaid balance through a loan agreement. SkyPharm S.A. (the “Lender”) entered into a loan agreement with Doc Pharma (the “Borrower”) for €4,000,000 ($4,279,200), all of which was financed through the outstanding prepaid balance. The duration of the loan is for a 10-year period up to December 1, 2032 (the “Maturity Date”). The loan bears a fixed interest rate of 5.5% payable on a monthly basis and will be repayable in 120 equal instalments of €33,333.33 ($35,660). The loan may be prepaid anytime during its duration in full or partially based on the Company’s product requirements and other factors, without Doc Pharma incurring any prepayment penalty. As of December 31, 2023 and December 31, 2022, the loan had a current portion of €400,000 ($442,480) and €400,000 ($427,720), and a non-current portion of €3,200,000 ($3,539,840), and €3,600,000 ($3,851,280), respectively, which is classified as “Loans receivable – related party” on the accompanying consolidated balance sheets. During the year ended December 31, 2023, the Company received €400,000 ($442,480) in principal repayments, and €209,917 ($232,210) of interest repayments. Additionally, during the year ended December 31, 2023, the Company recorded €201,057 ($217,476) as interest income relating to this loan. Cana Laboratories Holding Limited Cana was considered a related party as the Company had signed a binding letter of intent and an SPA for the acquisition of Cana. The acquisition was completed on June 30, 2023 according to the SPA signed on May 31, 2023. Thus, all balances between the Company and Cana were eliminated upon consolidation as of December 31, 2023. The Secured Promissory Note discussed below was included in consideration transferred upon acquisition. Loans receivable - Related Party - Long Term On February 28, Panagiotis Kozaris Panagiotis Kozaris is considered a related party due to the fact that he is a former General operational manager and current employee of Cosmofarm S.A. Prepaid Expenses and Other Current Assets - Related Party From time-to-time the Company purchases back shares that Panagiotis Kozaris owns and records them as treasury shares. The Company pays Panagiotis Kozaris in advance for the shares owned and obtains the shares upon execution of a cumulative stock-purchase agreement (“SPA”). During the years ended December 31, 2023 and 2022, the Company paid Panagiotis Kozaris an additional sum of $51,159 and $143,056 respectively for shares owned, however, no SPA for these funds has been executed as of December 31, 2023. The Company intends to execute a cumulative SPA for these amounts during 2024. The total balances owed of $194,215 and $143,056 are included in “Prepaid expenses and other current assets - related party”, on the accompanying consolidated balance sheets as of December 31, 2023 and 2022, respectively. Basotho Investment Limited Basotho Investment Limited is considered a related party once Panagiotis Kozaris (former General operational manager and current employee of Cosmofarm S.A) is one of its directors. General and administrative expenses On November 21, 2023, the Company issued 120,000 shares of common stock to Basotho Investment Limited for services rendered. The fair value of these shares for the period ended December 31, 2023 was $10,300, which was recorded as general and administrative expense. Maria Kozari Maria Kozari is considered a related party to the Company due to the fact that she is the daughter of Panagiotis Kozaris, a former Operational General Manager and current employee of Cosmofarm S.A. Accounts Receivable - Related Party During 2021, the Company, through its subsidiary, Cosmofarm SA, commenced a partnership with a pharmacy called “Pharmacy & More”, owned by Maria Kozari. The transactions with the respective pharmacy were in Cosmofarm’s normal course of business, however, a more flexible credit policy was allowed as the pharmacy was new and needed to be established in the market. During the years ended December 31, 2023 and 2022 the Company’s net sales to Pharmacy & More amounted to $480,029 and $463,467 respectively. As of December 31, 2023 and 2022 the Company’s outstanding receivable balance due from the pharmacy amounted to $1,142,402 (€1,032,726) and $760,025 (€710,436), respectively, and are included in “Accounts receivable - related party”, on the accompanying consolidated balance sheets. The Company plans to acquire Pharmacy & More within fiscal year 2024. Upon acquisition, the Company intends to offset the outstanding receivable balance with the corresponding purchase price and additionally plans to make Pharmacy & More the first shop-in-shop of its own branded line of nutraceutical products, Sky Premium Life® (SPL). Other Related Parties Additionally, the Company has the following balances as of December 31, 2023: a) a balance of $98,000 relating to unpaid salaries and bonuses due to George Terzis, the CFO of the Company, classified as “Accounts payable and accrued expenses - related party” in the Company’s consolidated balance sheets, b) a net payable balance of $85,332 due to Konstantinos Gaston Kanaroglou, former manager and current employee of the Company’s wholly owned subsidiary Cana, classified as "Accounts receivable" in the Company’s consolidated balance sheets. Notes Payable – Related Party A summary of the Company’s related party notes payable during the years ended December 31, 2023 and 2022 is presented below: 2023 2022 Beginning Balance $ 10,912 $ 464,264 Payments - (472,920 ) Foreign currency translation 371 19,568 Ending Balance $ 11,283 $ 10,912 Grigorios Siokas Grigorios Siokas is the Company’s CEO and principal shareholder. On December 20, 2018, the €1,500,000 ($1,718,400) note payable, originally borrowed pursuant to a Loan Agreement with a third-party lender, dated March 16, 2018, was transferred to Grigorios Siokas. The note bore an interest rate of 4.7% per annum, originally matured on March 18, 2019 pursuant to the original agreement which was extended to December 31, 2021, and again to December 31, 2023. During the year ended December 31, 2022, the Note was paid in full and as of December 31, 2023 the Company had no outstanding balance. As of December 31, 2023 and 2022, the Company had accrued interest of $0 and €192,891 ($206,355), respectively, outstanding related to this loan, classified under “Accrued interest” in the Company’s consolidated balance sheets. Dimitrios Goulielmos Dimitris Goulielmos was the Company’s former CEO and a Director of the Company. On November 21, 2014, the Company entered into an agreement with Dimitrios Goulielmos, as amended on November 4, 2016. Pursuant to the amendment, this loan has no maturity date and is non-interest bearing. As of December 31, 2023 and 2022, the Company had a principal balance of €10,200 ($11,283) and €10,200 ($10,912), respectively. The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the years ended December 31, 2023 and 2022, the Company recorded a foreign currency translation loss of $371 and $19,568, respectively. Loans Payable – Related Party A summary of the Company’s related party loans payable during the years ended December 31, 2023 and 2022 is presented below: 2023 2022 Beginning balance $ 12,821 $ 1,293,472 Proceeds - 3,635,756 Payments - (4,851,678 ) Foreign currency translation 436 (64,729 ) Ending balance $ 13,257 $ 12,821 Grigorios Siokas From time to time, Grigorios Siokas loans the Company funds in the form of non-interest bearing, no-term loans. As of December 31, 2022, the Company had an outstanding principal balance under these loans of $12,821 in loans payable to Grigorios Siokas. As of December 31, 2023, the Company had an outstanding principal balance of $13,257 related to this payable. The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the years ended December 31, 2023 and 2022, the Company recorded a loss of $436 and a gain of $64,729, respectively. Except as set forth above, we have not entered into any material transactions with any director, executive officer, and promoter, beneficial owner of five percent or more of our common stock, or family members of such persons.

LINES OF CREDIT

LINES OF CREDIT	9 Months Ended	12 Months Ended
LINES OF CREDIT	Sep. 30, 2024	Dec. 31, 2023
LINES OF CREDIT
LINES OF CREDIT	NOTE 10 – LINES OF CREDIT A summary of the Company’s lines of credit as of September 30, 2024 and December 31, 2023, is presented below: September 30, 2024 December 31, 2023 National $ 3,011,102 $ 3,918,523 Alpha 1,030,943 1,130,140 Pancreta 1,560,803 1,122,210 EFG 386,577 459,400 Ending balance $ 5,989,425 $ 6,630,273 The Company has three lines of credit with the National Bank of Greece, which are renewed annually. The three lines have interest rates of 6.00% (the "National Bank LOC"), 3.6% (the "COSME 2 Facility"), and 3.6% plus the six-month Euribor rate and any contributions currently in force by law on certain lines of credit (the "COSME 1 Facility"). The maximum borrowing allowed for the 6% line of credit was $3,315,638 and $3,290,945 as of September 30, 2024 and December 31, 2023, respectively. The outstanding balance of the facility was $2,102,765 and $2,829,828, as of September 30, 2024 and December 31, 2023, respectively. The cumulative maximum borrowing allowed for the COSME 1 Facility and COSME 2 Facility (collectively, the "Facilities") was $1,114,500 and $1,106,200 as of September 30, 2024 and December 31, 2023, respectively. The outstanding balance of the Facilities was $943,466 and $1,099,255 as of September 30, 2024 and December 31, 2023, respectively. The Company maintains a line of credit with Alpha Bank of Greece ("Alpha LOC"), which is renewed annually and has a current interest rate of 6.00%. The maximum borrowing allowed was $1,114,500 and $1,106,200 as of September 30, 2024 and December 31, 2023, respectively. The outstanding balance of the Alpha LOC was $1,030,944 and $1,130,141, as of September 30, 2024 and December 31, 2023, respectively. The Company holds a line of credit with Pancreta Bank ("Pancreta LOC"), which is renewed annually and has a current interest rate of 4.10%. The maximum borrowing allowed as of September 30, 2024 and December 31, 2023 was $1,549,155 and $1,537,618, respectively. The outstanding balance of the Pancreta LOC as of September 30, 2024 and December 31, 2023 was $1,560,802 and $1,122,210, respectively. The Company maintains a line of credit with EGF ("EGF LOC"), which is renewed annually and has a current interest rate of 4.49% plus 3-month Euribor. The maximum borrowing allowed as of September 30, 2024 and December 31, 2023 was $445,800 and $459,400, respectively. The outstanding balance of the EGF LOC as of September 30, 2024 and December 31, 2023 was $386,577 and $459,400, respectively. Under the aforementioned line of credit agreements, the Company is required to maintain certain financial ratios and covenants. As of September 30, 2024, and December 31, 2023, the Company was in compliance with these ratios and covenants. All lines of credit are guaranteed by customer receivable checks, which are a type of factoring in which postponed customer checks are assigned by the Company to the bank, in order to be financed at an agreed upon rate. Interest expense on the Company’s outstanding lines of credit balances for the three and nine months ended September 30, 2024 and 2023, was $89,868 and $37,536, and 275,246 and $204,654, respectively.	NOTE 10 – LINES OF CREDIT A summary of the Company’s lines of credit as of December 31, 2023 and 2022, is presented below: December 31, 2023 December 31, 2022 National $ 3,918,523 $ 3,103,605 Alpha 1,130,140 991,492 Pancreta 1,122,210 1,232,128 EFG 459,400 431,512 Ending balance $ 6,630,273 $ 5,758,737 The Company has three lines of credit with the National Bank of Greece, which are renewed annually. The three lines have interest rates of 6.00% (the “National Bank LOC”), 3.6% (the “COSME 2 Facility”), and 3.6% plus the six-month Euribor rate and any contributions currently in force by law on certain lines of credit (the “COSME 1 Facility”). The maximum borrowing allowed for the 6% line of credit was $3,290,945 and $3,182,655 as of December 31, 2023 and 2022, respectively. The outstanding balance of the facility was $2,829,828 and $2,118,952, as of December 31, 2023 and 2022, respectively. The cumulative maximum borrowing allowed for the COSME 1 Facility and COSME 2 Facility (collectively, the “Facilities”) was $1,106,200 and $1,069,800 as of December 31, 2023 and 2022, respectively. The outstanding balance of the Facilities was $1,099,255 and $984,653 as of December 31, 2023 and 2022, respectively. The Company maintains a line of credit with Alpha Bank of Greece (“Alpha LOC”), which is renewed annually and has a current interest rate of 6.00%. The maximum borrowing allowed was $1,106,200 and $1,069,800 as of December 31, 2023 and 2022, respectively. The outstanding balance of the Alpha LOC was $1,130,141 and $991,429, as of December 31, 2023 and 2022, respectively. The Company holds a line of credit with Pancreta Bank (“Pancreta LOC”), which is renewed annually and has a current interest rate of 4.10%. The maximum borrowing allowed as of December 31, 2023 and 2022 was $1,537,618 and $1,487,022, respectively. The outstanding balance of the Pancreta LOC as of December 31, 2023 and 2022 was $1,122,210 and $1,232,128, respectively. The Company maintains a line of credit with EGF (“EGF LOC”), which is renewed annually and has a current interest rate of 4.49%. The maximum borrowing allowed as of December 31, 2023 and 2022 was $442,480 and $427,920, respectively. The outstanding balance of the EGF LOC as of December 31, 2023 and 2022 was $459,400 and $431,512, respectively. Under the aforementioned line of credit agreements, the Company is required to maintain certain financial ratios and covenants. As of December 31, 2023 and 2022, the Company was in compliance with these ratios and covenants. All lines of credit are guaranteed by customer receivable checks, which are a type of factoring in which postponed customer checks are assigned by the Company to the bank, in order to be financed at an agreed upon rate. Interest expense on the Company’s outstanding lines of credit balances for the years ended December 31, 2023 and 2022, was $393,628 and $294,156, respectively.

CONVERTIBLE DEBT

CONVERTIBLE DEBT	12 Months Ended
CONVERTIBLE DEBT	Dec. 31, 2023
CONVERTIBLE DEBT
CONVERTIBLE DEBT	NOTE 11 – CONVERTIBLE DEBT A summary of the Company’s convertible debt during the years ended December 31, 2023 and 2022 is presented below: 2023 2022 Beginning balance convertible notes $ 100,000 $ 640,000 New notes - Payments (100,000 ) (525,000 ) Conversion to common stock (15,000 ) Subtotal notes - 100,000 Debt discount at year end - - Convertible note payable, net of discount $ - $ 100,000 December 21, 2020 Securities Purchase Agreement On December 21, 2020 the Company entered into a convertible promissory note with Platinum Point Capital, LLC (the “Holder”, “Lender” or “Platinum”) pursuant to a Securities Purchase Agreement (the “SPA”). The Company issued the $540,000 Note in exchange for $500,000 in cash and included a $40,000 Original Issue Discount (“OID”) and paid $3,000 in financing costs. The principal amount together with interest at the rate of eight percent (8.0%) per annum, compounded annually (the “Interest Rate”), will be paid to the Lenders on or before the Maturity Date (December 31, 2021 or as defined below). Accrued interest shall be calculated on the basis of a 360-day year for the actual number of days elapsed. In the event that on or before the Maturity Date, the Note either (i) had not been converted or have not been otherwise satisfied in full or (ii) an Event of Default (as defined in the SPA) occurs, then the applicable rate of interest on the outstanding amount of the Note since inception shall be the Interest Rate plus eighteen percent (18.0%), the Default Interest. Unless previously converted, the principal and accrued interest on the Note is due and payable in cash (USD) upon the earlier of (i) December 31, 2021, (ii) a Change of Control (as defined in the SPA) or (iii), an Event of Default (collectively, the “Maturity Date”). On May 1, 2022, the Company issued 1,574 shares of common stock to convert the outstanding principal and accrued interest balance of $26,515. Following the conversion, the outstanding balance of the above Note is $0. Upon conversion, the 1,574 shares were issued at a fair value of $38,144 which was recorded as equity. Accordingly, upon conversion, the Company reduced its derivative liability by $11,629 (see Note 7). The Company determined that the embedded conversion feature of the convertible promissory note meets the definition of a derivative liability which is accounted for separately. The Company determined a derivative liability exists and determined that the embedded derivative was valued at $456,570 which was recorded as a debt discount, and together with the original issue discount and transaction expenses of $43,000, in the aggregate of $499,570, is being amortized over the life of the loan. As of December 31, 2022 the full amount of the debt discount has been amortized. Therefore, as of December 31, 2023 and 2022, the fair value of the derivative liability was $0 and $0, respectively. For the years ended December 31, 2023 and 2022, the Company recorded a loss on the change in fair value of the derivative of $0 and a loss of $5,807, respectively. January 7, 2021 Subscription Agreement On January 7, 2021 (the “Issue Date”), the Company entered into a subscription agreement with an unaffiliated third party, whereby the Company issued for a purchase price of $100,000 in principal amount, a convertible promissory note. The note bore an interest rate of 8% per annum and originally matured on the earlier of (i) consummation of the Company listing its common shares on the NEO Stock Exchange or (ii) October 31, 2021. However, the listing to NEO Stock Exchange did not occur. As of December 31, 2022, the Company had a principal balance of $100,000 and had accrued $13,740 in interest expense. During the year ended December 31, 2023, the Company paid the balance in full. The Company determined that the embedded conversion feature of the convertible promissory note meets the definition of a derivative liability which is accounted for separately. The Company measured the embedded derivative valued at $62,619 which was recorded as a debt discount and additional paid-in capital and was being amortized over the life of the loan. As of December 31, 2022, the debt discount had been fully amortized. As of December 31, 2023 and 2022, the fair value of the derivative liability was $0 and $54,293, respectively. For the years ended December 31, 2023 and 2022, the Company recorded a loss of $3,384 and $14,450, respectively, from the change in fair value of derivative liability, which is included in “Other expense, net" in the consolidated statements of operations and comprehensive loss. The Company considered both the note payable and conversion feature separately and upon settlement. The Company re-valued the conversion feature to fair value and applied extinguishment accounting as the debt has now been settled. Because the conversion feature is extinguished upon settling the note, the value of the conversion feature goes though debt extinguishment and the Company recorded a gain on settlement of debt, which totaled $50,909 for the year ended December 31, 2023. Convertible Promissory Note and Securities Purchase Agreement On September 17, 2021 (the “Issue Date”), the Company entered into a convertible promissory note and securities purchase agreement with an unaffiliated third party. Convertible Promissory Note The Company issued the convertible promissory note for a purchase price of $525,000 in principal amount for cash proceeds of $500,000. The note was issued with an original issue discount (“OID”) of $25,000, bears an interest rate of 10% per annum and matures on the earlier of (i) the consummation of the Company listing its common shares on the Nasdaq Stock Market or (ii) September 17, 2022. Upon the consummation of our Nasdaq listing in 2022, the total principal and accrued interest outstanding on the note would convert into shares of the Company’s common stock at a 30% discount to the prices of the common shares sold in the financing to be conducted in conjunction with our Nasdaq listing, subject to a conversion floor of $75.00. However, the Company, upon agreement with the third party, did not convert the note and fully repaid it in cash on October 21, 2022. As of December 31, 2022, the Company repaid the remaining outstanding balance of the note and thus its outstanding balance as of the end of the period was $0. For the years ended December 31, 2023 and 2022, the Company recorded amortization of debt discount in the amount of $0 and $18,185, respectively, which is included in "Non-cash interest expense" on the accompanying statements of operations and comprehensive loss. Securities Purchase Agreement On September 17, 2021, the Company entered into a Securities Purchase Agreement (the “SPA”) with a third party whereby the Company agree to issue 5,000,000 shares of Series A Preferred Stock at a purchase price of $1.00 per share or $5,000,000 in the aggregate, and a Warrant (the “Warrant”) to purchase 100% of the number of shares of the Company’s Common Stock issuable upon conversion of the Series A Preferred Stock. The Series A Preferred Stock will be convertible into the Company’s Common Stock as determined by multiplying the number of shares of Series A Preferred Stock to be converted by the lower of (i) $100.00 or (ii) 80% of the average volume weighted average price for the Company’s Common Stock for the five days prior to the date of Uplisting, subject to a floor of $75.00 per share. The shares of common stock issuable upon conversion of Series A Preferred Stock and exercise of the Warrants are subject to a Registration Right Agreement. The Warrant has an exercise price equal to 110% of the Conversion Price of the Series A Preferred Stock and expires five years from the date of issuance. The SPA is subject to certain conditions to close. As of December 31, 2023 and the date of this filing, the conditions to close had not been met, the funds have not been transferred, the preferred shares and the warrant was not issued. The SPA automatically terminated on March 31, 2022. Derivative Liabilities The table below provides a summary of the changes in fair value, including net transfers in and/or out of all financial liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the years ended December 31, 2023 and 2022: Amount Balance on January 1, 2022 $ 45,665 Issuances to debt discount - Reduction of derivative related to conversions (11,629 ) Change in fair value of derivative liabilities 20,257 Balance on December 31, 2022 54,293 Reduction of derivative related to conversions (50,909 ) Change in fair value of derivative liabilities (3,384 ) Balance on December 31, 2023 $ - The fair value of the derivative conversion features as of December 31, 2023 and 2022 were calculated using a Monte-Carlo option model valued with the following assumptions: December 31, December 31, 2023 2022 Dividend yield - 0% Expected volatility - 87.9%-157.2 Risk free interest rate - 1.46%-3.75 Contractual terms (in years) - 1.25 - 0.75

NOTES PAYABLE

NOTES PAYABLE	9 Months Ended	12 Months Ended
NOTES PAYABLE	Sep. 30, 2024	Dec. 31, 2023
NOTES PAYABLE
NOTES PAYABLE	NOTE 11 – NOTES PAYABLE A summary of the Company’s third-party debt as of and for the nine months ended September 30, 2024, and the year ended December 31, 2023 is presented below: September 30, 2024 Trade Facility Third Party COVID Loans Total Beginning balance, December 31, 2023 $ 1,908,195 $ 2,511,148 $ 186,884 $ 4,606,227 Proceeds - 445,800 - 445,800 Payments (334,350 ) (481,254 ) (19,073 ) (834,677 ) Conversion of debt - - - - Recapitalized upon debt modification - - - - Accretion of debt and debt discount - - - - Foreign currency translation 14,318 32,613 3,691 50,622 Ending balance, September 30, 2024 1,588,163 2,508,307 171,502 4,267,972 Notes payable - long-term (1,086,638 ) (1,416,802 ) 142,183 ) (2,645,623 ) Notes payable - short-term $ 501,525 $ 1,091,505 $ 29,319 1,622,349 December 31, 2023 Trade Facility Third Party COVID Loans Total Beginning balance, December 31, 2022 $ 3,305,532 $ 1,505,078 $ 207,377 $ 5,017,987 Proceeds - 1,082,231 - 1,082,231 Payments (1,155,310 ) (415,557 ) (27,027 ) (1,597,894 ) Oher additions - 317,880 - 317,880 Debt forgiveness (306,637 ) - - (306,637 ) Foreign currency translation 64,610 21,516 6,534 92,660 Ending balance, December 31, 2023 1,908,195 2,511,148 186,884 4,606,227 Notes payable – long-term (1,327,440 ) (1,549,768 ) (158,133 ) (3,035,341 ) Notes payable - short-term $ 580,755 $ 961,380 $ 28,751 $ 1,570,886 Our outstanding debt as of September 30, 2024 is repayable as follows: September 30, 2024 2025 $ 1,622,349 2026 1,717,738 2027 420,633 2028 353,961 2029 and thereafter 153,291 Total debt 4,267,972 Less: notes payable - current portion (1,622,349 ) Notes payable - long term portion $ 2,645,623 Trade Facility Agreements On May 12, 2017, SkyPharm entered into a Trade Finance Facility Agreement (the “TFF”) with Synthesis Structured Commodity Trade Finance Limited (the “Lender”) as amended on November 16, 2017, and May 16, 2018. On October 17, 2018, the Company entered into a further amended agreement with Synthesis whereby the current balance on the TFF as of October 1, 2018, which was €4,866,910 ($5,629,555) and related accrued interest of €453,094 ($524,094) would be split into two principal balances of Euro €2,000,000 ($2,316,000), (the "EURO Loan") and USD $4,000,000 (the "USD Loan"). Interest on both the EURO Loan and USD Loan commenced on October 1, 2018, at 6% per annum plus one-month Euribor (3.90% as of December 31, 2023), and 6% plus one-month LIBOR (fully paid as of December 31, 2023), respectively. On December 30, 2020, the Company transferred the EURO Loan to a new third-party lender. The terms remained the same except interest accrues at 5.5% per annum plus one-month Euribor (3.87% as of December 31, 2023). The principal was scheduled to be repaid in a total of five quarterly installments beginning October 31, 2021 of €50,000 ($54,600) each with a final repayment of €1,800,000 ($1,965,600) Euro payable on October 31, 2022. On March 3, 2022, the Company entered into a modification agreement to extend the maturity date to January 10, 2023 and payments under the USD Loan. During June 2022, the Company agreed with the Lender to postpone the repayment of an installment of $500,000 due on June 30, 2022 (based on the modification agreement signed on March 3, 2022) until January 2023. During September 2022, the Company entered into an agreement with the Lender to postpone the repayment of the outstanding balance on the USD Loan of $3,950,000, plus unpaid accrued interest until January 2023. The Company capitalized fees paid upon modification of €200,000 ($221,060) that are being amortized over the life of the loan. The Company incurred non-cash interest expense of $200,000 during the year ended December 31, 2022 concerning the above capitalized fees. On December 22, 2022, SkyPharm signed an agreement for the extension of the payments and an increase in interest rate due under the EURO Loan that was extended to be repaid with a balloon payment now due on October 31, 2025. This extension was agreed upon in writing on December 22, 2022, with a retroactive modification date to October 31, 2022 (the original maturity date). As of December 31, 2023 the Company had an outstanding principal balance of €1,725,000 ($1,908,195), of which $1,327,440 is classified as ''Notes payable - long term portion" on the consolidated balance sheets. As of December 31, 2023, the Company had accrued $161,274 in interest expense related to these agreements. The Company repaid €300,000 ($334,350) of the EURO Loan during the nine months ended September 30, 2024. As of September 30, 2024, the Company had an outstanding principal balance of €1,425,000 ($1,588,163), of which $1,086,638 is classified as ''Notes payable - long term portion" on the consolidated balance sheets. For the three and nine months ended September 30, 2024, the Company had accrued $29,365 and $110,170, respectively, in interest expense related to these agreements. June 23, 2020 Debt Agreement On June 23, 2020, the Company’s subsidiary, Cosmofarm, entered into an agreement with the National Bank of Greece S.A. (the “Bank”) to borrow a maximum of €500,000 ($611,500). The note has a maturity date of sixty (60) months from the date of the first disbursement, which includes a grace period of nine months. The total amount of the initial proceeds was received in 3 equal monthly installments. The note is interest bearing from the date of receipt and is payable every three months at an interest rate of 3.06% plus 3-month Euribor (3.47% as of September 30, 2024). The outstanding balance was €117,647 ($131,118) and €205,882 ($227,747) as of September 30, 2024 and December 31, 2023, respectively, of which $0 and $97,606 was classified as “Notes payable - long-term portion”, on the accompanying condensed consolidated balance sheets. During the nine months ended September 30, 2024, the Company repaid €88,235 ($98,338) of the principal balance. June 24, 2020 Debt Agreement On June 24, 2020, the Company’s subsidiary, Decahedron, received a loan £50,000 ($68,310) from the United Kingdom government. The loan has a ten-year maturity and bears interest at a rate of 2.5% per annum beginning 12-months after the initial disbursement, which was on July 10, 2020. The Company may prepay this loan without penalty at any time. As of December 31, 2023, the principal balance was £40,858 ($52,066). As of September 30, 2024, the principal balance was £38,320 ($51,345). November 19, 2020 Debt Agreement On November 19, 2020, the Company entered into an agreement with a third-party lender in the principal amount of €500,000 ($611,500). The note matures on November 18, 2025 and bears an annual interest rate, based on a 360-day year, of 3% plus 0.6% plus 6-month Euribor when Euribor is positive (3.35% as of September 30, 2024). The principal is to be repaid in 18 quarterly installments of €27,778 ($30,333). During the nine months ended September 30, 2024, the Company repaid €88,333 ($92,875) of the principal. As of September 30, 2024 and December 31, 2023, the Company has accrued interest of €5,434 ($6,057) and €11,191 ($12,379) related to this note and a principal balance of €138,889 ($154,792) and €222,222 ($245,822), of which $30,958 and $122,911 is classified as "Notes payable - long term portion" on the accompanying condensed consolidated balance sheets. July 30, 2021 Debt Agreement On July 30, 2021, the Company entered into an agreement with a third-party lender in the principal amount of €500,000 ($578,850). The note matures on August 5, 2026 and bears an annual interest rate that applies to 60% of the principal of the note that is based on a 365-day year, of 5.84% plus 3-month Euribor when Euribor is positive (3.47% as of September 30, 2024). Pursuant to the terms of the agreement, there is a nine-month grace period for principal repayment during which interest is accrued. The principal is to be repaid in 18 quarterly installments of €27,778 commencing three months from the end of the grace period. During the nine months ended September 30, 2024, the Company repaid €81,891 ($91,267) of the principal. As of September 30, 2024 and December 31, 2023, the Company had accrued interest of €15,328 ($17,083) and €10,905 ($12,063), respectively, and principal of €262,662 ($281,338) and €235,009 ($261,918), respectively, of which $134,929 and $227,065 is classified as “Notes payable - long term portion” on the accompanying condensed consolidated balance sheets. June 9, 2022 Debt Agreement On June 9, 2022 the Company entered into an agreement with a third-party lender in the principal amount of €320,000 ($335,008), the “Note”. The Note matures on June 16, 2027 and bears an annual interest rate of 3.89% plus an additional rate of 0.60%, plus the 3-month Euribor (3.47% as of September 30, 2024). Pursuant to the agreement, there is a twelve-month grace period for principal repayment during which interest is accrued. The principal is to be repaid in 16 equal quarterly installments of €20,000 commencing on June 30, 2023. During the nine months ended September 30, 2024, the Company repaid €60,000 ($66,870) of the principal. As of September 30, 2024 and December 31, 2023, the Company has accrued interest of €4,673 ($5,208) and €11,043 ($12,215), respectively, and an outstanding balance of €200,000 ($222,900) and €260,000 ($287,612) of which $133,740 and $204,322, respectively, is classified as “Notes payable - long term portion” on the accompanying condensed consolidated balance sheets. July 14, 2023 Debt Agreement On July 14, 2023 the Company entered into an agreement with a third-party lender in the principal amount of €1,000,000 ($1,123,700), the “Note”. The Note matures on July 31, 2028 and bears an annual interest rate of 2.46% plus the 3-month Euribor (3.47% as of September 30, 2024). Pursuant to the agreement, there is a nine-month grace period for interest and principal repayment. The principal is to be repaid in 18 equal quarterly installments of €55,556 commencing on May 2, 2024. During the nine months ended September 30, 2024, the Company repaid €108,633 ($58,179) of the principal. As of September 30, 2024, and December 31, 2023, the Company has accrued interest of €7,845 ($8,743) and €19,820 ($21,925), respectively. As of September 30, 2024, and December 31, 2023 the Company an outstanding balance of €869,067 ($968,575) and €977,700 ($1,081,532), of which $720,908 and $897,165, respectively, is classified as “Notes payable - long term portion” on the accompanying condensed consolidated balance sheets. July 29, 2024 Debt Agreement On July 29, 2024 the Company entered into an agreement with a third-party lender in the principal amount of €400,000 ($432,760), the “Note”. The Note matures on July 31, 2029 and bears an annual interest rate of 2.58% plus the 3-month Euribor (3.47% as of September 30, 2024). Pursuant to the agreement, there is a six-month grace period for principal and interest repayment. The principal is to be repaid in 18 equal quarterly installments of €22,222 commencing on April 30, 2025. During the nine months ended September 30, 2024, the Company repaid no principal and had not accrued any interest. As of September 30, 2024, and December 31, 2023 the Company an outstanding balance of €400,000 ($445,800) and €0 ($0), of which $396,367 and $0, respectively, is classified as “Notes payable - long term portion” on the accompanying condensed consolidated balance sheets. COVID-19 Loans On May 12, 2020, the Company’s subsidiary, SkyPharm, was granted and on May 22, 2020 received a €300,000 ($366,900) loan from the Greek government. The loan will be repaid in 40 equal monthly installments beginning on July 29, 2022. As a condition to the loan, the Company was required to retain the same number of employees until October 31, 2020. As of December 31, 2023, the principal balance was $134,818. During the nine months ended September 30, 2024, the Company repaid €14,063 ($15,673) of the principal balance. The outstanding balance as of September 30, 2024 is €107,813 ($120,157) of which $99,260, is classified as “Notes payable - long term portion” on the accompanying condensed consolidated balance sheet. Cloudscreen Promissory Note On January 23, 2024 the Company entered into an agreement with a third-party in the principal amount of €300,000 ($324,870), the “Promissory Note”. The Promissory Note matures on March 25, 2025 and is interest free. This Note is being given in connection with the Closing of the Asset Purchase, Sale and Transfer Agreement dated as of October 9, 2023 and as amended from time to time pursuant to which the Company agreed to purchase from the third-party a drug repurposing Artificial Intelligence “AI” powered platform known as “Cloudscreen®” (refer to Note 2, section “Acquisition accounting”). The principal is to be repaid in 15 equal monthly installments of €20,000 commencing on January 25, 2024. During the 9 months ended September 30, 2024, the Company repaid €10,000 ($10,830) of the principal and recorded a foreign currency loss of $16,155. As of September 30, 2024, and December 31, 2023 the Company had an outstanding balance of $323,205 and $317,880 of which $0 and $0, respectively, is classified as “Notes payable - long term portion” on the accompanying condensed consolidated balance sheets. Distribution and Equity Agreement As discussed in Note 3 above, the Company entered into a Distribution and Equity Acquisition Agreement with Marathon. The Company was appointed the exclusive distributor of the Products (as defined) initially throughout Europe and on a non-exclusive basis wherever else lawfully permitted. As consideration for its services, Company received: (a) a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in Common Shares of the Company if it fails to meet certain performance milestones. The Company is entitled to receive an additional CAD $2,750,000 upon the Company’s receipt of gross sales of CAD $6,500,000 and an additional CAD $2,750,000 upon receipt of gross sales of CAD $13,000,000. As discussed in Note 3, the Company attributed no value to the shares received in Marathon pursuant to (a) above. In relation to the CAD $2 million cash received noted in (b) above, the Company accounted for its obligation to issue a variable number of the Company’s Common Shares as Share-settled debt obligation in accordance with ASC 480 measured at fair value or the settlement amount of $1,554,590 (CAD $2 million). If settlement had occurred on December 31, 2022, the Company would have been required to issue 420,471 common shares to settle its debt obligation. The Company could be obligated to potentially issue an unlimited number of common shares to settle its Share-settled debt obligation. On March 20, 2023, the Company’s legal counsel provided notice to Marathon Global Inc, that Cosmos terminated the Equity agreement dated on March 19, 2018 pursuant to Section 3.2 and that termination is effective thirty days from the date of the letter. None of the above loans were made by any related parties.	NOTE 12 – NOTES PAYABLE A summary of the Company’s third-party debt during the years ended December 31, 2023 and 2022 is presented below: December 31, 2023 Trade Facility Third Party COVID Loans Total Beginning balance, December 31, 2022 $ 3,305,532 $ 1,505,078 $ 207,377 $ 5,017,987 Proceeds - 1,082,231 - 1,082,231 Payments (1,155,310 ) (415,557 ) (27,027 ) (1,597,894 ) Oher additions - 317,880 - 317,880 Debt forgiveness (306,637 ) - - (306,637 ) Foreign currency translation 64,610 21,516 6,534 92,660 Ending balance, December 31, 2023 1,908,195 2,511,148 186,884 4,606,227 Notes payable – long-term (1,327,440 ) (1,549,768 ) (158,133 ) (3,035,341 ) Notes payable - short-term $ 580,755 $ 961,380 $ 28,751 $ 1,570,886 December 31, 2022 Loan Facility Trade Facility Third Party COVID Loans Total Beginning balance $ 1,299,784 $ 6,207,010 $ 10,077,977 $ 641,291 $ 18,226,062 Proceeds - - 492,336 - 492,336 Payments (240,705 ) (2,795,786 ) (9,494,823 ) (10,029 ) (12,541,343 ) Conversion of debt (1,190,000 ) - - - (1,190,000 ) Recapitalized upon debt modification (81,923 ) (221,060 ) (781,752 ) - (1,084,735 ) Accretion of debt and debt discount 81,910 216,182 781,752 - 1,079,844 Prior year reclassification from Line of Credit - - 407,174 (407,174 ) - Foreign currency translation 130,934 (100,814 ) 22,414 (16,711 ) 35,823 Subtotal - 3,305,532 1,505,078 207,377 5,017,987 Notes payable - long-term - (1,604,700 ) (1,076,698 ) (178,172 ) (2,859,570 ) Notes payable - short-term $ - $ 1,700,832 $ 428,380 $ 29,205 $ 2,158,417 Our outstanding debt as of December 31, 2023 is repayable as follows: December 31, 2023 2024 $ 1,570,886 2025 2,032,967 2026 457,784 2027 312,314 2028 and thereafter 232,276 Total debt 4,606,227 Less: notes payable - current portion (1,570,886 ) Notes payable - long term portion $ 3,035,341 Loan Facility Agreement On August 4, 2021, the Company entered into an exchange agreement for the existing loan facility agreement with Synthesis Peer-to-Peer Income Fund, whereby the Company agreed to the following: • issue on August 4, 2021, 12,852 shares of common stock to settle $1,606,500 (€1,350,000) of debt. The Company recorded a gain on settlement of $292,383 upon the issuance of the 12,852 shares; and • issue no more than 9,520 shares of common stock upon approval of the listing of the Company’s common stock on Nasdaq to settle $1,190,000 (€1,000,000) of debt. The Company issued these shares on February 28, 2022. Upon issuance of the 9,520 shares of common stock, the Company recorded a gain on extinguishment of debt in the amount of $216,580 determined using the fair value of the Company’s common stock at the commitment date of $102.25 per share. The principal debt balance was paid in full during the year ended December 31, 2022. As of December 31, 2023 and 2022, the outstanding principal balance on the debt was $0, and it had accrued interest expense of $0 and $12,853, respectively. The debt is subject to acceleration in an Event of Default (as defined in the Notes). This agreement is secured by a personal guaranty of Grigorios Siokas, which is secured by a pledge of 40,000 shares of common stock of the Company owned by Mr. Siokas. During the year ended December 31, 2022, the maturity of the facility was informally extended to December 31, 2022. The Company reassessed and adjusted accordingly the accretion of the debt extinguishment effect described above. Trade Facility Agreements On May 12, 2017, SkyPharm entered into a Trade Finance Facility Agreement (the “TFF”) with Synthesis Structured Commodity Trade Finance Limited (the “Lender” or “Synthesis”) as amended on November 16, 2017, and May 16, 2018. On October 17, 2018, the Company entered into a further amended agreement with Synthesis whereby the current balance on the TFF as of October 1, 2018, which was €4,866,910 ($5,629,555) and related accrued interest of €453,094 ($524,094) would be split into two principal balances of Euro €2,000,000 ($2,316,000), (the “EURO Loan”) and USD $4,000,000 (the “USD Loan”). Interest on both the EURO Loan and USD Loan commenced on October 1, 2018, at 6% per annum plus one-month Euribor (3.90% as of December 31, 2023), and 6% plus one-month LIBOR (fully paid as of December 31, 2023), respectively. On December 30, 2020, the Company transferred the EURO Loan to a new third-party lender. The terms remained the same except interest accrues at 5.5% per annum plus one-month Euribor (3.87% as of December 31, 2023). The principal was scheduled to be repaid in a total of five quarterly installments beginning October 31, 2021 of €50,000 ($54,600) each with a final repayment of €1,800,000 ($1,965,600) Euro payable on October 31, 2022. On March 3, 2022, the Company entered into a modification agreement to extend the maturity date to January 10, 2023 and payments under the USD Loan. During June 2022, the Company agreed with the Lender to postpone the repayment of an installment of $500,000 due on June 30, 2022 (based on the modification agreement signed on March 3, 2022) until January 2023. During September 2022, the Company entered into an agreement with the Lender to postpone the repayment of the outstanding balance on the USD Loan of $3,950,000, plus unpaid accrued interest until January 2023. The Company capitalized fees paid upon modification of €200,000 ($221,060) that are being amortized over the life of the loan. The Company incurred non-cash interest expense of $200,000 during the year ended December 31, 2022 concerning the above capitalized fees. During the year ended December 31, 2022, the Company repaid €175,000 ($191,100) of the EURO Loan and $2,593,363 of the USD Loan such that as of December 31, 2022, the Company had principal balances of €1,775,000 ($1,898,895) and $1,406,637 under the agreements, respectively. As of December 31, 2022, the Company had accrued $4,878 in interest expense related to these agreements. On December 21, 2022 the USD Loan was assigned to GIB Fund Solutions ICAV (the “Fund”). On January 31, 2023, the Company paid $1,100,000 to the Fund under a full and final settlement agreement for the USD Loan, recording a gain on extinguishment of debt of $306,637 relating to the waiver of the unpaid balance. Additionally, the Company repaid €50,000 ($55,310) of the EURO Loan during the year ended December 31, 2023. As of December 31, 2023 the Company had an outstanding principal balance of €1,725,000 ($1,908,195), of which $1,327,440 is classified as “Notes payable - long term portion” on the consolidated balance sheets. As of December 31, 2023, the Company had accrued $161,274 in interest expense related to these agreements. On December 22, 2022, SkyPharm signed an agreement for the extension of the payments and an increase in interest rate due under the EURO loan that was extended to be repaid with a balloon payment now due on October 31, 2025. This extension was agreed upon in writing on December 22, 2022, with a retroactive modification date to October 31, 2022 (the original maturity date). Third Party Debt On November 16, 2015, the Company entered into a Loan Agreement with Panagiotis Drakopoulos, the Company’s former Director and former Chief Executive Officer, pursuant to which the Company borrowed €40,000 ($42,832) as a note payable from Mr. Drakopoulos. The note bore an interest rate of 6% per annum and was due and payable in full on November 15, 2016. As of December 31, 2022, the Company had an outstanding principal balance of €8,000 ($8,558) and accrued interest of €6,797 ($7,271). During the year ended December 31, 2023, the Company repaid the entire outstanding balance of €8,000. Therefore, as of December 31, 2023, the outstanding principal balance was $0. Mr. Drakopoulos is not considered a related party since he is no longer employed by the Company and currently holds no equity position in the Company. May 18, 2020, July 3, 2020, and August 4, 2020 Senior Promissory Notes Modification of May 18, 2020, July 3, 2020, and August 4, 2020 Senior Promissory Notes On February 23, 2022, the Company entered into modification agreements to extend the due dates of the May 18 Note, July 3 Note, and August 4 Note to June 30, 2023, totaling $9,000,000, in the aggregate. The Company paid restructuring fees totaling $506,087 upon modification. The Company determined the modification should be recorded as debt extinguishment in accordance with ASC 470 because the present value of the remaining cash flows under the terms of the new debt instrument is at least 10% different from the present value of the remaining cash flows under the terms of the original instrument. The Company recorded the new debt at fair value in the amount of $7,706,369 and a gain upon extinguishment in the amount of $787,544. During the year ended December 31, 2022, the Company repaid the aggregate principal balance of $7,000,000 and the aggregate accrued interest related to these notes in full. June 23, 2020 Debt Agreement On June 23, 2020, the Company’s subsidiary, Cosmofarm, entered into an agreement with the National Bank of Greece S.A. (the “Bank”) to borrow a maximum of €500,000 ($611,500). The note has a maturity date of 60 months from the date of the first disbursement, which includes a grace period of nine months. The total amount of the initial proceeds was received in three equal monthly installments. The note is interest bearing from the date of receipt and is payable every three months at an interest rate of 3.06% plus 3-month Euribor (3.96% as of December 31, 2023). The outstanding balance was €205,882 ($227,747) and €323,529 ($346,111) as of December 31, 2023 and 2022, respectively, of which $97,606 and $220,253 was classified as “Notes payable - long-term portion” respectively, on the accompanying consolidated balance sheets. During the year ended December 31, 2023, the Company repaid €117,647 ($130,141) of the principal balance. June 24, 2020 Debt Agreement On June 24, 2020, the Company’s subsidiary, Decahedron, received a loan £50,000 ($68,310) from the United Kingdom government. The loan has a ten-year maturity and bears interest at a rate of 2.5% per annum beginning 12-months after the initial disbursement, which was on July 10, 2020. The Company may prepay this loan without penalty at any time. As of December 31, 2022, the principal balance was £47,144 ($56,936). As of December 31, 2023, the principal balance was £40,858 ($52,066). November 19, 2020 Debt Agreement On November 19, 2020, the Company entered into an agreement with a third-party lender in the principal amount of €500,000 ($611,500). The note matures on November 18, 2025 and bears an annual interest rate, based on a 360-day year, of 3% plus .6% plus 6-month Euribor when Euribor is positive (4% as of December 31, 2023). The principal is to be repaid in 18 quarterly installments of €27,778 ($30,333). During the year ended December 31, 2022, the Company repaid €111,111 ($118,867) of the principal and as of December 31, 2022, the Company had accrued interest of $8,069 related to this note and a principal balance of €333,333 ($356,600), of which $237,733 is classified as “Notes payable - long term portion” on the accompanying consolidated balance sheets. During the year ended December 31, 2023, the Company repaid €111,111 ($122,911) of the principal and as of December 31, 2023, the Company has accrued interest of €11,191 ($12,379) related to this note and a principal balance of €222,222 ($245,822), of which $122,911 is classified as “Notes payable - long term portion” on the accompanying consolidated balance sheets. July 30, 2021 Debt Agreement On July 30, 2021, the Company entered into an agreement with a third-party lender in the principal amount of €500,000 ($578,850). The note matures on August 5, 2026 and bears an annual interest rate that applies to 60% of the principal of the note that is based on a 365-day year, of 5.84% plus 3-month Euribor when Euribor is positive (3.96% as of December 31, 2023). Pursuant to the terms of the agreement, there is a nine-month grace period for principal repayment during which interest is accrued. The principal is to be repaid in 18 quarterly installments of €27,778 commencing three months from the end of the grace period. During the year ended December 31, 2022, the Company repaid €77,985 ($83,428) of the principal balance. As of December 31, 2022, the Company had accrued interest of €2,509 ($2,728) and a principal balance of €422,016 ($451,472), of which $336,788 is classified as notes payable – long term portion on the accompanying consolidated balance sheet. During the year ended December 31, 2023, the Company repaid €79,006 ($87,396) of the principal. As of December 31, 2023 and 2022, the Company had accrued interest of €10,905 ($12,063) and €2,898 ($3,100) principal of €316,900 ($350,555) and €500,000 ($565,900), of which $227,065 and $477,637 is classified as “Notes payable - long term portion” on the accompanying consolidated balance sheets. June 9, 2022 Debt Agreement On June 9, 2022 the Company entered into an agreement with a third-party lender in the principal amount of €320,000 ($335,008), the “Note”. The Note matures on June 16, 2027 and bears an annual interest rate of 3.89% plus an additional rate of 0.60%, plus the 3-month Euribor (3.96% as of December 31, 2023). Pursuant to the agreement, there is a 12-month grace period for principal repayment during which interest is accrued. The principal is to be repaid in 17 equal quarterly installments of €18,824 commencing on June 30, 2023. During the year ended December 31, 2023, the Company repaid €60,000 ($66,372) of the principal. As of December 31, 2023 and 2022 the Company has accrued interest of €11,043 ($12,215) and €7,707 ($8,379), respectively, and an outstanding balance of €260,000 ($287,612) and €320,000($342,336), of which $204,322 and $281,924, respectively, is classified as “Notes payable - long term portion” on the accompanying consolidated balance sheets. August 29, 2022 Promissory Note On August 29, 2022, the Company entered into a promissory note for the principal amount of $166,667. The Company received $150,000 in cash and recorded $16,667 as an original issue discount upon issuance. The promissory note matured on the earlier of (a) December 27, 2022, or (b) the date the Company completes a debt or equity financing of at least $1,000,000. The debt carried an annual interest rate of 12% which was due upon maturity. As of December 31, 2022, the Company had repaid the principal balance in full and had a balance of $5,041 in accrued interest related to this note. The Company repaid the outstanding interest during the year ended December 31, 2023 and thus the balance of both principal and interest as of December 31, 2023 is $0. July 14, 2023 Debt Agreement On July 14, 2023 the Company entered into an agreement with a third-party lender in the principal amount of €1,000,000 ($1,123,700), the “Note”. The Note matures on July 31, 2028 and bears an annual interest rate of 2.46% plus the 3-month Euribor (3.96% as of December 31, 2023). Pursuant to the agreement, there is a nine-month grace period for interest and principal repayment. The principal is to be repaid in 18 equal quarterly installments of €55,556 commencing on May 2, 2024. As of December 31, 2023 and 2022 the Company an outstanding balance of €977,700 ($1,081,532) and $0, of which $897,165 and $0, respectively, is classified as “Notes payable - long term portion” on the accompanying consolidated balance sheets. COVID-19 Loans On May 12, 2020, the Company’s subsidiary, SkyPharm, was granted and on May 22, 2020 received a €300,000 ($366,900) loan from the Greek government. The loan will be repaid in 40 equal monthly installments beginning on July 29, 2022. As a condition to the loan, the Company was required to retain the same number of employees until October 31, 2020. As of December 31, 2022, the principal balance was $150,441. During the year ended December 31, 2023, the Company repaid €18,750 ($20,741) of the principal balance. The outstanding balance as of December 31, 2023 is €121,875 ($134,818). Distribution and Equity Agreement As discussed in Note 3 above, the Company entered into a Distribution and Equity Acquisition Agreement with Marathon. The Company was appointed the exclusive distributor of the Products (as defined) initially throughout Europe and on a non-exclusive basis wherever else lawfully permitted. As consideration for its services, Company received: (a) a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in Common Shares of the Company if it fails to meet certain performance milestones. The Company is entitled to receive an additional CAD $2,750,000 upon the Company’s receipt of gross sales of CAD $6,500,000 and an additional CAD $2,750,000 upon receipt of gross sales of CAD $13,000,000. As discussed in Note 3, the Company attributed no value to the shares received in Marathon pursuant to (a) above. In relation to the CAD $2 million cash received noted in (b) above, the Company accounted for its obligation to issue a variable number of the Company’s Common Shares as Share-settled debt obligation in accordance with ASC 480 measured at fair value or the settlement amount of $1,554,590 (CAD $2 million). If settlement were to occur on December 31, 2022, the Company would be required to issue 420,471 common shares to settle its debt obligation. The Company could be obligated to potentially issue an unlimited number of common shares to settle its Share-settled debt obligation. On March 20, 2023, the Company’s legal counsel provided notice to Marathon, that the Company terminated the Distribution and Equity Acquisition agreement dated on March 19, 2018 pursuant to Section 3.2 and that termination is effective thirty days from the date of the letter. None of the above loans were made by any related parties.

LEASES

LEASES	9 Months Ended	12 Months Ended
LEASES	Sep. 30, 2024	Dec. 31, 2023
LEASES
LEASES	NOTE 12 – LEASES The Company has various operating and finance lease agreements with terms up to 10 years, for various types of property and equipment (such as office space and vehicles) etc. Some leases include options to purchase, terminate or extend for one or more years. These options are included in the lease term when it is reasonably certain that the option will be exercised. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term. Operating Leases The Company’s weighted-average remaining lease term relating to its operating leases is 4.08 years, with a weighted-average discount rate of 6.74%. The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s operating leases as of September 30, 2024: Maturity of Operating Lease Liability 2024 82,319 2025 243,175 2026 179,151 2027 and thereafter 300,301 Total undiscounted operating lease payments $ 804,946 Less: Imputed interest (95,366 ) Present value of operating lease liabilities $ 709,580 The Company incurred lease expense, due to amortization of operating lease right-of-use assets, of $76,229 and $50,690 and $235,659 and $158,407, which was included in “General and administrative expenses,” for the three and nine months ended September 30, 2024 and 2023, respectively. Finance Leases The Company’s weighted-average remaining lease term relating to its finance leases is 1.19 years, with a weighted-average discount rate of 6.74%. The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s finance leases as of September 30, 2024: Maturity of Lease Liability 2024 9,039 2025 12,892 2026 3,712 Total undiscounted finance lease payments $ 25,643 Less: Imputed interest (910 ) Present value of finance lease liabilities $ 24,733 The Company had financing cash flows used in finances leases of $9,765 and $41,094 and $27,118 and $118,847 for the three and nine months ended September 30, 2024 and 2023, respectively. The Company incurred interest expense on its finance leases of $457 and $6,920 and interest expense of $1,765 and $20,629 which was included in “Interest expense”, for the three and nine months ended September 30, 2024 and 2023, respectively. The Company incurred amortization expense on its finance leases of $7,589 and $35,452 and amortization expense of $22,507 and $102,549 which was included in “Depreciation and amortization expense,” for the three and nine months ended September 30, 2024 and 2023, respectively.	NOTE 13 – LEASES The Company has various operating and finance lease agreements with terms up to ten years, for various types of property and equipment (such as office space and vehicles) etc. Some leases include options to purchase, terminate or extend for one or more years. These options are included in the lease term when it is reasonably certain that the option will be exercised. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term. Operating Leases The Company’s weighted-average remaining lease term relating to its operating leases is 5.66 years, with a weighted-average discount rate of 6.74%. The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s operating leases as of December 31, 2023: Maturity of Operating Lease Liability 2024 350,428 2025 264,420 2026 199,155 2027 and thereafter 541,818 Total undiscounted operating lease payments $ 1,355,821 Less: Imputed interest (225,392 ) Present value of operating lease liabilities $ 1,130,429 The Company incurred lease expense, due to amortization of operating lease right-of-use assets, of $364,968 and $210,463 which was included in “General and administrative expenses,” for the 12 months ended December 31, 2023 and 2022, respectively. Finance Leases The Company’s weighted-average remaining lease term relating to its finance leases is 1.16 years, with a weighted-average discount rate of 6.74%. The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s finance leases as of December 31, 2023: Maturity of Lease Liability 2024 28,420 2025 5,337 Total undiscounted finance lease payments $ 33,757 Less: Imputed interest (1,274 ) Present value of finance lease liabilities $ 32,483 The Company had financing cash flows used in finances leases of $ 28,420 and $99,906 for the years ended December 31, 2023 and 2022, respectively. The Company incurred interest expense on its finance leases of $ 2,903 and $16,467 which was included in “Interest expense,” for the years ended December 31, 2023 and 2022, respectively. The Company incurred amortization expense on its finance leases of $23,685 and $85,696 which was included in “Depreciation and amortization expense,” for the years ended December 31, 2023 and 2022, respectively.

OTHER LIABILITIES

OTHER LIABILITIES	9 Months Ended	12 Months Ended
OTHER LIABILITIES	Sep. 30, 2024	Dec. 31, 2023
OTHER LIABILITIES
OTHER LIABILITIES	NOTE 13 – OTHER LIABILITIES The Company’s other liabilities include but are not limited to liabilities to local tax authorities, fines and payroll taxes, which comprise the largest portion of the balance as of September 30, 2024. The Company’s Greek subsidiaries have $1,812,919 in settled tax liabilities payable to the tax authorities in installments and $1,799,431 in payroll and other tax related current liabilities. Moreover, we have recorded a provision relating to the unaudited tax years of our subsidiary SkyPharm SA, of $644,779 and a provision for staff leaving compensation, based on the corresponding actuarial reports, of $411,732. Additionally, we have received prepayments from our customers of $451,575 and recorded accrued sales discounts of $407,725 included in “Other current liabilities” as of September 30, 2024. We classify the liabilities payable within the twelve months following the balance sheet date in “Other current liabilities” and the remaining balance is included in “Other Liabilities”.	NOTE 14 – OTHER LIABILITIES The Company’s other liabilities include but are not limited to liabilities to local tax authorities, fines and payroll taxes, which comprise the largest portion of the balance as of December 31, 2023. The Company’s Greek subsidiaries have $2,430,517 in settled tax liabilities payable to the tax authorities in installments and $1,046,507 in payroll tax related current liabilities. Moreover, we have recorded a provision relating to the unaudited tax years of our subsidiary SkyPharm SA, of $591,547 and a provision for staff leaving compensation, based on the corresponding actuarial reports, of $408,665. Additionally, we have received prepayments from our customers of $207,204, included in “Other current liabilities” as of December 31, 2023. We classify the liabilities payable within the 12 months following the balance sheet date in “Other current liabilities” and the remaining balance is included in “Other Liabilities”.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended	12 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2024	Dec. 31, 2023
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	NOTE 14 – COMMITMENTS AND CONTINGENCIES Legal Matters From time to time, the Company may be involved in litigation relating to claims arising out of the Company’s operations in the normal course of business. As of September 30, 2024, the following litigations were pending. None of the below is expected to have a material financial or operational impact. On July 22, 2015, the National Medicines Agency approved the license of wholesale sale of pharmaceutical products under the name SkyPharm SA with set validity at five years and an expiration date of July 22, 2020. Subsequently, SkyPharm on June 15, 2020, legally and timely submitted the application for renewal of the wholesale license of pharmaceutical products to the National Medicines Agency. The National Medicines Agency did not respond, therefore the Company asked for an immediate decision on the renewal. Two months after the filing of the no. 3459 / 15.01.2021 letter and almost nine months after the no. 627615.06.2020 Company application for the renewal, the National Medicines Agency replied by rejecting the renewal request on March 9, 2021 (ref. 62769 / 20-25.02.2021). In addition, document No. 127351-16.12.2021 of EOF (Greek National Medicines Organization) to SkyPharm states that after an inspection of EOF at the premises of Doc Pharma, we did not have a wholesale license in violation of article 106 par. 1b and par. 1c of the ministerial decision D.YG3a / GP.32221 / 29-4-2019. The National Medicines Agency imposed a fine of €15,000 ($16,214) on SkyPharm for the above case, which was included in “General and administrative expenses” on the accompany statement of operations and comprehensive loss for the twelve-month ended December 31, 2023. There has been a payment request by the Greek court, which relates to a fine arising from Cosmofarm’s tax audit for financial year 2014. The law with no. 483/16.12.2020 was used by the court against Cosmofarm (the “defendant”). The defendant appealed against the decision using the law with no.11541/09.03.2021. This appeal was dismissed after 120 days from its submission to the court. Additionally, there had been an obligation for payment of additional tax and fines related to this matter in the amount of €91,652 ($99,644), which the defendant has already settled. However, the defendant has claimed back the respective amount through appeal. As of September 30, 2024, the trial is still pending. On January 25, 2023, a criminal case of dishonored checks against Cosmofarm’s customer Filippou, was heard at the Z’ Three-Member Misdemeanor Court of Athens, which was postponed to November 27, 2023, when the defendant was tried and found guilty. On January 26, 2023, the appeal of the Company against Eleutheria Drakopoulou and decision 1389/2021of the Single-Member Court of First Instance of Athens was heard at the Athens Court of Appeal. The appeal was partially accepted. The Court ordered the return of the fee to the appellants, dismissed the action against the third defendant, Kozaris and accepted the action as regards the first and the second defendants (Kastrantas & Cosmofarm). On October 23, 2023, a criminal case of dishonored checks against Cosmofarm’s customer Kafantaris was heard at the Sixth Single-Member Misdemeanor Court of Athens, which was postponed to January 26, 2024, when the defendant was convicted by decision no. 1599/2024. In October 2023, the Company’s subsidiary, Cana Laboratories was approached by an attorney on behalf of two clients which were requesting an amount of €39,211 as compensation for the value of 34.70 square meters in relation to an urban sprawl with respect to which an Act of Imputation had been issued by the department of Urban Planning. Our legal counsel’s response was that CANA was not obliged to accept the compensatory value agreed and suggested exploring out of court settlement. As of today, the clients’ Attorney at law has not come back with any suggestions. Our subsidiary, Cana Laboratories, has two pending lawsuits against Euaggelismos Hospital for a total sum of EUR 526,436 due to unpaid bills. The court date for one of the two lawsuits is set for December 11, 2024, and for the other one has not yet been set. The opinion of our legal advisor is that the collection of the total sum by the Company is almost certain. Our subsidiary, Cana Laboratories, has an unasserted claim against Papanikolaou Hospital for a total sum of EUR 89,300 due to unpaid bills, which will be asserted through a lawsuit. The opinion of our legal advisor is that the collection of the sum by the Company is almost certain. A lawsuit dated April 5, 2018 against the Company’s subsidiary Cana Laboratories by a former employee before the Athens court of instance was initially heard on October 12, 2018. The former employee was seeking that the termination of her employment contract to be considered null and void and was requesting compensation for late wages and moral damages. Following numerous appeals, Judgment No. 1192/2024 was issued on September 26, 2023, which as explicitly stated by our legal counsel, requires CANA to rehire the former employee with the threat of a penalty of €200 for each day of non-compliance. As informed by our legal counsel, in order for the penalty to be effective the former employee should file a new lawsuit against CANA and request to get rehired. In case CANA denies employment, then the penalty should be in effect. As of today, we have not received neither a lawsuit nor any request of employment by the former employee. Advisory Agreements On July 1, 2021, the Company entered into a two-year advisory agreement with a third party (the “Consultant”) for advisory and consulting services related to the Company’s intention to become listed on Nasdaq. Peter Goldstein, a then director of the Company is a principal of the Consultant. As consideration for services rendered, and successful Nasdaq listing, the Company paid $100,000. The $100,000 bonus was incurred and settled within 2022. Finally, the Consultant received a total of 10,000 shares of the Company’s common stock, 2,000 of such shares that have been previously issued pursuant to previous agreements and additional 15,258 shares that were issued on February 2, 2023, based on the amendment signed on February 1, 2023. On November 21, 2023, the Company entered into certain consulting agreements with four third-party consultants for the provision of a variety of services such as digital marketing, advisory services relating to target acquisitions and M&As and other additional services as described in the respective agreements. The agreements have a duration from 10 to 18 months and the consultants will solely receive stock consideration for the services rendered. More precisely, they have been awarded a total of 970,000 shares of the Company’s common stock valued at a total of $999,100 based on the fair value of the Company’s common stock as of the agreements’ date. On September 17, 2024 the termination of two out of the four aforementioned consulting agreements was extended and the consultants received additional 440,000 shares as complementary compensation for the extended services to be provided. The additional stock consideration was valued at a total of $501,600 based on the fair value of the Company’s common stock as of the agreements’ date. On July 1, 2024 the Company entered into a consulting agreement with a third-party consultant for the provision of a variety of services such as preparation of press releases and other publications, relationship management and other additional services as described in the respective agreement. The agreement has a duration of sixteen months and the consultant will solely receive stock consideration for the services rendered. More precisely, they have been awarded a total of 240,000 shares of the Company’s common stock valued at a total of $264,000 based on the fair value of the Company’s common stock as of the agreements’ date. The corresponding consulting expense is accrued evenly over the term of the agreements. For the twelve-month period ended December 31, 2023 the Company has recorded $77,250 as stocked based compensation for the above agreements, classified as “General and administrative expenses” in the Company’s consolidated statements of operations and comprehensive loss. For the three and nine months ended September 30, 2024 and 2023 the Company has recorded $264,750 and $728,250 and $0 and $0 as stocked based compensation for the above agreements, classified as “General and administrative expenses” in the Company’s Condensed Consolidated Statements of Operations and Comprehensive Loss. Research and Development Agreements The Company entered into a Research & Development agreement with Doc Pharma S.A. on May 17, 2021. Under this agreement, Doc Pharma is responsible for the research, development, design, registration, copy rights and licenses of 250 nutritional supplements for the final products called Sky Premium Life ® On June 26, 2022, the Company signed a research and development (“R&D”) agreement with a third party, through which the Company assigns to the third party the development of new products and services in the field of health, focusing on the human intestinal microbiome. The project includes two phases. Phase 1 has a 20-month duration and its cost amounts to EUR 758,000 ($838,450) and phase 2, has a 22-month duration and a cost of EUR 820,000 ($907,084). The amount will be due and payable upon completion of the corresponding phases. The Company records the corresponding R&D expense based on the project’s progress, which is invoiced by the third party in the relevant period. For the nine-month period ended September 30, 2024, the Company has not incurred such costs.	NOTE 15 – COMMITMENTS AND CONTINGENCIES Legal Matters From time to time, the Company may be involved in litigation relating to claims arising out of the Company’s operations in the normal course of business. As of December 31, 2023, the following litigations were pending. None of the below is expected to have a material financial or operational impact. Solgar Inc., a competitor of the Company, sued SkyPharm for product homogeneity regarding the nutraceutical line “Sky Premium Life”. As a result, Solgar requested the prohibition for SkyPharm to manufacture, import and sell, market or in any way possess and distribute, including internet sales and advertise in any way in the Greek market of “Sky Premium Life” due to homogeneity with Solgar’s products. Solgar Inc. has further requested to be awarded compensation for non-pecuniary damage amounting to €20,000 ($21,744). The case was heard on January 28, 2022, and the decision numbered 8842/2022 of the court of Thessaloniki was issued, which, accepted our claims and dismissed the Solgar Inc.’s lawsuit. On July 22, 2015, the National Medicines Agency approved the license of wholesale sale of pharmaceutical products under the name SkyPharm SA with set validity at five years and an expiration date of July 22, 2020. Subsequently, SkyPharm on June 15, 2020, legally and timely submitted the application for renewal of the wholesale license of pharmaceutical products to the National Medicines Agency. The National Medicines Agency did not respond, therefore the Company asked for an immediate decision on the renewal. Two months after the filing of the no. 3459 / 15.01.2021 letter and almost nine months after the no. 627615.06.2020 Company application for the renewal, the National Medicines Agency replied by rejecting the renewal request on March 9, 2021 (ref. 62769 / 20-25.02.2021). In addition, document No. 127351-16.12.2021 of EOF (Greek National Medicines Organization) to SkyPharm states that after an inspection of EOF at the premises of Doc Pharma, we did not have a wholesale license in violation of article 106 par. 1b and par. 1c of the ministerial decision D.YG3a / GP.32221 / 29-4-2019. The National Medicines Agency imposed a fine of €15,000 ($16,214) on SkyPharm for the above case, which was included in “General and administrative” expense on the accompany statement of operations and comprehensive loss for the fiscal year ended December 31, 2023. There has been a payment request by the Greek court, which relates to a fine arising from Cosmofarm’s tax audit for financial year 2014. The law with no. 483/16.12.2020 was used by the court against Cosmofarm (the “defendant”). The defendant appealed against the decision using the law with no.11541/09.03.2021. This appeal was dismissed after 120 days from its submission to the court. Additionally, there had been an obligation for payment of additional tax and fines related to this matter in the amount of €91,652 ($99,644), which the defendant has already settled. However, the defendant has claimed back the respective amount through appeal. As of December 31, 2023, the trial is still pending. On January 25, 2023, a criminal case of dishonored checks against Cosmofarm’s customer Filippou, was heard at the Z’ Three-Member Misdemeanor Court of Athens, which was postponed to November 27, 2023, when the defendant was tried and found guilty. On January 26, 2023, the appeal of the Company against Eleutheria Drakopoulou and decision 1389/2021of the Single-Member Court of First Instance of Athens was heard at the Athens Court of Appeal. The appeal was partially accepted. The Court ordered the return of the fee to the appellants, dismissed the action against the third defendant, Kozaris and accepted the action as regards the first and the second defendants (Kastrantas & Cosmofarm). On October 23, 2023, a criminal case of dishonored check against Cosmofarm’s customer Kafantaris was heard at the Sixth Single-Member Misdemeanor Court of Athens, which was postponed to January 26, 2024, when the defendant was convicted by decision no. 1599/2024. In October 2023, the Company’s subsidiary, Cana Laboratories Holding (Cyprus) Limited (“Cana”) was approached by an attorney at law on behalf of two clients which were requesting an amount of €39,211 as compensation for the value of 34.70 square meters in relation to an urban sprawl with respect to which an Act of Imputation had been issued by the department of Urban Planning. Our legal counsel’s response was that Cana was not obliged to accept the compensatory value agreed and suggested exploring out of court settlement. As of today, the clients’ Attorney at law has not come back with any suggestions. Our subsidiary, Cana, has two pending lawsuits against Euaggelismos Hospital for a total sum of EUR 526,436 due to unpaid bills. The court date for one of the two lawsuits is set for December 11, 2024, and for the other one has not yet been set. The opinion of our legal advisor is that the collection of the total sum by the Company is almost certain. Our subsidiary, Cana, has an unasserted claim against Papanikolaou Hospital for a total sum of EUR 89,300 due to unpaid bills, which will be asserted through a lawsuit. The opinion of our legal advisor is that the collection of the sum by the Company is almost certain. A lawsuit dated on April 5, 2018 against the Company’s subsidiary Cana by a former employee before the Athens court of instance was initially heard on October 12, 2018. The former employee was seeking that the termination of her employment contract to be considered null and void and was requesting compensation for late wages and moral damages. Following, numerous appeals the Judgment No. 1192/2024 was issued on September 26, 2023, which as explicitly stated by our legal counsel, requires Cana to rehire the former employee with the threat of a penalty of €200 for each day of non-compliance. As informed by our legal counsel, in order for the penalty to be effective the former employee should file a new lawsuit against Cana and request to get rehired. In case Cana denies the employment, then the penalty should be in effect. As of today, we have not received neither a lawsuit nor any request of employment by the former employee. Advisory Agreements On July 1, 2021, the Company entered into a two-year advisory agreement with a third party (the “Consultant”) for advisory and consulting services related to the Company’s intention to become listed on Nasdaq. Peter Goldstein, a then director of the Company is a principal of the Consultant. As consideration for services rendered, and successful Nasdaq listing, the Company paid $100,000. The $100,000 bonus was incurred and settled within 2022. Finally, the Consultant received a total of 10,000 shares of the Company’s common stock, 2,000 of such shares that have been previously issued pursuant to previous agreements and additional 15,258 shares that were issued on February 2, 2023, based on the amendment signed on February 1, 2023. On November 21, 2023, the Company entered into certain consulting agreements with four third-party consultants for the provision of a variety of services such as digital marketing, advisory services relating to target acquisitions and M&As and other additional services as described in the respective agreements. The agreements have duration from ten to 18 months and the consultants will solely receive stock consideration for the services rendered. More precisely, they have been awarded a total of 970,000 shares of the Company’s common stock valued at a total of $999,100 based on the fair value of the Company’s common stock as of the agreements’ date. The corresponding consulting expense is accrued evenly over the term of the agreements. For the fiscal year ended December 31, 2023 the Company has recorded $77,250 as stocked based compensation for the above agreements, classified as “General and administrative expenses” in the Company’s consolidated statements of operations and comprehensive loss. Research and Development Agreements The Company entered into a Research & Development agreement with Doc Pharma S.A. on May 17, 2021. Under this agreement, Doc Pharma is responsible for the research, development, design, registration, copy rights and licenses of 250 nutritional supplements for the final products called Sky Premium Life ® On June 26, 2022, the Company signed a research and development (“R&D”) agreement with a third party, through which the Company assigns to the third party the development of new products and services in the field of health, focusing on the human intestinal microbiome. The project includes two phases. Phase 1 has a 20-month duration and its cost amounts to EUR 758,000 ($838,450) and phase 2, has a 22-month duration and a cost of EUR 820,000 ($907,084). The amount will be due and payable upon completion of the corresponding phases. The Company records the corresponding R&D expense based on the project’s progress, which is invoiced by the third party in the relevant period. For the 12-month period ended December 31, 2023, the Company has incurred $164,859 of such costs included in “General and administrative expenses” in the Company’s Consolidated Statements of Operations and Comprehensive Loss.

EARNINGS PER SHARE

EARNINGS PER SHARE	12 Months Ended
EARNINGS PER SHARE	Dec. 31, 2023
EARNINGS PER SHARE
EARNINGS PER SHARE	NOTE 16 – EARNINGS PER SHARE Basic net loss per share is computed by dividing net loss attributable to the common stockholders, decreased with respect to net income or increased with respect to net loss by dividends declared on preferred stock by using the weighted-average number of common shares outstanding. The dilutive effect of incremental common shares potentially issuable under outstanding options, warrants and restricted shares is included in diluted earnings per share in 2023 and 2022 utilizing the treasury stock method. The computations of basic and diluted per share data were as follows: 2023 2022 Numerator for Basic and Diluted Earnings Per Share: Net loss attributable to common stockholders $ (25,783,834 ) $ (63,945,285 ) Denominator for Basic Earnings Per Share: Weighted Average Shares 11,968,665 1,928,172 Potentially Dilutive Common Shares - - Adjusted Weighted Average Shares 11,968,665 1,928,172 Basic and Diluted Net Loss per Share (2.15 ) (33.16 ) The following table summarized the potential shares of common stock that were excluded from the computation of diluted net loss per share for the years ended December 31, 2023 and 2022 as such shares would have had an anti-dilutive effect: 2023 2022 Common Stock Warrants 8,561,476 4,194,236 Common Stock Options - - Convertible Debt - 8,827 Total 8,561,476 4,203,063

STOCK OPTIONS AND WARRANTS

STOCK OPTIONS AND WARRANTS	9 Months Ended	12 Months Ended
STOCK OPTIONS AND WARRANTS	Sep. 30, 2024	Dec. 31, 2023
STOCK OPTIONS AND WARRANTS
STOCK OPTIONS AND WARRANTS	NOTE 15 – STOCK OPTIONS AND WARRANTS Omnibus Equity Incentive Plan On September 19, 2022, the Company held a Board of Directors meeting, whereas, the Board of Directors had elected to adopt an Omnibus Equity Incentive Plan (the “2022 Plan”), that includes reserving 200,000 shares of common stock eligible for issuance under the 2022 Plan to be registered on a Form S-8 Registration Statement with the SEC. The 2022 Plan is designed to enable the flexibility to grant equity awards to the Company’s officers, employees, non-employee directors and consultants and to ensure that it can continue to grant equity awards to eligible recipients at levels determined to be appropriate by the Board and/or the Compensation Committee. According to the Proxy Statement filed with the SEC on October 20, 2022 the 2022 Plan received final approval by the Company’s stockholders at the Annual Meeting of Stockholders held on December 2, 2022. On April 3, 2023, the Company approved incentive stock awards for the CFO, certain officers and directors and other employees of the Company. The awards are in the form of restricted stock and will vest in two parts: 50% on October 2, 2023 and 50% on October 2, 2024. A total of 185,000 shares were awarded and a corresponding share-based compensation expense of $109,636 and $326,525 was recorded for the three and nine months ended September 30, 2024, based on the amortization of fair value from the date of issuance of April 3, 2023, through September 30, 2024. The equivalent share-based compensation expense for the three and nine months ended September 30, 2023 was $109,636 and $214,505, respectively. On August 21, 2023, the Board adopted, subject to stockholder approval, the Cosmos Health Inc. 2023 Omnibus Equity Incentive Plan (the “2023 Plan”). The 2023 Plan is designed to enable the flexibility to grant equity awards to our officers, employees, non-employee directors and consultants and to ensure that we can continue to grant equity awards to eligible recipients at levels determined to be appropriate by the Board and/or the Compensation Committee. Subject to certain adjustments (as provided in Section 4.2 of the 2023 Plan) and exception (as provided in Section 5.6(b) of the 2023 Plan), the maximum number of shares reserved for issuance under the 2023 Plan (including incentive share options) is 2,500,000 shares. The 2023 Plan was approved by the Company’s stockholders at the Annual Meeting of Stockholders held on September 18, 2023. On September 16, 2024 the Company’s Board of Directors approved incentive stock awards for the CEO, the CFO, certain officers and directors and other key employees of the Company pursuant to the 2023 Plan adopted on August 21, 2023. The awards are in the form of restricted stock and will vest in two parts: 50% on September 16, 2025 and 50% on September 16, 2026. A total of 2,500,000 shares were awarded and a corresponding share-based compensation expense of $48,425 was recorded for the three and nine months ended September 30, 2024, based on the amortization of fair value from the date of issuance of September 16, 2024, through September 30, 2024. Warrant Anti-Dilution Adjustment and Deemed Dividend The Company’s warrants outstanding contain certain anti-dilution adjustments if the Company issues shares of its common stock at a lower price per share than the applicable exercise price of the underlying warrant. If any such dilutive issuance occurs prior to the exercise of such warrant, the exercise price will be adjusted downward to a price equal to the common stock issuance, and the number of warrants that may be purchase upon exercise is increased proportionately so that the aggregate exercise price payable under the warrant shares shall be the same as the aggregate exercise price in effect immediately prior to such adjustment. On December 29, 2023, the Company entered into a warrant exchange agreement (the “Warrant Exchange”) with an investor to reduce the exercise price of 2,437,063 warrants from $2.75 per share to $1.45 per shares as an inducement to exercise. The Company issued 1,487,000 shares of common stock, held 950,063 shares in escrow until the investor’s beneficial ownership limitation allows for the transfer of the escrow shares, and received gross cash proceeds of 3,533,741. The Company contingently granted 4,874,126 additional warrants to be issued upon shareholder approval, with an exercise price of $1.45 and a term of five years. For the year ended December 31, 2023, the Company recorded a deemed dividend of $7,642 for the inducement to exercise and $7,218,485 for the grant of new warrants. The Company valued (a) the fair value of the warrants immediately before the re-pricing in the amount of $3,603,183, (b) the fair value of the warrants immediately after the re-pricing in the amount of $3,610,825, and (c) recorded the difference as deemed dividend in the amount of $7,642. The warrants were valued using the Black-Scholes option pricing model using the following terms: a) fair value of common stock of $1.49, b) exercise price of $1.45 before re-pricing, c) exercise price of $2.75 after re-pricing, d) terms of 5.07 years and 5.02 years, e) dividend rate of 0%, and f) risk free interest rate of 3.83%. Regarding the valuation of the 4,874,126 new warrants (and the recognition of a deemed dividend of $7,218,485) the following terms were used: a) fair value of common stock of $1.49, b) exercise price of $1.45, d) term of 5 years, e) dividend rate of 0%, and f) risk free interest rate of 3.83%. On September 26, 2024, the Company entered into a Warrant Inducement Letter (the “Letter”) with an investor pursuant to which the Company issued 9,748,252 new warrants (the “New Warrants”) and reduced the exercise price of 4,874,126 warrant shares from $1.45 to $0.8701 to induce exercise and receive gross cash proceeds of $4,240,977 (the “Original Warrants”). Of the 9,748,252 warrants 4,874,126 of them have a term of 5 years (“Series A Warrants”) and the remaining 4,874,126 have a term of 1.5 years (“Series B Warrants”). The Company issued 2,332,000 shares of common stock, held 2,532,126 shares in escrow until the investor’s beneficial ownership limitation allows for the transfer of the escrow shares. For the period ended September 30, 2024, the Company recorded a deemed dividend of $9,793 for the inducement to exercise and $6,185,231 for the grant of new warrants. The Company valued (a) the fair value of the warrants immediately before the re-pricing in the amount of $4,197,280, (b) the fair value of the warrants immediately after the re-pricing in the amount of $4,207,073, and (c) recorded the difference as deemed dividend in the amount of $9,793. The warrants were valued using the Black-Scholes option pricing model using the following terms: a) fair value of common stock of $0.8701, b) exercise price of $1.45 before re-pricing, c) exercise price of $0.8701 after re-pricing, d) term of 4.26 years, e) dividend rate of 0%, and f) risk free interest rate of 3.55%. Regarding the valuation of the 9,748,252 new warrants (and the recognition of a deemed dividend of $6,185,321) the following terms were used: a) fair value of common stock of $0.8701, b) exercise price of $0.95, d) terms of 5 years for the Series A Warrants and 1.5 years for the Series B Warrants, e) dividend rate of 0%, and f) risk free interest rate of 3.55% for the Series A Warrants and 3.57% for the Series B Warrants. As of September 30, 2024, there were 13,432,506 warrants outstanding and 8,558,380 warrants exercisable with 13,419,172 warrants having expiration dates from October 2024 through October 2029 and 13,334 warrants with no expiration date. A summary of the Company’s warrant activity for the nine months ended September 30, 2024 and the year ending December 31, 2023 is as follows: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Warrants Shares Price Term Value Balance Outstanding, January 1, 2023 4,194,236 $ 8.31 5.04 $ 2,562,600 Granted 7,524,933 1.65 5.13 - Forfeited - - - - Exercised (3,152,386 ) - - - Expired (5,307 ) - - - Balance Outstanding, December 31, 2023 8,561,476 $ 3.91 4.64 $ 18,801 Granted 9,748,252 0.95 3.24 - Forfeited - - - - Exercised (4,874,126 ) - - - Expired (3,096 ) - - - Balance Outstanding, September 30, 2024 13,432,506 $ 2.64 3.28 $ 11,681 - - - Exercisable, September 30, 2024 13,432,506 $ 2.64 3.28 $ 11,681 Omnibus Equity Incentive Plan On September 19, 2022 the Company held a Board of Directors meeting, whereas, the Board of Directors had elected to adopt an Omnibus Equity Incentive Plan (the “2022 Plan”), that includes reserving 200,000 shares of common stock eligible for issuance under the 2022 Plan to be registered on a Form S-8 Registration Statement with the SEC. The 2022 Plan is designed to enable the flexibility to grant equity awards to the Company’s officers, employees, non-employee directors and consultants and to ensure that it can continue to grant equity awards to eligible recipients at levels determined to be appropriate by the Board and/or the Compensation Committee. According to the Proxy Statement filed with the SEC on October 20, 2022, the 2022 Plan received final approval by the Company’s stockholders at the Annual Meeting of Stockholders held on December 2, 2022. On April 3, 2023, the Company approved incentive stock awards for the CFO, certain officers and directors and other employees of the Company. The awards are in the form of restricted stock and will vest in two parts: 50% on October 2, 2023 and 50% on October 2, 2024. A total of 185,000 shares were awarded and a corresponding share-based compensation expense of $323,957 was recorded for the 12 months ended December 31, 2023, respectively, based on the amortization of fair value from the date of issuance of April 3, 2023 through December 31, 2023. On August 21, 2023, the Board adopted, subject to stockholder approval, the Cosmos Health Inc. 2023 Omnibus Equity Incentive Plan (the “2023 Plan”). The 2023 Plan is designed to enable the flexibility to grant equity awards to our officers, employees, non-employee directors and consultants and to ensure that we can continue to grant equity awards to eligible recipients at levels determined to be appropriate by the Board and/or the Compensation Committee. Subject to certain adjustments (as provided in Section 4.2 of the 2023 Plan) and exception (as provided in Section 5.6(b) of the 2023 Plan), the maximum number of shares reserved for issuance under the Plan (including incentive share options) is 2,500,000 shares. The 2023 Plan was approved by the Company’s stockholders at the Annual Meeting of Stockholders held on September 18, 2023. Warrant Anti-Dilution Adjustment and Deemed Dividend The Company’s warrants outstanding contain certain anti-dilution adjustments if the Company issues shares of its common stock at a lower price per share than the applicable exercise price of the underlying warrant. If any such dilutive issuance occurs prior to the exercise of such warrant, the exercise price will be adjusted downward to a price equal to the common stock issuance, and the number of warrants that may be purchase upon exercise is increased proportionately so that the aggregate exercise price payable under the warrant shares shall be the same as the aggregate exercise price in effect immediately prior to such adjustment. On December 21, 2021, the Company issued its common stock upon conversion of its convertible debt at an issuance price of $50.50 per share. As a result, the Company issued additional warrants to the Company’s existing warrant holders to purchase 101,343 shares of common stock with an exercise price of $50.50 per share. The new warrants were issued with a weighted average contractual term of 2.04 years. The deemed dividend was recorded as an increase to accumulated deficit and additional paid-in capital and reduced net income available to common shareholders by the same amount. The Company valued (a) the fair value of the warrants immediately before the re-pricing in the amount of $1,915,077, (b) the fair value of the warrants immediately after the re-pricing in the amount of $9,548,110, and (c) recorded the difference as deemed dividend in the amount of $7,633,033. The warrants were valued using the Black-Scholes option pricing model using the following terms: a) fair value of common stock of $93.75, b) exercise prices of $125.00, $150.00 and $187.50 before re-pricing, c) exercise price of $50.50 after re-pricing, d) terms of 1.40 years, 1.97 years, 2.20 years and 2.26 years, e) dividend rate of 0%, and f) risk free interest rate of 0.41%. As of December 31, 2023, there were 8,561,476 warrants outstanding and 8,548,142 warrants exercisable with 8,548,142 warrants having expiration dates from March 2024 through October 2029 and 13,334 warrants with no expiration date.	NOTE 17 – STOCK OPTIONS AND WARRANTS Options As of December 31, 2023, there were 0 options outstanding and 0 options exercisable. A summary of the Company’s option activity during the years ended December 31, 2023 and 2022 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Shares Price Term Value Balance Outstanding, January 1, 2022 37,000 $ 1.32 0.01 $ 75,850 Granted - - - - Forfeited - - - - Exercised - - - - Expired (37,000 ) - - - Balance Outstanding, December 31, 2022 - $ - - $ - Granted - - - - Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2023 - $ - - $ - Exercisable, December 31, 2023 - $ - - $ - A summary of the Company’s warrant activity for the years ending December 31, 2023 and 2022 is as follows: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Warrants Shares Price Term Value Balance Outstanding, January 1, 2022 147,930 $ 50.50 2.04 $ 4,992,621 Granted 9,030,301 5.96 4.18 - Forfeited (424,767 ) - - - Exercised (4,559,228 ) - - - Expired - - - - Balance Outstanding, December 31, 2022 4,194,236 $ 8.31 5.04 $ 2,562,600 Granted 7,524,933 1.65 5.13 - Forfeited - - - - Exercised (3,152,386 ) - - - Expired (5,307 ) - - - Balance Outstanding, December 31, 2023 8,561,476 $ 3.91 4.64 $ 18,801 Exercisable, December 31, 2023 8,548,142 $ 3.91 4.64 $ 18,801

DISAGGREGATION OF REVENUE

DISAGGREGATION OF REVENUE	9 Months Ended	12 Months Ended
DISAGGREGATION OF REVENUE	Sep. 30, 2024	Dec. 31, 2023
DISAGGREGATION OF REVENUE
DISAGGREGATION OF REVENUE	NOTE 16 – DISAGGREGATION OF REVENUE ASC 606-10-50-5 requires that entities disclose disaggregated revenue information in categories (such as type of good or service, geography, market, type of contract, etc.). ASC 606-10-55-89 explains that the extent to which an entity’s revenue is disaggregated depends on the facts and circumstances that pertain to the entity’s contracts with customers and that some entities may need to use more than one type of category to meet the objective for disaggregating revenue. The Company disaggregates revenue by country to depict the nature and economic characteristics affecting revenue. The following table presents our revenue disaggregated by country for the three months ended: Country September 30, 2024 September 30, 2023 Croatia $ 107 14,159 Cyprus 16,519 72,754 Bulgaria 25,507 - Greece 12,247,597 12,544,643 USA - 210 Ireland - 1,417 UK 121,318 190,614 Total $ 12,411,048 $ 12,823,797 The following table presents our revenue disaggregated by country for the nine months ended: Country September 30, 2024 September 30, 2023 Croatia $ 19,370 14,159 Cyprus 89,064 141,402 Bulgaria 43,849 - Greece 39,385,730 36,041,012 USA - 504 Ireland - 1,417 UK 664,225 1,338,509 Total $ 40,202,238 $ 37,537,003	NOTE 18 – DISAGGREGATION OF REVENUE ASC 606-10-50-5 requires that entities disclose disaggregated revenue information in categories (such as type of good or service, geography, market, type of contract, etc.). ASC 606-10-55-89 explains that the extent to which an entity’s revenue is disaggregated depends on the facts and circumstances that pertain to the entity’s contracts with customers and that some entities may need to use more than one type of category to meet the objective for disaggregating revenue. The Company disaggregates revenue by country to depict the nature and economic characteristics affecting revenue. The following table presents our revenue disaggregated by country for the years ended: Country 2023 2022 Croatia $ 26,985 $ 38,596 Cyprus 180,404 92,685 Bulgaria 210,033 - Ireland 1,636 - Greece 50,526,307 49,812,839 United States 504 - Cayman Islands 12,632 - UK 2,418,373 403,532 Total $ 53,376,874 $ 50,347,652

SEGMENT REPORTING

SEGMENT REPORTING	12 Months Ended
SEGMENT REPORTING	Dec. 31, 2023
SEGMENT REPORTING
SEGMENT REPORTING	NOTE 19 – SEGMENT REPORTING A. Basis for segmentation The Group operates through various operating segments, which are the wholesale sector, the pharmaceutical manufacturing sector, the nutraceuticals and pharmaceuticals sectors and other, with only the first three of them being reportable segments based on the criteria (quantitative thresholds) of ASC 280. The financial information reviewed by our Chief Operating Decision Maker, which is our Board of Directors, is included within the operating segments mentioned above for purposes of allocating resources and evaluating financial performance. B. Information about reportable segments The table below present's information about the Company's reportable segments for the 12-month period ended December 31, 2023. The accounting policies followed in the preparation of the reportable segments are the same with those followed in the preparation of the Company's consolidated financial statements. 12-month period ended December 31, 2023 Wholesale Pharma manufacturing Nutraceuticals & Pharmaceuticals Other Total Revenues 50,744,468 344,708 2,287,698 - 53,376,874 Segment profit / (loss) (1,661,252 ) (1,232,732 ) (3,552,718 ) (2,993,026 ) (9,439,727 ) Total assets 28,193,797 15,605,459 28,054,242 3,871,101 75,724,599 The following summary describes the operations of the reportable segment: Reportable segments Operations Wholesale Distribution and export of pharmaceutical products Pharma manufacturing Production of pharmaceutical products Nutraceutical and pharmaceuticals Trade of owned nutraceutical & pharmaceutical products

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended	12 Months Ended
SUBSEQUENT EVENTS	Sep. 30, 2024	Dec. 31, 2023
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	NOTE 17 – SUBSEQUENT EVENTS On November 6, 2024, the Company received a non-compliance letter from Nasdaq for its failure to maintain a minimum bid price of 1.00 per share for thirty consecutive business days in accordance with Nasdaq Listing Rule 5550(a)(2). The Company has one hundred eighty calendar days from November 6, 2024, to regain compliance by the closing bid price of the Company’s common stock being at least $1.00 per share for ten consecutive business days. In the event the Company cannot otherwise regain compliance with the listing rule, it intends to effect a reverse stock split to regain compliance.	NOTE 20 – SUBSEQUENT EVENTS On January 23, 2024, the Company completed the acquisition of Cloudscreen, a cutting-edge Artificial Intelligence (AI) powered platform. The acquisition is pursuant to the purchase agreement announced on October 11, 2023. Cloudscreen is a multimodal platform specialized in drug repurposing, a process that involves uncovering new target proteins or indications for existing drugs for use in treating different diseases. The total purchase price amounted to $637,080 and consisted of 280,000 shares of common stock with a fair value of $319,200 and an amount of $317,880 to be settled in cash during 2024 based on the Promissory Note signed on October 10, 2023. The Company accounted for the acquisition as an asset acquisition in accordance with Accounting Standards Codification (“ASC”) Topic 805, Business Combinations, (“ASC 805”) and recorded $637,080 as an intangible asset related to the technology platform acquired. During the period March 15 to March 21, 2024, the Company raised additional equity funds through a Baby Shelf supplement to its Registration Statement on Form S-3 (No. 333-267550) filed with the SEC on February 29 and March 7, 2024. More specifically, the Company sold 901,488 shares of common stock for gross proceeds of $648,893. Placement agent’s fees and other commissions amounted to $23,153 and thus the total net proceeds for the period were $625,740. On April 17, 2024, the Company received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that, because the Company had not yet filed its Annual Report on Form 10-K for the period ended December 31, 2023, it is no longer in compliance with Nasdaq Listing Rule 5250(c)(1). The Nasdaq letter had no immediate effect on the listing of the Company’s shares. The Nasdaq notification letter stated that the Company had 60 calendar days to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rules. If a compliance plan is accepted, Nasdaq may grant up to 180 days from the prescribed due date to regain compliance. On May 21, 2024, the Company received an additional delinquency letter from Nasdaq notifying the Company that it continued to be out of compliance with Nasdaq’s continued listing requirements set forth in Nasdaq Listing Rule 5250(c)(1) due to the Company’s failure to timely file its Form 10-Q for the period ended March 31, 2024, as well as remaining delinquent in filing its Annual Report on Form 10-K for the period ended December 31, 2023. The additional delinquency letter had no immediate effect on the listing of the Company’s shares on Nasdaq. On May 31, 2024, the Company provided its compliance plan to Nasdaq, in relation to the filing of its Form 10-K and Form 10-Q for the period ended March 31, 2024. On June 20, 2024, Nasdaq accepted the plan and initially granted the Company a period ending July 29, 2024 to file the delinquent reports. On July 30, 2024, Nasdaq further extended the filing deadline through October 14, 2024. On April 22, 2024, the Company entered into a Rights Agreement by and between the Company and Globex Transfer, LLC, as Rights Agent, which Rights Agreement was previously approved and adopted by the Board of Directors of the Company on November 21, 2023. Pursuant to the Rights Agreement, the Board declared a dividend of one common share purchase right for each outstanding share of common stock, par value $0.001 of the Company. The Rights are distributable to stockholders of record as of the close of business on April 19, 2024. In general, the Rights Agreement works by causing substantial dilution to any person or group that acquires beneficial ownership of twenty percent (20%) or more of the Common Shares without the approval of the Board. On April 26, 2024, the Company dismissed KPMG as the Company’s independent registered accountant, effective immediately. The Company’s Audit Committee, mindful of certain filing deadlines under the US securities laws, unanimously voted in favor to dismiss KPMG as the Company’s independent auditors. KPMG was unable to complete the audit of the Company’s financial statements for the year ended December 31, 2023, on a timely basis. The Company’s Board of Directors agreed with such recommendation. The Company’s opinion was that there were no disagreements with KPMG on any matter of accounting principles or practices, financial statement disclosures, or auditing scope or procedure. In their letter, KPMG has the contrary opinion that there have been disagreements, between KPMG and the Company on the above. The Company objected to such statements made by KPMG and provided a relevant response letter. On April 29, 2024, RBSM LLP (“RBSM”) was appointed by the Company’s Audit Committee as the Company’s independent registered public accounting firm, to audit the Company’s consolidated financial statements as of and for the fiscal year ended December 31, 2023, subject to customary client acceptance procedures. On June 27, 2024, the Company signed an exclusive distribution agreement (the “Agreement”) with Pharmalink for its Sky Premium Life products in the United Arab Emirates (UAE). As part of the Agreement, Pharmalink will be responsible for all key functions, including sales and marketing, regulatory affairs, logistics, supply, and distribution of Sky Premium Life products in the UAE. Cosmos Health has secured its first purchase order from Pharmalink for 130,000 units and anticipates receiving orders of more than 500,000 units in the first year and in excess of 3,000,000 units over the next five years. On July 19, 2024, the Company received a notification letter from Nasdaq, informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). To regain compliance with the Minimum Bid Price Requirement, the closing bid of the Company’s shares of common stock needed to be at least $1.00 per share for a minimum of ten consecutive business days. The notification letter confirmed that the Company achieved a closing bid price of $1.00 or greater per common share for ten consecutive business days from July 5, 2024 to July 18, 2024, thereby regaining compliance with the Minimum Bid Price Requirement. Accordingly, Nasdaq has determined that this matter is now closed. This cured the delinquency notified by Nasdaq on March 20, 2024 that the Company’s common stock had failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Nasdaq Listing Rules.

ORGANIZATION AND NATURE OF BU_2

ORGANIZATION AND NATURE OF BU_3

ORGANIZATION AND NATURE OF BUSINESS (Tables)	9 Months Ended	12 Months Ended
ORGANIZATION AND NATURE OF BUSINESS (Tables)	Sep. 30, 2024	Dec. 31, 2023
ORGANIZATION AND NATURE OF BUSINESS (Tables)
Schedule of allocation of purchase price of acquisition	Consideration Cash $ 5,331,120 Fair value of common stock issued 138,667 Fair value of total consideration transferred $ 5,469,787 Recognized amounts of identifiable assets acquired Financial assets $ 1,796,911 Inventory 297,340 Property, plant and equipment 7,488,818 Identifiable intangible assets 562,200 Financial liabilities (3,235,233 ) Total identifiable net assets $ 6,910,036 Bargain purchase gain $ 1,440,249 Revenue for the 9 - month period ended September 30, 2024 $ 549,567 Loss for the 9 - month period ended September 30, 2024 $ (1,674,785 )	Consideration Cash $ 5,331,120 Fair value of common stock issued 138,667 Fair value of total consideration transferred $ 5,469,787 Recognized amounts of identifiable assets acquired Financial assets $ 1,796,911 Inventory 297,340 Property, plant and equipment 7,488,818 Identifiable intangible assets 562,200 Financial liabilities (3,235,233 ) Total identifiable net assets $ 6,910,036 Bargain purchase gain $ 1,440,249 Revenue for the 6- month period ended December 31, 2023 $ 344,708 Loss for the 6- month period ended December 31, 2023 $ (1,232,732 )
Schedule of Accounts Receivable & Allowance for Doubtful Accounts	September 30, 2024 Balance as of January 1st, 2024 $ 19,686,091 Provisions for credit losses - Write-offs 250,971 Foreign exchange adjustments Other adjustments (31,286 ) Balance as of September 30, 2024 $ 19,905,776	December 31, 2023 Balance as of January 1, 2023 $ 7,309,311 Provisions for credit losses 11,850,788 Write-offs - Foreign exchange adjustments 525,992 Other adjustments - Balance as of December 31, 2023 $ 19,686,091
Schedule of Property and Equipment, net	Estimated Useful Life Leasehold improvements and technical works Lesser of lease term or 25 years Buildings 25-30 years Vehicles 6 years Machinery 20 years Furniture, fixtures and equipment 5–10 years Computers and software 3-5 years	Estimated Useful Life Leasehold improvements and technical works Lesser of lease term or 25 years Buildings 25-30 years Vehicles 6 years Machinery 20 years Furniture, fixtures and equipment 5–10 years Computers and software 3-5 years
Schedule of Basic and Diluted Net Loss per Common Share	September 30, 2024 September 30, 2023 Weighted average number of common shares outstanding Basic 17,724,305 11,346,071 Potentially dilutive common stock equivalents - - Weighted average number of common and equivalent shares outstanding – Diluted 17,724,305 11,346,071
Schedule of potential shares of common stock	September 30, 2024 September 30, 2023 Warrants 13,432,507 6,124,412 Total 13,432,507 6,124,412

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	Sep. 30, 2024	Dec. 31, 2023
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Schedule of exchange rate		December 31, 2023 December 31, 2022 Exchange rate on balance sheet dates EUR: USD exchange rate 1.1062 1.0698 GBP: USD exchange rate 1.2743 1.2077 Average exchange rate for the period EUR: USD exchange rate 1.0817 1.0534 GBP: USD exchange rate 1.2440 1.2371
Schedule of Accounts Receivable & Allowance for Doubtful Accounts	September 30, 2024 Balance as of January 1st, 2024 $ 19,686,091 Provisions for credit losses - Write-offs 250,971 Foreign exchange adjustments Other adjustments (31,286 ) Balance as of September 30, 2024 $ 19,905,776	December 31, 2023 Balance as of January 1, 2023 $ 7,309,311 Provisions for credit losses 11,850,788 Write-offs - Foreign exchange adjustments 525,992 Other adjustments - Balance as of December 31, 2023 $ 19,686,091
Schedule of Property and Equipment, net	Estimated Useful Life Leasehold improvements and technical works Lesser of lease term or 25 years Buildings 25-30 years Vehicles 6 years Machinery 20 years Furniture, fixtures and equipment 5–10 years Computers and software 3-5 years	Estimated Useful Life Leasehold improvements and technical works Lesser of lease term or 25 years Buildings 25-30 years Vehicles 6 years Machinery 20 years Furniture, fixtures and equipment 5–10 years Computers and software 3-5 years
Schedule of Assets Measured and Recognized at Fair Value on a Recurring Basis		December 31, 2023 Total Carrying Level 1 Level 2 Level 3 Value Marketable securities – ICC International Cannabis Corp. $ - - - $ - Marketable securities – National Bank of Greece 11,596 - - 11,596 $ 11,596 $ 11,596 December 31, 2022 Total Carrying Level 1 Level 2 Level 3 Value Marketable securities – ICC International Cannabis Corp. $ - - - $ - Marketable securities – National Bank of Greece 6,681 - - 6,681 $ 6,681 $ 6,681
Schedule of Basic and Diluted Net Loss per Common Share		Years Ended December 31, 2023 2022 Weighted average number of common shares outstanding Basic 11,968,665 1,928,172 Potentially dilutive common stock equivalents - Weighted average number of common and equivalent shares outstanding – Diluted 11,968,665 1,928,172
Schedule of potential shares of common stock		2023 2022 Common Stock Warrants 8,561,476 4,194,236 Common Stock Options - - Convertible Debt - 8,827 Total 8,561,476 4,203,063

PROPERTY AND EQUIPMENT, NET (Ta

PROPERTY AND EQUIPMENT, NET (Tables)	9 Months Ended	12 Months Ended
PROPERTY AND EQUIPMENT, NET (Tables)	Sep. 30, 2024	Dec. 31, 2023
PROPERTY AND EQUIPMENT, NET
Schedule of Property and Equipment, net	September 30, 2024 December 31, 2023 Land $ 3,577,662 $ 3,551,020 Buildings and improvements 4,868,378 4,787,963 Leasehold improvements 3,667 3,639 Vehicles 285,609 285,388 Furniture, fixtures and equipment 3,014,683 2,707,442 Computers and software 203,215 168,173 11,953,214 11,503,625 Less: Accumulated depreciation and amortization (1,377,286 ) (1,048,126 ) Total $ 10,575,928 $ 10,455,499	2023 2022 Land $ 3,551,020 $ - Buildings and improvements 4,787,963 - Leasehold improvements 3,639 502,882 Vehicles 285,388 107,976 Furniture, fixtures and equipment 2,707,442 1,945,207 Computers and software 168,173 138,783 11,503,625 2,694,848 Less: Accumulated depreciation and amortization (1,048,126 ) (877,823 ) Total $ 10,455,499 $ 1,817,025

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	9 Months Ended	12 Months Ended
INTANGIBLE ASSETS (Tables)	Sep. 30, 2024	Dec. 31, 2023
INTANGIBLE ASSETS
Schedule of Intangible Assets	September 30, 2024 December 31, 2023 License $ 6,976,209 $ 6,876,169 Trade name / mark 390,188 392,197 Customer base 602,204 602,204 Software 795,867 158,787 8,764,468 8,029,357 Less: Accumulated amortization License (805,555 ) (235,925 ) Trade name / mark (36,997 ) (36,997 ) Customer base (157,333 ) (110,160 ) Software (67,520 ) (11,789 ) Subtotal 7,697,064 7,634,486 Goodwill 49,697 49,697 Total $ 7,746,761 $ 7,684,183	2023 2022 License $ 6,876,169 $ 643,204 Trade name / mark 392,197 36,997 Customer base 602,204 176,793 Software 158,788 - 8,029,358 856,994 Less: Accumulated amortization License (235,925 ) (98,686 ) Trade name / mark (36,997 ) (29,881 ) Customer base (110,161 ) (71,210 ) Software (11,789 ) - Subtotal 7,634,486 657,217 Goodwill 49,697 49,697 Total $ 7,684,183 $ 706,914
Schedule of amortization expense for intangible assets	Year Amount 2024 $ 208,530 2025 833,637 2026 834,846 2027 834,846 2028 783,423 Thereafter 3,846,582 Total $ 7,341,864	Year Amount 2024 $ 763,292 2025 763,026 2026 764,213 2027 764,213 2028 735,772 Thereafter 3,488,769 Sum $ 7,279,285

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
INCOME TAXES (Tables)	Dec. 31, 2023
INCOME TAXES
Schedule of income tax before income tax domestic and foreign	December 31, 2023 December 31, 2022 Domestic $ (2,832,980 ) $ (7,093,161 ) Foreign (15,709,674 ) (5,962,159 ) $ (18,542,654 ) $ (13,055,320 )
Schedule of provision for income tax	December 31, 2023 December 31, 2022 Current tax provision Federal $ - $ - State - - Foreign - (75,724 ) Total current tax provision $ - $ (75,724 ) Deferred tax provision Domestic $ - $ - State - - Foreign - 850,775 Total deferred tax provision $ - $ 850,775 Total current provision $ - $ 775,051
Schedule of reconciliation of income tax	December 31, 2023 December 31, 2022 US Loss before income taxes $ (18,542,654 ) $ (13,055,320 ) Taxes under statutory US tax rates $ (3,893,957 ) $ (2,741,617 ) Increase (decrease) in taxes resulting from: Increase in valuation allowance $ 4,339,572 $ 3,989,786 Foreign tax rate differential $ 245,518 $ 34,601 Permanent differences $ (448,032 ) $ 128,705 Prior period adjustments $ (151,879 ) $ (186,143 ) State taxes $ (91,222 ) $ (450,280 ) Income tax expense $ - $ 775,052
Schedule of significant components of deferred tax assets and liabilities	December 31, 2023 December 31, 2022 Net operating loss carryforward $ 7,621,277 $ 5,899,702 Capital loss carryforward 801,744 801,744 Section 163(j) carryforward 563,138 561,130 Foreign exchange 129,916 297,263 Allowance for doubtful accounts 4,404,277 1,616,926 Accrued expenses 261,466 352,025 Mark to market adjustment in securities 358,761 358,761 Lease liability 261,377 259,381 Capitalized research & development costs 52,261 - Depreciation (35,734 ) (22,914 ) Total deferred tax assets 14,418,483 10,124,018 Intangibles (15,845 ) (8,139 ) Inventory 4,853 (49,961 ) Right of use asset (258,770 ) (256,769 ) Goodwill (10,980 ) (10,979 ) Total deferred tax liabilities (280,742 ) (325,848 ) Valuation allowance (14,137,741 ) (9,798,170 ) Net deferred tax assets $ - $ -

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	9 Months Ended	12 Months Ended
RELATED PARTY TRANSACTIONS (Tables)	Sep. 30, 2024	Dec. 31, 2023
RELATED PARTY TRANSACTIONS
Schedule of Related Party Notes Payable activity	September 30, 2024 December 31, 2023 Beginning Balance $ 11,283 $ 10,912 Payments - - Foreign currency translation 85 371 Ending Balance $ 11,368 $ 11,283	2023 2022 Beginning Balance $ 10,912 $ 464,264 Payments - (472,920 ) Foreign currency translation 371 19,568 Ending Balance $ 11,283 $ 10,912
Schedule of Related Party Loans Payable	September 30, 2024 December 31, 2023 Beginning balance $ 13,257 $ 12,821 Proceeds 18,344 - Payments (8,918 ) - Foreign currency translation (1,525 ) 436 Ending balance $ 21,158 $ 13,257	2023 2022 Beginning balance $ 12,821 $ 1,293,472 Proceeds - 3,635,756 Payments - (4,851,678 ) Foreign currency translation 436 (64,729 ) Ending balance $ 13,257 $ 12,821

LINES OF CREDIT (Tables)

LINES OF CREDIT (Tables)	9 Months Ended	12 Months Ended
LINES OF CREDIT (Tables)	Sep. 30, 2024	Dec. 31, 2023
LINES OF CREDIT
Schedule of Lines of Credit	September 30, 2024 December 31, 2023 National $ 3,011,102 $ 3,918,523 Alpha 1,030,943 1,130,140 Pancreta 1,560,803 1,122,210 EFG 386,577 459,400 Ending balance $ 5,989,425 $ 6,630,273	December 31, 2023 December 31, 2022 National $ 3,918,523 $ 3,103,605 Alpha 1,130,140 991,492 Pancreta 1,122,210 1,232,128 EFG 459,400 431,512 Ending balance $ 6,630,273 $ 5,758,737

CONVERTIBLE DEBT (Tables)

CONVERTIBLE DEBT (Tables)	12 Months Ended
CONVERTIBLE DEBT (Tables)	Dec. 31, 2023
CONVERTIBLE DEBT
Schedule of Convertible Debt Activity	2023 2022 Beginning balance convertible notes $ 100,000 $ 640,000 New notes - Payments (100,000 ) (525,000 ) Conversion to common stock (15,000 ) Subtotal notes - 100,000 Debt discount at year end - - Convertible note payable, net of discount $ - $ 100,000
Summary of Derivative Liabilities	Amount Balance on January 1, 2022 $ 45,665 Issuances to debt discount - Reduction of derivative related to conversions (11,629 ) Change in fair value of derivative liabilities 20,257 Balance on December 31, 2022 54,293 Reduction of derivative related to conversions (50,909 ) Change in fair value of derivative liabilities (3,384 ) Balance on December 31, 2023 $ - December 31, December 31, 2023 2022 Dividend yield - 0% Expected volatility - 87.9%-157.2 Risk free interest rate - 1.46%-3.75 Contractual terms (in years) - 1.25 - 0.75

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	9 Months Ended	12 Months Ended
NOTES PAYABLE (Tables)	Sep. 30, 2024	Dec. 31, 2023
NOTES PAYABLE
Summary of roll forward of the third party Debt	September 30, 2024 Trade Facility Third Party COVID Loans Total Beginning balance, December 31, 2023 $ 1,908,195 $ 2,511,148 $ 186,884 $ 4,606,227 Proceeds - 445,800 - 445,800 Payments (334,350 ) (481,254 ) (19,073 ) (834,677 ) Conversion of debt - - - - Recapitalized upon debt modification - - - - Accretion of debt and debt discount - - - - Foreign currency translation 14,318 32,613 3,691 50,622 Ending balance, September 30, 2024 1,588,163 2,508,307 171,502 4,267,972 Notes payable - long-term (1,086,638 ) (1,416,802 ) 142,183 ) (2,645,623 ) Notes payable - short-term $ 501,525 $ 1,091,505 $ 29,319 1,622,349 December 31, 2023 Trade Facility Third Party COVID Loans Total Beginning balance, December 31, 2022 $ 3,305,532 $ 1,505,078 $ 207,377 $ 5,017,987 Proceeds - 1,082,231 - 1,082,231 Payments (1,155,310 ) (415,557 ) (27,027 ) (1,597,894 ) Oher additions - 317,880 - 317,880 Debt forgiveness (306,637 ) - - (306,637 ) Foreign currency translation 64,610 21,516 6,534 92,660 Ending balance, December 31, 2023 1,908,195 2,511,148 186,884 4,606,227 Notes payable – long-term (1,327,440 ) (1,549,768 ) (158,133 ) (3,035,341 ) Notes payable - short-term $ 580,755 $ 961,380 $ 28,751 $ 1,570,886	December 31, 2023 Trade Facility Third Party COVID Loans Total Beginning balance, December 31, 2022 $ 3,305,532 $ 1,505,078 $ 207,377 $ 5,017,987 Proceeds - 1,082,231 - 1,082,231 Payments (1,155,310 ) (415,557 ) (27,027 ) (1,597,894 ) Oher additions - 317,880 - 317,880 Debt forgiveness (306,637 ) - - (306,637 ) Foreign currency translation 64,610 21,516 6,534 92,660 Ending balance, December 31, 2023 1,908,195 2,511,148 186,884 4,606,227 Notes payable – long-term (1,327,440 ) (1,549,768 ) (158,133 ) (3,035,341 ) Notes payable - short-term $ 580,755 $ 961,380 $ 28,751 $ 1,570,886 December 31, 2022 Loan Facility Trade Facility Third Party COVID Loans Total Beginning balance $ 1,299,784 $ 6,207,010 $ 10,077,977 $ 641,291 $ 18,226,062 Proceeds - - 492,336 - 492,336 Payments (240,705 ) (2,795,786 ) (9,494,823 ) (10,029 ) (12,541,343 ) Conversion of debt (1,190,000 ) - - - (1,190,000 ) Recapitalized upon debt modification (81,923 ) (221,060 ) (781,752 ) - (1,084,735 ) Accretion of debt and debt discount 81,910 216,182 781,752 - 1,079,844 Prior year reclassification from Line of Credit - - 407,174 (407,174 ) - Foreign currency translation 130,934 (100,814 ) 22,414 (16,711 ) 35,823 Subtotal - 3,305,532 1,505,078 207,377 5,017,987 Notes payable - long-term - (1,604,700 ) (1,076,698 ) (178,172 ) (2,859,570 ) Notes payable - short-term $ - $ 1,700,832 $ 428,380 $ 29,205 $ 2,158,417
Summary of Outstanding Debt	Our outstanding debt as of September 30, 2024 is repayable as follows: September 30, 2024 2025 $ 1,622,349 2026 1,717,738 2027 420,633 2028 353,961 2029 and thereafter 153,291 Total debt 4,267,972 Less: notes payable - current portion (1,622,349 ) Notes payable - long term portion $ 2,645,623	December 31, 2023 2024 $ 1,570,886 2025 2,032,967 2026 457,784 2027 312,314 2028 and thereafter 232,276 Total debt 4,606,227 Less: notes payable - current portion (1,570,886 ) Notes payable - long term portion $ 3,035,341

LEASES (Tables)

LEASES (Tables)	9 Months Ended	12 Months Ended
LEASES (Tables)	Sep. 30, 2024	Dec. 31, 2023
LEASES
Schedule of maturity of Operating Lease liability	Maturity of Operating Lease Liability 2024 82,319 2025 243,175 2026 179,151 2027 and thereafter 300,301 Total undiscounted operating lease payments $ 804,946 Less: Imputed interest (95,366 ) Present value of operating lease liabilities $ 709,580	Maturity of Operating Lease Liability 2024 350,428 2025 264,420 2026 199,155 2027 and thereafter 541,818 Total undiscounted operating lease payments $ 1,355,821 Less: Imputed interest (225,392 ) Present value of operating lease liabilities $ 1,130,429
Schedule of maturity of finance lease liability	Maturity of Lease Liability 2024 9,039 2025 12,892 2026 3,712 Total undiscounted finance lease payments $ 25,643 Less: Imputed interest (910 ) Present value of finance lease liabilities $ 24,733	Maturity of Lease Liability 2024 28,420 2025 5,337 Total undiscounted finance lease payments $ 33,757 Less: Imputed interest (1,274 ) Present value of finance lease liabilities $ 32,483

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	12 Months Ended
EARNINGS PER SHARE (Tables)	Dec. 31, 2023
EARNINGS PER SHARE
Schedule of earning per share	2023 2022 Numerator for Basic and Diluted Earnings Per Share: Net loss attributable to common stockholders $ (25,783,834 ) $ (63,945,285 ) Denominator for Basic Earnings Per Share: Weighted Average Shares 11,968,665 1,928,172 Potentially Dilutive Common Shares - - Adjusted Weighted Average Shares 11,968,665 1,928,172 Basic and Diluted Net Loss per Share (2.15 ) (33.16 )
Schedule of potential shares of common stock	2023 2022 Common Stock Warrants 8,561,476 4,194,236 Common Stock Options - - Convertible Debt - 8,827 Total 8,561,476 4,203,063

STOCK OPTIONS AND WARRANTS (Tab

STOCK OPTIONS AND WARRANTS (Tables)	9 Months Ended	12 Months Ended
STOCK OPTIONS AND WARRANTS (Tables)	Sep. 30, 2024	Dec. 31, 2023
STOCK OPTIONS AND WARRANTS
Schedule of option activity	Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Warrants Shares Price Term Value Balance Outstanding, January 1, 2023 4,194,236 $ 8.31 5.04 $ 2,562,600 Granted 7,524,933 1.65 5.13 - Forfeited - - - - Exercised (3,152,386 ) - - - Expired (5,307 ) - - - Balance Outstanding, December 31, 2023 8,561,476 $ 3.91 4.64 $ 18,801 Granted 9,748,252 0.95 3.24 - Forfeited - - - - Exercised (4,874,126 ) - - - Expired (3,096 ) - - - Balance Outstanding, September 30, 2024 13,432,506 $ 2.64 3.28 $ 11,681 - - - Exercisable, September 30, 2024 13,432,506 $ 2.64 3.28 $ 11,681	Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Shares Price Term Value Balance Outstanding, January 1, 2022 37,000 $ 1.32 0.01 $ 75,850 Granted - - - - Forfeited - - - - Exercised - - - - Expired (37,000 ) - - - Balance Outstanding, December 31, 2022 - $ - - $ - Granted - - - - Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2023 - $ - - $ - Exercisable, December 31, 2023 - $ - - $ -
Schedule of warrants activity		Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Warrants Shares Price Term Value Balance Outstanding, January 1, 2022 147,930 $ 50.50 2.04 $ 4,992,621 Granted 9,030,301 5.96 4.18 - Forfeited (424,767 ) - - - Exercised (4,559,228 ) - - - Expired - - - - Balance Outstanding, December 31, 2022 4,194,236 $ 8.31 5.04 $ 2,562,600 Granted 7,524,933 1.65 5.13 - Forfeited - - - - Exercised (3,152,386 ) - - - Expired (5,307 ) - - - Balance Outstanding, December 31, 2023 8,561,476 $ 3.91 4.64 $ 18,801 Exercisable, December 31, 2023 8,548,142 $ 3.91 4.64 $ 18,801

DISAGGREGATION OF REVENUE (Tabl

DISAGGREGATION OF REVENUE (Tables)	9 Months Ended	12 Months Ended
DISAGGREGATION OF REVENUE (Tables)	Sep. 30, 2024	Dec. 31, 2023
DISAGGREGATION OF REVENUE
Schedule of Revenue Disaggregation	Country September 30, 2024 September 30, 2023 Croatia $ 107 14,159 Cyprus 16,519 72,754 Bulgaria 25,507 - Greece 12,247,597 12,544,643 USA - 210 Ireland - 1,417 UK 121,318 190,614 Total $ 12,411,048 $ 12,823,797 Country September 30, 2024 September 30, 2023 Croatia $ 19,370 14,159 Cyprus 89,064 141,402 Bulgaria 43,849 - Greece 39,385,730 36,041,012 USA - 504 Ireland - 1,417 UK 664,225 1,338,509 Total $ 40,202,238 $ 37,537,003	Country 2023 2022 Croatia $ 26,985 $ 38,596 Cyprus 180,404 92,685 Bulgaria 210,033 - Ireland 1,636 - Greece 50,526,307 49,812,839 United States 504 - Cayman Islands 12,632 - UK 2,418,373 403,532 Total $ 53,376,874 $ 50,347,652

SEGMENT REPORTING (Tables)

SEGMENT REPORTING (Tables)	12 Months Ended
SEGMENT REPORTING (Tables)	Dec. 31, 2023
SEGMENT REPORTING
Schedule of segment reporting	Wholesale Pharma manufacturing Nutraceuticals & Pharmaceuticals Other Total Revenues 50,744,468 344,708 2,287,698 - 53,376,874 Segment profit / (loss) (1,661,252 ) (1,232,732 ) (3,552,718 ) (2,993,026 ) (9,439,727 ) Total assets 28,193,797 15,605,459 28,054,242 3,871,101 75,724,599 Reportable segments Operations Wholesale Distribution and export of pharmaceutical products Pharma manufacturing Production of pharmaceutical products Nutraceutical and pharmaceuticals Trade of owned nutraceutical & pharmaceutical products

BASIS OF PRESENTATION (Details

BASIS OF PRESENTATION (Details Narrative) - USD ($)	9 Months Ended		12 Months Ended
BASIS OF PRESENTATION (Details Narrative) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023
Net loss	$ (6,639,935)	$ (4,790,597)	$ (18,542,654)	$ (13,830,371)
Net cash used in operations			14,998,919
Working capital			12,285,310
Amortization of right-of-use assets	22,507	102,549	23,686	85,696
Accumulated deficit	$ (104,479,192)		(91,644,233)	(66,232,813)
Description of the warrants and reduced the exercise price	which the Company issued 9,748,252 new warrants and reduced the exercise price of 4,874,126 warrant shares from $1.45 to $0.8701 to induce exercise and receive gross cash proceeds of $4,240,977.
Stockholders' equity	$ 34,976,599	$ 44,195,740	$ 36,043,028	$ 39,284,295	$ 32,119,574	$ 34,546,682	$ 43,669,058	$ 44,007,783
CANA Pharmaceutical Laboratories, S.A. ("Cana") [Member]
Net cash used in operations	3,883,215
Working capital	11,027,653
Amortization of right-of-use assets	1,588,163
Cash proceed	$ 629,426
Proceeds from sale of common stock	901,488

ORGANIZATION AND NATURE OF BU_4

ORGANIZATION AND NATURE OF BUSINESS (Details) - USD ($)	1 Months Ended	3 Months Ended						6 Months Ended	9 Months Ended		12 Months Ended
ORGANIZATION AND NATURE OF BUSINESS (Details) - USD ($)	Jun. 30, 2023	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Financial assets		$ 64,519,982						$ 66,014,811	$ 64,519,982		$ 66,014,811	$ 68,038,621
Net loss		(2,182,534)	$ (2,590,711)	$ (1,866,690)	$ (3,349,204)	$ (981,530)	$ (459,863)		(6,639,935)	$ (4,790,597)	(18,542,654)	$ (13,830,371)
CANA Pharmaceutical Laboratories, S.A. ("Cana") [Member]
Cash									5,331,120		5,331,120
Fair value of common stock issued	$ 138,667				$ 138,667				138,667		138,667
Fair value of total consideration transferred									5,469,787		5,469,787
Financial assets		1,796,911						1,796,911	1,796,911		1,796,911
Inventory		297,340						297,340	297,340		297,340
Property, plant and equipment		7,488,818						7,488,818	7,488,818		7,488,818
Identifiable intangible assets		562,200						562,200	562,200		562,200
Financial liabilities		(3,235,233)						(3,235,233)	(3,235,233)		(3,235,233)
Total identifiable net assets		6,910,036						6,910,036	6,910,036		6,910,036
Bargain purchase gain		$ 1,440,249						1,440,249	1,440,249		$ 1,440,249
Revenue								344,708	549,567
Net loss								$ (1,232,732)	$ (1,674,785)

ORGANIZATION AND NATURE OF BU_5

ORGANIZATION AND NATURE OF BUSINESS (Details 1) - USD ($)	9 Months Ended	12 Months Ended
ORGANIZATION AND NATURE OF BUSINESS (Details 1) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
ORGANIZATION AND NATURE OF BUSINESS
Balance as of January 1st, 2024	$ 19,686,091	$ 7,309,311
Provisions for credit losses	0	11,850,788
Write-offs	250,971	0
Foreign exchange adjustments	0	525,992
Other adjustments	(31,286)	0
Balance as of September 30, 2024	$ 19,905,776	$ 19,686,091

ORGANIZATION AND NATURE OF BU_6

ORGANIZATION AND NATURE OF BUSINESS (Details 2)	9 Months Ended	12 Months Ended
ORGANIZATION AND NATURE OF BUSINESS (Details 2)	Sep. 30, 2024	Dec. 31, 2023
Vehicles [Member]
Estimated Useful Life	6 years	6 years
Machinery [Member]
Estimated Useful Life	20 years	20 years
Leasehold improvements and technical works [Member]
Estimated useful life, description	Lesser of lease term or 25 years	Lesser of lease term or 25 years
Buildings [Member] \| Minimum [Member]
Estimated Useful Life	25 years	25 years
Buildings [Member] \| Maximum [Member]
Estimated Useful Life	30 years	30 years
Furniture, fixtures and equipment [Member] \| Minimum [Member]
Estimated Useful Life	5 years	5 years
Furniture, fixtures and equipment [Member] \| Maximum [Member]
Estimated Useful Life	10 years	10 years
Computers and software [Member] \| Minimum [Member]
Estimated Useful Life	3 years	3 years
Computers and software [Member] \| Maximum [Member]
Estimated Useful Life	5 years	5 years

ORGANIZATION AND NATURE OF BU_7

ORGANIZATION AND NATURE OF BUSINESS (Details 3) - shares	3 Months Ended		9 Months Ended		12 Months Ended
ORGANIZATION AND NATURE OF BUSINESS (Details 3) - shares	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
ORGANIZATION AND NATURE OF BUSINESS
Weighted average number of common shares outstanding Basic	18,418,287	12,585,479	17,724,305	11,346,071	11,968,665	1,928,172
Weighted average number of common and equivalent shares outstanding - Diluted			17,724,305	11,346,071	11,968,665	1,928,172

ORGANIZATION AND NATURE OF BU_8

ORGANIZATION AND NATURE OF BUSINESS (Details 4) - shares	9 Months Ended		12 Months Ended
ORGANIZATION AND NATURE OF BUSINESS (Details 4) - shares	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
ORGANIZATION AND NATURE OF BUSINESS
Common Stock Warrants	13,432,507	6,124,412	8,561,476	4,194,236
Convertible Debt	13,432,507	6,124,412		8,827

ORGANIZATION AND NATURE OF BU_9

ORGANIZATION AND NATURE OF BUSINESS (Details Narrative) - USD ($)		1 Months Ended							3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 06, 2023	Jan. 23, 2024	Jun. 30, 2023	Jun. 15, 2023	Apr. 30, 2023	Apr. 24, 2023	Mar. 17, 2023	Feb. 28, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Jun. 30, 2024	Mar. 31, 2024	Mar. 31, 2023	Dec. 19, 2018
VAT net receivable and payable balance									$ 322,576		$ 322,576		$ 187,512	$ 79,373
Long-term liability									395,698		395,698		408,665	0
Allowance for doubtful accounts											19,905,776		19,686,091	7,309,311
Foreign accounts									12,655,615		12,655,615		532,704
Deferred amount													397,000
Depreciation expense									89,694	$ 124,910	306,126	$ 237,479	353,043	70,109
Amortization expense									196,183	88,168	579,556	138,438	239,841	33,085
Stockholders' equity			$ 43,669,058						34,976,599	44,195,740	34,976,599	44,195,740	36,043,028	39,284,295	$ 32,119,574	$ 34,546,682	$ 44,007,783
Accumulated deficit									(104,479,192)		(104,479,192)		(91,644,233)	(66,232,813)
Working capital													12,285,310
Revenue									12,411,048	12,823,797	40,202,238	37,537,003	53,376,874	50,347,652
Net loss											(6,639,935)	(4,790,597)	(18,542,654)	(13,830,371)
Net cash used in operations													14,998,919
Repayment of outstanding Facility													1,908,195
Goodwill									49,697		49,697		49,697	49,697				$ 49,697
Building Acquision [Member]
Cash	$ 3,950,000					$ 1,054,872
Equity method investment aggregate cost	$ 2,000,020
ICC International Cannabis Corp [Member]
Equity method investment aggregate cost									0		0		$ 0	$ 0
Equity method investment shares acquired, shares													3,000,000	3,000,000
Closing price													$ 0	$ 0
National Bank of Greece [Member]
Equity method investment aggregate cost									12,416		$ 12,416		$ 11,596	$ 6,681
Equity method investment shares acquired, shares											16,666		16,666	16,666
Closing price											$ 0.75		$ 0.70	$ 0.40
Pancreta Bank [Member]
Equity method investment aggregate cost									7,665		$ 7,665		$ 8,479	$ 8,200
Greece [Member]
Cash				$ 109,330
Revenue									12,247,597	12,544,643	$ 39,385,730	$ 36,041,012	$ 50,526,307	$ 49,812,839
Issuable stock amount				$ 316,081
Income tax rate											22%		22%
Shares issued				99,710
Intangible assets				$ 425,411
United Kingdom Of England [Member]
Income tax rate											25%		25%
CANA Pharmaceutical Laboratories, S.A. ("Cana") [Member]
Cash			873,600							873,600
Working capital									$ 11,027,653		$ 11,027,653
Net cash used in operations											3,883,215
Issuable stock amount			$ 138,667							$ 138,667	$ 138,667		$ 138,667
Shares issued			46,377							46,377
Asset acquision								$ 5,469,787
Secured Promissory Note								$ 4,457,520
Zip Doctor Inc [Member]
Cash							$ 150,000
Payment in fees							8,788
Intangible assets							$ 158,788
Cloudscreen [Member]
Cash		$ 317,880			$ 1,054,872
Equity method investment shares acquired, shares		280,000
Total purchase price amount		$ 637,080
Shares of common fair value		319,200
Asset acquisition		$ 637,080

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	Dec. 31, 2023	Dec. 31, 2022
Euro [Member]
USD exchange rate	1.1062	1.0698
USD average exchange rate	1.2743	1.0534
GBP [Member]
USD exchange rate	1.0817	1.2077
USD average exchange rate	1.2440	1.2371

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Balance as of January 1, 2023	$ 19,686,091	$ 7,309,311
Provisions for credit losses	0	11,850,788
Write-offs	250,971	0
Foreign exchange adjustments	0	525,992
Other adjustments	(31,286)	0
Balance as of December 31, 2023	$ 19,905,776	$ 19,686,091

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)	9 Months Ended	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)	Sep. 30, 2024	Dec. 31, 2023
Vehicles [Member]
Estimated Useful Life	6 years	6 years
Machinery [Member]
Estimated Useful Life	20 years	20 years
Leasehold improvements and technical works [Member]
Estimated useful life, description	Lesser of lease term or 25 years	Lesser of lease term or 25 years
Buildings [Member] \| Minimum [Member]
Estimated Useful Life	25 years	25 years
Buildings [Member] \| Maximum [Member]
Estimated Useful Life	30 years	30 years
Furniture, fixtures and equipment [Member] \| Minimum [Member]
Estimated Useful Life	5 years	5 years
Furniture, fixtures and equipment [Member] \| Maximum [Member]
Estimated Useful Life	10 years	10 years
Computers and software [Member] \| Minimum [Member]
Estimated Useful Life	3 years	3 years
Computers and software [Member] \| Maximum [Member]
Estimated Useful Life	5 years	5 years

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Fair value of assets and liabilities	$ 11,596	$ 6,681
Marketable securities - National Bank of Greece [Member]
Fair value of assets and liabilities	11,596	6,681
Marketable securities - ICC International Cannabis Corp. [Member]
Fair value of assets and liabilities	0	0
Level 1 [Member]
Fair value of assets and liabilities	11,596	6,681
Level 1 [Member] \| Marketable securities - National Bank of Greece [Member]
Fair value of assets and liabilities	11,596	6,681
Level 1 [Member] \| Marketable securities - ICC International Cannabis Corp. [Member]
Fair value of assets and liabilities	0	0
Level 2 [Member] \| Marketable securities - National Bank of Greece [Member]
Fair value of assets and liabilities	0	0
Level 2 [Member] \| Marketable securities - ICC International Cannabis Corp. [Member]
Fair value of assets and liabilities	0	0
Level 3 [Member] \| Marketable securities - National Bank of Greece [Member]
Fair value of assets and liabilities	0	0
Level 3 [Member] \| Marketable securities - ICC International Cannabis Corp. [Member]
Fair value of assets and liabilities	$ 0	$ 0

SUMMARY OF SIGNIFICANT ACCOUN_7

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 4) - shares	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Weighted average number of common shares outstanding Basic	18,418,287	12,585,479	17,724,305	11,346,071	11,968,665	1,928,172
Weighted average number of common and equivalent shares outstanding - Diluted			17,724,305	11,346,071	11,968,665	1,928,172

SUMMARY OF SIGNIFICANT ACCOUN_8

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 5) - shares	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Common Stock Warrants	13,432,507	6,124,412	8,561,476	4,194,236
Potential common shares			8,561,476	4,203,063
Convertible Debt	13,432,507	6,124,412		8,827

SUMMARY OF SIGNIFICANT ACCOUN_9

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 19, 2018
Reclassified from line of credit to Notes payable						$ 930,006
Operating lease right-of-use asset						247,595
Financing lease right-of-use asset						248,678
Reclassified from accounts receivable						1,784,751
Payable to actuarial expert					$ 408,665	147,776
VAT net receivable and payable balance	$ 322,576		$ 322,576		187,512	79,373
Long-term liability	395,698		395,698		408,665	0
Allowance for doubtful accounts			19,905,776		19,686,091	7,309,311
Foreign accounts					1,047,738	831,793
Cash on hand					48,590	15,690
Sales to Medihelm					397,000
Depreciation expense	89,694	$ 124,910	306,126	$ 237,479	353,043	70,109
Amortization expense	196,183	$ 88,168	579,556	$ 138,438	239,841	33,085
Goodwill	49,697		49,697		49,697	49,697	$ 49,697
ICC International Cannabis Corp [Member]
Equity method investment aggregate cost	0		0		$ 0	$ 0
Equity method investment shares acquired, shares					3,000,000	3,000,000
Closing price					$ 0	$ 0
National Bank of Greece [Member]
Equity method investment aggregate cost	12,416		$ 12,416		$ 11,596	$ 6,681
Equity method investment shares acquired, shares			16,666		16,666	16,666
Closing price			$ 0.75		$ 0.70	$ 0.40
Pancreta Bank [Member]
Equity method investment aggregate cost	$ 7,665		$ 7,665		$ 8,479	$ 8,200
Greece [Member]
Income tax rate			22%		22%
United Kingdom Of England [Member]
Income tax rate			25%		25%

EQUITY METHOD INVESTMENTS (Deta

EQUITY METHOD INVESTMENTS (Details Narrative)	3 Months Ended		9 Months Ended				12 Months Ended
EQUITY METHOD INVESTMENTS (Details Narrative)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 EUR (€)	Sep. 30, 2024 USD ($)	Sep. 30, 2024 CAD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2023 EUR (€)	Dec. 31, 2023 USD ($)	Dec. 31, 2023 CAD ($)	Dec. 31, 2022 USD ($)
Gain on extinguishment of debt	$ 0	$ 706		$ 0		$ 1,911,476		$ 1,910,967		$ 1,004,124
Cosmo Farmacy LP [Member]
Initial share capital \| €			€ 150,000				€ 150,000
Initial share capital increased \| €			500,000				500,000
Pharmacy license value \| €			€ 350,000				€ 350,000
Maturity period of license			30 years	30 years	30 years		30 years	30 years	30 years
Ownership equity	70%			70%				70%
Cash contributed to limited partner \| €			€ 150,000				€ 150,000
Equity ownership remaining	30%			30%				30%
Marathon Global Inc [Member] \| Distribution and Equity Acquisition Agreement [Member]
Upfront cash received					$ 2,000,000				$ 2,000,000
Fair value of settlement account				$ 1,554,590				$ 1,554,590
Gain on extinguishment of debt				$ 1,554,590				$ 1,554,590
Agreement term			five (5) years	five (5) years	five (5) years		five years	five years	five years
Cash received upon gross sales					$ 2,750,000				$ 2,750,000
Marathon Global Inc [Member] \| Distribution and Equity Acquisition Agreement [Member] \| Gross Sales One [Member]
Cash received upon gross sales					2,750,000				2,750,000
Gross sales					13,000,000				13,000,000
Marathon Global Inc [Member] \| Distribution and Equity Acquisition Agreement [Member] \| Gross Sales [Member]
Cash received upon gross sales					2,750,000				2,750,000
Gross sales					$ 6,500,000
Marathon Global Inc [Member] \| Distribution and Equity Acquisition Agreement [Member] \| Gross Sales [Member]
Gross sales									$ 6,500,000
Share Exchange Agreement [Member] \| ICC [Member]
Investement	$ 167,175			$ 167,175				$ 165,930		$ 160,470

PROPERTY PLANT AND EQUIPMENT (D

PROPERTY PLANT AND EQUIPMENT (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Property plant and equipment		$ 11,503,625	$ 2,694,848
Less: Accumulated depreciation	$ (1,377,286)	(1,048,126)	(877,823)
Total	10,575,928	10,455,499	1,817,025
Land [Member]
Property plant and equipment	3,577,662	3,551,020	0
Computers and software [Member]
Property plant and equipment	203,215	168,173	138,783
Vehicles [Member]
Property plant and equipment	285,609	285,388	107,976
Leasehold Improvements [Member]
Property plant and equipment	3,667	3,639	502,882
Furniture, fixtures and equipment [Member]
Property plant and equipment	3,014,683	2,707,442	1,945,207
Building And Improvements [Member]
Property plant and equipment	$ 4,868,378	$ 4,787,963	$ 0

INTANGIBLE ASSETS NET (Details)

INTANGIBLE ASSETS NET (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 19, 2018
Goodwill and intangible assets, gross		$ 8,029,358	$ 856,994
Subtotal	$ 7,697,064	7,634,486	657,217
Goodwill	49,697	49,697	49,697	$ 49,697
Total	7,746,761	7,684,183	706,914
Customer Base [Member]
Goodwill and intangible assets, gross	602,204	602,204	176,793
Less: Accumulated Amortization	(157,333)	(110,161)	(71,210)
Trade name / mark [Member]
Goodwill and intangible assets, gross	390,188	392,197	36,997
Less: Accumulated Amortization	(36,997)	(36,997)	(29,881)
License [Member]
Goodwill and intangible assets, gross	6,976,209	6,876,169	643,204
Less: Accumulated Amortization	(805,555)	(235,925)	(98,686)
Software [Member]
Goodwill and intangible assets, gross	795,867	158,788	0
Less: Accumulated Amortization	$ (67,520)	$ (11,789)	$ 0

INTANGIBLE ASSETS NET (Details

INTANGIBLE ASSETS NET (Details 1) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
INTANGIBLE ASSETS
2024	$ 208,530	$ 763,292
2025	833,637	763,026
2026	834,846	764,213
2027	834,846	764,213
2028	783,423	735,772
Thereafter	3,846,582	3,488,769
Total amortization	$ 7,341,864	$ 7,279

LOAN RECEIVABLE (Details Narrat

LOAN RECEIVABLE (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended	12 Months Ended
LOAN RECEIVABLE (Details Narrative) - USD ($)	Oct. 30, 2021	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
LOAN RECEIVABLE
Prepayments of loan	$ 4,849,221
Interest rate	5.50%
Principal payments			$ 389,867
Short-term receivable		$ 249,552	411,858	$ 377,038
Interest payments		$ 119,411	193,265
Long term receivables			$ 3,509,200	$ 3,792,034
Loan receivables term	360 years
Decription of loan payment	the Company is to receive 120 equal payments over the term of the loan

CAPITAL STRUCTURE (Details Narr

CAPITAL STRUCTURE (Details Narrative) - USD ($)						1 Months Ended									3 Months Ended					9 Months Ended		12 Months Ended
CAPITAL STRUCTURE (Details Narrative) - USD ($)	Oct. 09, 2023	Apr. 03, 2023	Dec. 15, 2022	Jun. 07, 2022	May 02, 2022	Sep. 26, 2024	Dec. 29, 2023	Nov. 21, 2023	Jul. 20, 2023	Jan. 24, 2023	Dec. 19, 2022	Oct. 20, 2022	May 25, 2022	Feb. 28, 2022	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Oct. 24, 2023	Jun. 30, 2023	Jun. 15, 2023	May 01, 2022	Dec. 31, 2021	Dec. 31, 2020
Preferred stock, shares authorized																						100,000,000	100
Preferred stock, shares outstanding																						0	0
Preferred stock, shares issued																						0	0
Preferred stock, shares authorized															100,000,000					100,000,000		100,000,000	100,000,000
Shares issued to raised additional equity funds, shares																				901,488
Shares issued to raised additional equity funds, value																				$ 648,893
Description of late filing of registration statement													the 1st anniversary (30 days following the event date) of the event, which, along with an additional lump sum amount of $2,000,000 agreed to be paid to the investors as additional damages, led to a total amount of $2,250,260 concerning liquidated damages related to the February Private Placement within the year ended December 31, 2022
Liquidated damages payable													$ 250,260
Deemed dividend													$ 8,189,515		$ 6,185,231			$ 0		$ 6,185,231		$ 0	$ 32,004,730
Conversion price description													from $75.00 to $15.54
Conversion price													$ 15.54
Issued shares of common stock upon the cashless exercise																							526,112
Cashless exercise warrants																							776,674
Issued shares of common stock upon the exercise																						2,437,063	3,608,667
Proceeds upon the exercise of warrants																						$ 3,533,741	$ 10,826,000
Convertible stock																							6,000
Conversion of stock in to common stock																						15,000	386,588
Conversion of stock value																						$ 0	$ 5,452,300
Common stock, shares issued															23,346,023					23,346,023		15,982,472	10,605,412
Common stock, shares purchased amount																				$ 0	$ 100,251	$ 100,452	$ 0
Common stock shares issued for services																							300
Common stock shares value															$ 23,346					23,346		15,983	$ 10,606
Stock-based compensation expense																				1,103,200	214,505	577,931	24,401
Gross proceeds from sale of stock																				$ 649,039	9,950,037	$ 10,000,017	$ 35,275,573
Common stock, price per share															$ 0.001					$ 0.001		$ 0.001	$ 0.001
Compensation expense for services																							$ 3,120
Common stock, shares outstanding															23,259,526					23,259,526		15,895,975	10,589,915
Series A preferred stock																						$ 5,452,300
Description of reverse split			the Company announced a reverse stock split with a ratio of 1-for-25 (one-for-twenty five) effective at the opening of the business day on Friday, December 16, 2022. The CUSIP number of the Company after the split will change to 221413-305. The reverse stock split was authorized at the Company’s Annual General Meeting (“AGM”) on December 2, 2022 and was approved by the Company’s Board of Directors on December 15, 2022
Issued shares of common stock, value															$ 158,061	$ 108,444	$ 108,297		$ 96,888
Common stock, shares issued						2,332,000	1,487,000								17,834,023					17,834,023		15,982,472
Common stock, shares authorized															300,000,000					300,000,000		300,000,000	300,000,000
Derivative liability																						$ 0	$ 54,293				$ 11,629	$ 45,665	$ 460,728
Gain on debt extinguishment															$ 0			706		$ 0	1,911,476	1,910,967	1,004,124
Stockholders' equity															$ 34,976,599	$ 32,119,574	$ 34,546,682	$ 44,195,740	$ 44,007,783	34,976,599	44,195,740	36,043,028	39,284,295		$ 43,669,058
Gross cash proceeds from warrants exercised																				$ 4,240,977	$ 0	$ 3,533,741	$ 10,826,000
Shares held in escrow						2,532,126
Dividend rate																						0%	0%
Common stock, shares outstanding															21,346,023					21,346,023		15,982,472
George Terzis [Member]
Common stock, shares issued																								51,485
Common stock shares value																								$ 52,000
Common stock, price per share																								$ 1.01
Cloudscreen [Member]
Common stock, shares issued	280,000
Fair value of shares	$ 319,200
Placement Agent [Member]
Fees and other commissions																				$ 19,467
Net proceeds																				$ 629,426
General And Administrative Expense [Member]
Common stock shares issued for services																							300
Issued shares of consultant for services, value																							$ 3,120
Warrant Exchange [Member]
Deemed dividend																						$ 7,642
Common stock, shares issued						2,332,000	1,487,000								2,332,000					2,332,000
Pre-funded warrants issued						4,874,126	2,437,063								2,332,000					2,332,000
Warrants exercise price							$ 1.45
Warrants newly granted							4,874,126															7,218,485
Gross cash proceeds from warrants exercised						$ 4,240,977	$ 3,533,741
Shares held in escrow						2,532,126	950,063
Term						5 years	5 years
Escrow fees															$ 372,109					$ 372,109
Issuance of Common Stock [Member]
Common stock shares issued for services								970,000													15,258	15,258
Common stock shares value								$ 77,448														$ 96,888			$ 138,667	$ 316,081
Common stock shares issued for acquisition																									46,377	99,710
Minimum [Member]
Volatility																							87.90%
Term																							1 year 3 months
Risk free interest rate																							1.46%
Minimum [Member] \| Warrant Exchange [Member]
Warrants exercise price						$ 0.8701	$ 2.75
Maximum [Member]
Volatility																							157.20%
Term																							9 months
Risk free interest rate																							3.75%
Maximum [Member] \| Warrant Exchange [Member]
Warrants exercise price						$ 1.45	$ 1.45
Warrant Inducement Letter [Member]
Common stock, shares issued							1,487,000
Pre-funded warrants issued						9,748,252	2,437,063
Gross cash proceeds from warrants exercised						$ 4,240,977	$ 3,533,741
Shares held in escrow							950,063
Term							5 years
Debt Conversions [Member]
Convertible stock					26,515
Conversion of stock in to common stock					1,574
Conversion of stock value					$ 38,144
Common stock, shares issued																											1,574
Conversion of Debt																							$ 1,190,000				$ 0
Extinguishment of debt																							$ 216,580
Fair value, per share																							$ 102.25
Derivative liability																											$ 11,629
Shares issued																							9,520
Capital contribution																							$ 973,420
Gain on debt extinguishment																							216,580
Increase in equity related to the conversion																							$ 1,190,000
Series A Preferred Stock [Member]
Preferred stock, shares outstanding																						0	0
Preferred stock, shares issued																						0	0
Preferred stock, shares authorized																						6,000,000	6,000,000
Deemed dividend																				$ 372,414		$ 372,414	$ 372,414
Description of convertible into Common Stock																				The Series A Preferred Stock was initially convertible into the Company’s Common Stock as determined by dividing the number of shares of Series A Preferred Stock to be converted by the lower of (i) $75.00 or (ii) 80% of the average volume weighted average price for the Company’s Common Stock for the five trading days immediately following the effectiveness of the registration statement concerning the shares (the “Conversion Price”). On June 14, 2022, the Conversion Price was reset to $15.54 per share		Series A Preferred Stock was initially convertible into the Company’s Common Stock as determined by dividing the number of shares of Series A Preferred Stock to be converted by the lower of (i) $75.00 or (ii) 80% of the average volume weighted average price for the Company’s Common Stock for the five trading days immediately following the effectiveness of the registration statement concerning the shares (the “Conversion Price”). On June 14, 2022, the Conversion Price was reset to $15.54 per share
Dividend rate, per year																							8%
Stockholders' equity																						$ 0
Preferred stock, Liquidation Preference															6,000,000					6,000,000		6,000,000	6,000,000
Series A Preferred Stock [Member] \| Private Placement [Member]
Warrants exercise price														$ 82.50
Volatility														118%
Dividend rate														0%
Term														5 years 6 months
Discount rate before repricing														1.71%
Sales of shares														6,000
Warrants														80,000
Aggregate gross proceeds warrants														$ 6,000,000
Shares price, per share														$ 1,000
Fair value of common stock														$ 85.50
Warrants, Description														The Warrants were initially exercisable to purchase shares of common stock at $82.50 per share, or 110% of the Series A Shares initial conversion price and will expire five and one-half years following the initial exercise date of the Warrants
Additional value of Warrants														2,000,000
Issuance of common stock [Member] \| Equity Incentive Plan [Member]
Common stock shares value		$ 653,050
Common stock, shares issued to related party		185,000
Description of shares vested		1) 50% vesting on October 2, 2023, and 2) 50% vesting on October 2, 2024
Stock-based compensation expense																						$ 323,957
Unamortized stock-based compensation																						$ 329,093
Treasury Stocks One
Common stock, shares issued															86,497					86,497		86,497	15,497
Common stock, shares purchased																				0		71,000
Common stock, shares purchased amount																				$ 0		$ 100,452
Common stock, authorization to purchase										$ 3,000,000
Common stock shares value															$ 917,159					$ 917,159		$ 917,159	$ 816,707
November 21, 2022 [Member] \| General And Administrative Expense [Member]
Common stock, shares issued to related party																						40,000
Issued shares of common stock, value																						$ 173,121
Issuance of Warrants [Member]
Deemed dividend				$ 8,480,379
Conversion price description				from $82.50 to $15.54
Warrants exercise price				$ 82.50									$ 82.50
Warrants grant				344,765									1,333
Stock based compensation													$ 24,101
Common stock fair value				$ 26.75									$ 26.75
Volatility				121.47%									107.30%
Dividend rate				0%									0%
Term				5 years 2 months 26 days									5 years 6 months 3 days
Discount rate				2.99%									2.71%
Outstanding warrants				80,000
Securities Purchase Agreement [Member]
Shares issued to raised additional equity funds, shares							125,294		2,116,936
Common stock, shares issued									1,401,163																		1,574
Pre-funded warrants issued									715,773
Warrants exercise price									$ 0.01
Warrants shares to purchase									1,935,484
Exercise price									$ 2.75
Warrants shares expired									1,935,484
Period of warrants expired									Jan. 01, 2029
Common stock and warrants sale unit price									$ 2.75
Gross proceeds from sale of stock									$ 5,250,000
Financing fees									443,000
Proceeds from other shares									$ 4,807,038
Fair value of shares	$ 319,200						$ 176,665
Provision for issued warrants									782,610
Deemed dividend									$ 15,385
Exercise price before repricing									$ 11.50
Exercise price after repricing									2.75
Common stock fair value									$ 1.89
Volatility									253.10%
Dividend rate									0%
Term									4 years 5 months 1 day
Volatility after repricing									234.70%
Discount rate before repricing									4.26%
Discount rate after repricing									4.03%
Term after repricing									5 years 6 months 3 days
Securities Purchase Agreement [Member] \| Series A Preferred Stock [Member]
Warrants exercise price												$ 3
Preferred Stock, designated shares												2,500,000
Securities Purchase Agreement [Member] \| Series B Preferred Stock
Warrants exercise price												$ 3
Preferred Stock, designated shares												2,500,000
Securities Purchase Agreement [Member] \| Issuance of Warrants [Member]
Common stock, shares issued to related party												2,486,667
Warrants exercise price												$ 3
Issued shares of common stock, value												$ 7,500,000
Common stock fair value												$ 2.20
Volatility												135.05%
Dividend rate												0%
Warrants exercise price												$ 3
Warrants exercise term												7 years
Issued shares of warrants												5,000,000
Discount to common stock associated with warrants												$ 8,437,977
Issued shares of warrants, value												$ 5,000,000
Securities Purchase Agreement [Member] \| Issuance of Warrants [Member] \| Minimum [Member]
Volatility												129.02%
Term												2 years
Risk free interest rate												4.36%
Securities Purchase Agreement [Member] \| Issuance of Warrants [Member] \| Maximum [Member]
Volatility												135.05%
Term												7 years
Risk free interest rate												4.62%
Securities Purchase Agreement [Member] \| Issuance of Warrants [Member] \| October 20, 2022 [Member]
Deemed dividend												$ 1,067,876
Common stock fair value												$ 2.20
Dividend rate												0%
Description of warrants												The Company valued (a) the fair value of the 424,765 warrants immediately before exchange in the amount of $645,108, (b) the fair value of the warrants immediately after the exchange in the amount of $1,712,984, and (c) recorded the difference as a deemed dividend in the amount of $1,067,876
Cancelled warrants												424,765
Exchange for additional warrants with existing warrant holders												849,530
Warrants exercise price												$ 3
Warrants exercise term												7 years
Exercise price, pre-exchange												$ 15.54
Exercise price, pro-exchange												3
Securities Purchase Agreement [Member] \| Issuance of Warrants [Member] \| October 20, 2022 [Member] \| Minimum [Member]
Warrants exercise price												$ 3
Volatility												131.90%
Term												4 years 10 months 13 days
Risk free interest rate												4.36%
Securities Purchase Agreement [Member] \| Issuance of Warrants [Member] \| October 20, 2022 [Member] \| Maximum [Member]
Warrants exercise price												$ 15.54
Volatility												132.30%
Term												7 years
Risk free interest rate												4.45%
Securities Purchase Agreement [Member] \| Issuance of Warrants [Member] \| December 19, 2022 [Member]
Common stock, shares issued to related party											2,828,320
Warrants exercise price											$ 7.59
Common stock fair value											$ 11.50
Volatility											157.53%
Dividend rate											0%
Term											5 years
Risk free interest rate											3.70%
Cancelled warrants											260,870
Warrants exercise price											$ 11.50
Aggregate purchase price											$ 32,525,680
Issued shares of warrants											2,828,320
Discount to common stock associated with warrants											$ 17,778,260

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
INCOME TAXES (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Loss before provision for income taxes	$ (18,542,654)	$ (13,055,320)
Domestic [Member]
Loss before provision for income taxes	(2,832,980)	(7,093,161)
Foreign [Member]
Loss before provision for income taxes	$ (15,709,674)	$ (5,962,159)

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	12 Months Ended
INCOME TAXES (Details 1) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current tax provision
Federal	$ 0	$ 0
State	0	0
Foreign	0	(75,724)
Total current tax provision	0	(75,724)
Deferred tax provision
Domestic	0	0
State	0	0
Foreign	0	850,775
Total deferred tax provision	0	850,775
Total current provision	$ 0	$ 775,051

INCOME TAXES (Details 2)

INCOME TAXES (Details 2) - USD ($)	12 Months Ended
INCOME TAXES (Details 2) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
INCOME TAXES
Income (loss) before income taxes	$ (18,542,654)	$ (13,055,320)
Taxes under statutory US tax rates	(3,893,957)	(2,741,617)
Increase in valuation allowance	4,339,572	3,989,786
Foreign tax rate differential	245,518	34,601
Permanent differences	(448,032)	128,705
Prior period adjustments	(151,879)	(186,143)
State taxes	(91,222)	(450,280)
Income tax expense	$ 0	$ 775,052

INCOME TAXES (Details 3)

INCOME TAXES (Details 3) - Deferred Income Taxes [Member] - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Net operating loss carryforward	$ 7,621,277	$ 5,899,702
Capital loss carryforward	801,744	801,744
Section 163(j) carryforward	563,138	561,130
Foreign exchange	129,916	297,263
Allowance for doubtful accounts	4,404,277	1,616,926
Accrued expenses	261,466	352,025
Mark to market adjustment to securities	358,761	358,761
Lease liability	261,377	259,381
Capitalized research & development costs	52,261	0
Depreciation	(35,734)	(22,914)
Total Deferred tax assets	14,418,483	10,124,018
Intangibles	(15,845)	(8,139)
Inventory	4,853	(49,961)
Right of use asset	(258,770)	(256,769)
Goodwill	(10,980)	(10,979)
Total Deferred tax liabilities	(280,742)	(325,848)
Valuation allowance	(14,137,741)	(9,798,170)
Net deferred tax assets	$ 0	$ 0

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
INCOME TAXES (Details Narrative) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Federal Statutory Income Tax Rate, description					the $21.5 million Federal NOL carryforwards, $2.5 million are pre-2018 and begin to expire in 2031. The remaining balance of $19 million, are limited to utilization of 80% of taxable income but do not have an expiration
Net operating loss carry forward					$ 21,516,941
Income tax expenses benefit	$ 0	$ 65,873	$ 0	$ 0	0	$ (775,051)
Income tax expenses benefit	$ 0	$ (65,873)	$ 0	$ 0	0	$ 775,051
Greece [Member]
Corporate tax rate			22%
United Kingdom [Member]
Corporate tax rate			25%
United States [Member]
Net operating loss carry forward					1,753,800
Greek [Member]
Net operating loss carry forward					$ 2,240,902

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - Notes Payable - Related Party [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Payments	$ 0	$ 0	$ (472,920)
Foreign currency translation	85	371	19,568
Ending balance	11,368	11,283	10,912
Beginning balance	$ 11,283	$ 10,912	$ 464,264

RELATED PARTY TRANSACTIONS (D_2

RELATED PARTY TRANSACTIONS (Details 1) - Loans Payable - Related Party [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Proceeds	$ 18,344	$ 0	$ 3,635,756
Payments	(8,918)	0	(4,851,678)
Foreign currency translation	(1,525)	436	(64,729)
Ending balance	21,158	13,257	12,821
Beginning balance	$ 13,257	$ 12,821	$ 1,293,472

RELATED PARTY TRANSACTIONS (D_3

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	1 Months Ended					3 Months Ended		9 Months Ended		12 Months Ended
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Dec. 29, 2023	Jun. 28, 2023	Feb. 28, 2023	May 17, 2022	Dec. 20, 2018	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Oct. 24, 2023
Interest income						$ 101,236	$ 110,596	$ 309,031	$ 555,281	$ 662,859	$ 236,349
Principal repayments								$ 26,408	118,847	27,786	99,906
Outstanding principal balance										1,570,886	$ 2,158,417
General and administrative expenses										$ 164,859
Common stock share issued						23,346,023		23,346,023		15,982,472	10,605,412
Accrued interest						$ 185,561		$ 185,561		$ 166,348	$ 275,547
Accounts receivable balance						17,484,240		17,484,240		19,759,254	23,691,997
Prepaid expenses and other current assets - related party						1,914,881		1,914,881		1,811,911	1,546,225
Revenue						12,411,048	12,823,797	40,202,238	37,537,003	53,376,874	50,347,652
George Terzis [Member]
Unpaid salaries and bonuses						731,000		731,000		98,000
Unpaid salaries and bonuses dues						188,000		188,000
Common stock share issued												51,485
Basotho Investment Limited [Member]
General and administrative expenses								92,700		$ 10,300
Common stock share issued										120,000
Grigorios Siokas [Member]
Outstanding principal balance						21,158		21,158		$ 13,257	12,821
Foreign curreny translation								1,525		436	64,729
Borrowing					$ 1,718,400
Interest rate					4.70%
Maturity date					Mar. 18, 2019
Accrued interest										0	206,355
Cana Holdings Laboratories Holding Limited [Member]
Interest income			$ 148,789
Secured promissory note			$ 4,457,520
Description related to interest on principal			Interest on the Principal Amount under this Note shall accrue at a rate equal to Five Percent (5%) plus one month LIBOR per annum (5.47% as of December 31, 2023)
DOC Pharma S.A. [Member]
Interest income								143,000		217,476
Principal repayments								334,350	135,467	442,480
Interest repayments								$ 155,440		$ 232,210
Interest rate								5.50%		5.50%
Loan term								10 years		10 years
Maturity date								Dec. 31, 2032		Dec. 01, 2032
Accounts payable and accrued expenses - related party						72,968		$ 72,968		$ 34,217	201,991
Prepaid expenses											7,599,545
Accounts receivable - related party						2,448,517		2,448,517		2,386,721	2,070,570
Prepaid expenses and other current assets - related party						6,393,642		$ 6,393,642		4,347,184	3,320,345
Prepaid balance										$ 4,279,200
Agreement terminate								Dec. 31, 2025		Dec. 31, 2025
Pieces per product								1,000 pieces		1,000 pieces
Purchased of additional licenses								$ 525,461		$ 525,461
Loan current portion						445,800		445,800		442,480	427,720
Loan non-current portion						3,232,050		3,232,050		3,539,840	3,851,280
Inventroy purchase						85,073	456,257	510,711	1,057,621	1,365,324	1,755,103
Revenue						40,370	61,163	581,862	43,107	619,637	1,058,780
Monthly basis instalments						37,150		37,150		35,660
Purchase of branded pharmaceuticals	$ 3,539,840	$ 1,965,600
Description of research and development				The total cost of this project will be €1,425,000 plus VAT and will be done over three phases as follows: Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). SkyPharm has bought a total of as of 81 licenses at value of €554,500 ($593,204) which is 38.91% of the total cost, as of December 31, 2022
DOC Pharma S.A. [Member] \| Inventories Related Agreement [Member]
Inventroy purchase						38,096	455,586	175,123	1,048,557	1,237,467	1,742,282
Dimitrios Goulielmos [Member]
Outstanding principal balance						11,368		11,368		11,283	10,912
Foreign curreny translation								85		371	19,568
Panagiotis Kozaris [Member]
Shares owned						0	51,159			51,159	143,056
Prepaid expenses						194,215		194,215		194,215	143,056
Maria Kozari [Member]
Accounts receivable balance						1,123,835		1,123,835		1,142,402	760,025
Net sales						113,161	$ 310,126	122,969	$ 359,760	480,029	$ 463,467
Kanarogloy & Sia Epe [Member]
Accounts payable and accrued expenses - related party						$ 29,832		$ 29,832		$ 85,332

LINES OF CREDIT (Details)

LINES OF CREDIT (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Subtotal	$ 5,989,425	$ 6,630,273	$ 5,758,737
National [Member]
Subtotal	3,011,102	3,918,523	3,103,605
Alpha [Member]
Subtotal	1,030,943	1,130,140	991,492
Pancreta [Member]
Subtotal	1,560,803	1,122,210	1,232,128
EGF [Member]
Subtotal	$ 386,577	$ 459,400	$ 431,512

LINES OF CREDIT (Details Narrat

LINES OF CREDIT (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
LINES OF CREDIT (Details Narrative) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Line of credit description			The Company has three lines of credit with the National Bank of Greece, which are renewed annually. The three lines have interest rates of 6.00% (the “National Bank LOC”), 3.6% (the “COSME 2 Facility”), and 3.6% plus the six-month Euribor rate and any contributions currently in force by law on certain lines of credit (the “COSME 1 Facility”)
Line of credit facility outstanding balance					$ 1,908,195
Interest Expense	$ 181,429	$ 151,274	$ 692,547	$ 529,782	866,476	$ 2,345,410
Line of Credit [Member] \| National Bank of Greece Two [Member]
Borrowing	1,114,500		1,114,500		1,106,200	1,069,800
Outstanding debt balance					1,099,255	984,653
Line of credit facility outstanding balance			943,466		1,099,255
Line of Credit [Member] \| Alpha Bank of Greece [Member]
Borrowing	1,114,500		1,114,500		1,106,200	1,069,800
Outstanding debt balance					1,130,141	991,429
Line of credit facility outstanding balance			1,030,944		1,130,141
Line of Credit [Member] \| Pancreta Bank of Greece [Member]
Borrowing	1,549,155		1,549,155		1,537,618	1,487,022
Outstanding debt balance					1,122,210	1,232,128
Line of credit facility outstanding balance			1,560,802		1,122,210
National Bank of Greece One [Member] \| Line of Credit [Member]
Borrowing	3,315,638		3,315,638		3,290,945	3,182,655
Outstanding debt balance					2,829,828	2,118,952
Line of credit facility outstanding balance			2,102,765		2,829,828
EGF [Member] \| Line of Credit [Member]
Borrowing	445,800		445,800		442,480	427,920
Line of credit facility outstanding balance			386,577		459,400	431,512
Lines of credit [Member]
Interest Expense	$ 89,868	$ 37,536	$ 275,246	$ 204,654	$ 393,628	$ 294,156

CONVERTIBLE DEBT (Details)

CONVERTIBLE DEBT (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
CONVERTIBLE DEBT
Beginning balance convertible notes	$ 100,000	$ 640,000
New notes		0
Payments	(100,000)	(525,000)
Conversion to common stock		(15,000)
Subtotal notes	0	100,000
Debt discount at year end	0	0
Convertible note payable net of discount	$ 0	$ 100,000

CONVERTIBLE DEBT (Details 1)

CONVERTIBLE DEBT (Details 1) - USD ($)	12 Months Ended
CONVERTIBLE DEBT (Details 1) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
CONVERTIBLE DEBT
Beginning balance	$ 54,293	$ 45,665
Issuances to debt discount	62,619	0
Reduction of derivative related to conversions	(50,909)	(11,629)
Change in fair value of derivative liabilities	(3,384)	20,257
Ending balance	$ 0	$ 54,293

CONVERTIBLE DEBT (Details 2)

CONVERTIBLE DEBT (Details 2)	12 Months Ended
CONVERTIBLE DEBT (Details 2)	Dec. 31, 2023	Dec. 31, 2022
Dividend yield	0%	0%
Maximum [Member]
Contractual terms (in years)		9 months
Risk-free interest rate		3.75%
Expected volatility		157.20%
Minimum [Member]
Contractual terms (in years)		1 year 3 months
Risk-free interest rate		1.46%
Expected volatility		87.90%

CONVERTIBLE DEBT (Details Narra

CONVERTIBLE DEBT (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
CONVERTIBLE DEBT (Details Narrative) - USD ($)	Dec. 21, 2020	Dec. 31, 2023	Dec. 31, 2022	Sep. 30, 2024	Jul. 20, 2023	May 01, 2022	Dec. 31, 2021	Sep. 17, 2021	Jan. 07, 2021	Dec. 31, 2020	Dec. 16, 2020
Convertible note payable net		$ 525,000
Convertible notes payable, principal amount		100,000	$ 525,000
Accrued Interest expense		13,740
Derivative liability		$ 0	$ 54,293			$ 11,629	$ 45,665			$ 460,728
Common stock share issued		15,982,472	10,605,412	23,346,023
Interest expense		$ 411,858	$ 377,038	$ 249,552
Gain on settlement of debt		50,909
Securities Purchase Agreement [Member]
Convertible notes payable, principal amount			525,000
Loss on change in fair value of derivative liability		3,384	14,450
Accrued intetest						$ 26,515
Common stock share issued					1,401,163	1,574
Shares issued at a fair value						$ 38,144
Securities Purchase Agreement [Member] \| Convertible Promissory Note [Member]
Amortization of debt discount		62,619
Derivative liability		$ 0	54,293						$ 62,619
Debt original issue discount	$ 40,000		25,000					$ 25,000
Financing cost	$ 3,000
Interest rate	8%	10%
Default interest rate	18%								8%
Purchase price principal amount									$ 100,000
Note issued	$ 540,000
Cash proceeds from conversion		$ 500,000
Conversion discount to price		30%
Beneficial conversion feature's intrinsic value								$ 25,000
Note issued upon exchange for cash	$ 500,000
Convertible debt description		(i) $100.00 or (ii) 80% of the average volume weighted average price for the Company’s Common Stock for the five days prior to the date of Uplisting, subject to a floor of $75.00 per share. The shares of common stock issuable upon conversion of Series A Preferred Stock and exercise of the Warrants are subject to a Registration Right Agreement. The Warrant has an exercise price equal to 110% of the Conversion Price of the Series A Preferred Stock and expires five years from the date of issuance
Securities Purchase Agreement [Member] \| Senior Convertible Note 1 [Member] \| Institutional investors [Member]
Convertible notes payable, principal amount		$ 525,000
Derivative liability		0	0
Interest expense		0	18,185
Debt discount											$ 456,570
Transaction expenses											43,000
Amortized cost											$ 499,570
Loss on the change in fair value of the derivative		$ 0	$ 5,807

NOTES PAYABLE (Details)

NOTES PAYABLE (Details) - USD ($)	9 Months Ended	12 Months Ended
NOTES PAYABLE (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Beginning balance loans		$ 5,017,987	$ 18,226,062
Proceeds		1,082,231	492,336
Reclassification of Line of Credit			0
Payments		(1,597,894)	(12,541,343)
Conversion of debt			(1,190,000)
Recapitalized upon debt modification			(1,084,735)
Accretion of debt and debt discount			1,079,844
Foreign currency translation		92,660	35,823
Subtotal		4,606,227	5,017,987
Notes payable - long-term	$ (2,645,623)	(3,035,341)	(2,859,570)
Notes payable - short-term	1,622,349	1,570,886	2,158,417
Oher additions		317,880
Notes payable- short -term		1,570,886	2,158,417
Debt forgiveness		(306,637)	(306,637)
Trade Facility [Member]
Beginning balance loans	1,908,195	3,305,532	6,207,010
Proceeds	0	0	0
Reclassification of Line of Credit			0
Payments	(334,350)	(1,155,310)	(2,795,786)
Conversion of debt	0		0
Recapitalized upon debt modification	0		(221,060)
Accretion of debt and debt discount	0		216,182
Foreign currency translation	14,318	64,610	(100,814)
Subtotal	1,588,163	1,908,195	3,305,532
Notes payable - long-term	(1,086,638)	(1,327,440)	(1,604,700)
Oher additions		0
Notes payable- short -term	501,525	580,755	1,700,832
Debt forgiveness		(306,637)
COVID Loans
Beginning balance loans	186,884	207,377	641,291
Proceeds	0	0	0
Reclassification of Line of Credit			(407,174)
Payments	(19,073)	(27,027)	(10,029)
Conversion of debt	0		0
Recapitalized upon debt modification	0		0
Accretion of debt and debt discount	0		0
Foreign currency translation	3,691	6,534	(16,711)
Subtotal	171,502	186,884	207,377
Notes payable - long-term	(142,183)	(158,133)	(178,172)
Notes payable - short-term	29,319	28,751	29,205
Oher additions		0
Debt forgiveness		0
Loan Facility [Member]
Beginning balance loans	4,606,227	5,017,987	1,299,784
Proceeds	445,800	1,082,231	0
Reclassification of Line of Credit			0
Payments	(834,677)	(1,597,894)	(240,705)
Conversion of debt	0	(306,637)	(1,190,000)
Recapitalized upon debt modification	0	317,880	(81,923)
Accretion of debt and debt discount			81,910
Foreign currency translation	50,622	92,660	130,934
Subtotal	4,267,972	4,606,227	0
Notes payable - long-term	(2,645,623)	(3,035,341)	0
Notes payable - short-term	1,622,349	1,570,886	0
Third Party [Member]
Beginning balance loans	2,511,148	1,505,078	10,077,977
Proceeds	445,800	1,082,231	492,336
Reclassification of Line of Credit			407,174
Payments	(481,254)	(415,557)	(9,494,823)
Conversion of debt	0		0
Recapitalized upon debt modification	0		(781,752)
Accretion of debt and debt discount	0		781,752
Foreign currency translation	32,613	21,516	22,414
Subtotal	2,508,307	2,511,148	1,505,078
Notes payable - long-term	(1,416,802)	(1,549,768)	(1,076,698)
Notes payable - short-term	$ 1,091,505	961,380	$ 428,380
Oher additions		317,880
Debt forgiveness		$ 0

NOTES PAYABLE (Details 1)

NOTES PAYABLE (Details 1) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
NOTES PAYABLE
2024		$ 1,570,886
2025	$ 1,622,349	2,032,967
2026	420,633	457,784
2027	353,961	312,314
2029 and thereafter	153,291	232,276
Total Debt	4,267,972	4,606,227
Less: notes payable - current portion	(1,622,349)	1,570,886
Notes payable - long term portion	$ (2,645,623)	$ (3,035,341)

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative)			1 Months Ended						3 Months Ended	9 Months Ended			12 Months Ended
NOTES PAYABLE (Details Narrative)	Mar. 03, 2022 USD ($)	May 12, 2020 USD ($)	Dec. 21, 2022 USD ($)	Feb. 28, 2022 USD ($) shares	Feb. 23, 2022 USD ($)	Jul. 30, 2021 USD ($)	Nov. 19, 2020 USD ($)	Jun. 23, 2020 USD ($)	Sep. 30, 2024 USD ($) shares	Sep. 30, 2024 USD ($) shares	Sep. 30, 2024 CAD ($) shares	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($) shares	Dec. 31, 2023 CAD ($) shares	Dec. 31, 2022 USD ($) shares	Aug. 29, 2022	Jun. 09, 2022 USD ($)	Dec. 31, 2021 USD ($)	Aug. 04, 2021 USD ($) shares	Dec. 30, 2020	Oct. 17, 2018 USD ($)	Nov. 16, 2015 USD ($)
Gain on extinguishment of debt													$ 306,637		$ 306,637
Stock issued for debt obligation \| shares										420,471	420,471		420,471	420,471
Gain on extinguishment of debt										$ 0		$ 1,911,476	$ 1,910,967		876,894
Repayment of loan													0		1,065,000
Outstanding principal loan balance	$ 3,950,000					$ 578,850
Note payable long term									$ 2,645,623	$ 2,645,623			$ 3,035,341		2,859,570
Accrued interest expenses															4,878
Interest rate description										one-month Euribor (3.90% as of December 31, 2023), and 6% plus one-month LIBOR (fully paid as of December 31, 2023), respectively	one-month Euribor (3.90% as of December 31, 2023), and 6% plus one-month LIBOR (fully paid as of December 31, 2023), respectively		one-month Euribor (3.90% as of December 31, 2023), and 6% plus one-month LIBOR (fully paid as of December 31, 2023), respectively	one-month Euribor (3.90% as of December 31, 2023), and 6% plus one-month LIBOR (fully paid as of December 31, 2023), respectively
Non cash interest expenses										$ 221,060			$ 200,000		200,000
Repayment of installment													$ 500,000
Repayments of debt															191,100
Capitalized fees	$ 221,060
Debt instruments final payament															2,593,363
Loan principal balance															$ 1,898,895
Common stock share issued \| shares									23,346,023	23,346,023			15,982,472		10,605,412
Final repayment \| shares										1,965,600	1,965,600		1,965,600	1,965,600
Five quarterly installments \| shares										54,600	54,600
Full and Final Settlement Agreement [Member]
Payment of loan			$ 1,100,000
Gain on extinguishment of debt			306,637
Repayment of loan			$ 55,310							$ 334,350
Outstanding principal loan balance									$ 1,588,163	1,588,163			$ 1,908,195
Note payable long term									1,086,638	1,086,638			1,327,440
Accrued interest expenses													161,274
Interest expenses									29,365	110,170
Debt Exchange Agreement [Member]
Outstanding principal loan balance							$ 611,500		154,792	154,792			0		$ 0
Accrued interest expenses							$ 8,069		6,057	6,057			0		12,853
Repayments of debt										92,875			122,911		118,867
Agreement description							bears an annual interest rate, based on a 360-day year, of 3% plus .6% plus 6-month Euribor when Euribor is positive (4% as of December 31, 2023). The principal is to be repaid in 18 quarterly installments of €27,778 ($30,333)
Accrued expenses													0
Notes payable long term									30,958	30,958			122,911		237,733
Common stock share issued \| shares																			12,852
Gain on settlement of debt upon shares issuance																			$ 292,383
Common stock shares issuable upon listing on nasdaq \| shares																			9,520
Settlement of debt, shares issuable upon listing on nasdaq																			$ 1,190,000
Settlement of debt																			$ 1,606,500
Gain from extinguishment of debt				$ 216,580
Principal amount of existing loan													245,822		$ 356,600
Upon issuance of common stock \| shares				9,520
Maturity of note							Nov. 18, 2025
Restricted shares \| shares															40,000
July 30, 2021 Debt Agreement [Member]
Outstanding principal loan balance									281,338	281,338			350,555		$ 565,900
Note payable long term									134,929	134,929			227,065		477,637
Accrued interest expenses									17,083	17,083			12,063		3,100
Repayments of debt										91,267			87,396		83,428
Agreement description						The note matures on August 5, 2026 and bears an annual interest rate that applies to 60% of the principal of the note that is based on a 365-day year, of 5.84% plus 3-month Euribor when Euribor is positive (3.96% as of December 31, 2023). Pursuant to the terms of the agreement, there is a nine-month grace period for principal repayment during which interest is accrued. The principal is to be repaid in 18 quarterly installments of €27,778 commencing three months from the end of the grace period
Notes payable long term													247,186		336,788
Covid Ninteen [Member]
Outstanding principal loan balance													134,818		150,441
Loan received from related party		$ 366,900								1,123,700
Debt principal balance									720,908	$ 720,908			20,741
Covid Ninteen [Member] \| United Kingdom Government [Member]
Interest rate description		The loan will be repaid in 40 equal monthly installments beginning on July 29, 2022. As a condition to the loan, the Company was required to retain the same number of employees until October 31, 2020. As of December 31, 2023, the principal balance was $134,818. During the nine months ended September 30, 2024, the Company repaid €14,063 ($15,673) of the principal balance. The outstanding balance as of September 30, 2024 is €107,813 ($120,157) of which $99,260, is classified as “Notes payable - long term portion” on the accompanying condensed consolidated balance sheet								The loan has a ten-year maturity and bears interest at a rate of 2.5% per annum beginning 12-months after the initial disbursement, which was on July 10, 2020	The loan has a ten-year maturity and bears interest at a rate of 2.5% per annum beginning 12-months after the initial disbursement, which was on July 10, 2020
Loan received from related party		$ 366,900								$ 68,310
Loan prinipal amount									51,345	$ 51,345			52,066		56,936
June 9, 2022 Debt Agreement One [Member]
Outstanding principal loan balance													287,612		342,336		$ 335,008	$ 4,000,000
Repayments of debt													$ 66,372
Agreement description										the Company entered into an agreement with a third-party lender in the principal amount of €320,000 ($335,008), the “Note”. The Note matures on June 16, 2027 and bears an annual interest rate of 3.89% plus an additional rate of 0.60%, plus the 3-month Euribor (3.47% as of September 30, 2024). Pursuant to the agreement, there is a twelve-month grace period for principal repayment during which interest is accrued. The principal is to be repaid in 16 equal quarterly installments of €20,000 commencing on June 30, 2023. During the nine months ended September 30, 2024, the Company repaid €60,000 ($66,870) of the principal. As of September 30, 2024 and December 31, 2023, the Company has accrued interest of €4,673 ($5,208) and €11,043 ($12,215), respectively, and an outstanding balance of €200,000 ($222,900) and €260,000 ($287,612) of which $133,740 and $204,322, respectively, is classified as “Notes payable - long term portion” on the accompanying condensed consolidated balance sheets	the Company entered into an agreement with a third-party lender in the principal amount of €320,000 ($335,008), the “Note”. The Note matures on June 16, 2027 and bears an annual interest rate of 3.89% plus an additional rate of 0.60%, plus the 3-month Euribor (3.47% as of September 30, 2024). Pursuant to the agreement, there is a twelve-month grace period for principal repayment during which interest is accrued. The principal is to be repaid in 16 equal quarterly installments of €20,000 commencing on June 30, 2023. During the nine months ended September 30, 2024, the Company repaid €60,000 ($66,870) of the principal. As of September 30, 2024 and December 31, 2023, the Company has accrued interest of €4,673 ($5,208) and €11,043 ($12,215), respectively, and an outstanding balance of €200,000 ($222,900) and €260,000 ($287,612) of which $133,740 and $204,322, respectively, is classified as “Notes payable - long term portion” on the accompanying condensed consolidated balance sheets		the Company entered into an agreement with a third-party lender in the principal amount of €320,000 ($335,008), the “Note”. The Note matures on June 16, 2027 and bears an annual interest rate of 3.89% plus an additional rate of 0.60%, plus the 3-month Euribor (3.96% as of December 31, 2023). Pursuant to the agreement, there is a 12-month grace period for principal repayment during which interest is accrued. The principal is to be repaid in 17 equal quarterly installments of €18,824 commencing on June 30, 2023	the Company entered into an agreement with a third-party lender in the principal amount of €320,000 ($335,008), the “Note”. The Note matures on June 16, 2027 and bears an annual interest rate of 3.89% plus an additional rate of 0.60%, plus the 3-month Euribor (3.96% as of December 31, 2023). Pursuant to the agreement, there is a 12-month grace period for principal repayment during which interest is accrued. The principal is to be repaid in 17 equal quarterly installments of €18,824 commencing on June 30, 2023
Accured interest expense													$ 12,215		8,379
Notes payable long term													204,322		281,924
Synthesis Facility Agreement [Member] \| TFF [Member]
Outstanding principal loan balance																					$ 5,629,555
Accrued expenses																					524,094
Synthesis Facility Agreement [Member] \| TFF [Member] \| Principal Balance One [Member]
Debt instrument, accrue interest rate																				5.50%
Debt intrument split, principal balance																					$ 2,316,000
Synthesis Facility Agreement [Member] \| TFF [Member] \| Principal balance 2 [Member]
Stated interest rate																					6%
Debt split, balance																					$ 4,000,000
July 29, 2024 [Member]
Interest rate description										The Note matures on July 31, 2029 and bears an annual interest rate of 2.58% plus the 3-month Euribor (3.47% as of September 30, 2024). Pursuant to the agreement, there is a six-month grace period for principal and interest repayment	The Note matures on July 31, 2029 and bears an annual interest rate of 2.58% plus the 3-month Euribor (3.47% as of September 30, 2024). Pursuant to the agreement, there is a six-month grace period for principal and interest repayment
Repayments of debt										$ 445,800
Debt amount received from related party								$ 611,500
Notes payable long term									396,367	396,367			0
National Bank of Greece SA [Member] \| June 23, 2020 [Member]
Outstanding principal loan balance									131,118	131,118			227,747		346,111
Interest rate description								The note is interest bearing from the date of receipt and is payable every three months at an interest rate of 3.06% plus 3-month Euribor (3.96% as of December 31, 2023)
Repayments of debt										98,338			130,141
Debt amount received from related party								$ 611,500
Notes payable long term									0	$ 0			97,606		220,253
Maturity date								60 months
Panagiotis Drakopoulos [Member] \| Loan Agreement [Member]
Outstanding principal loan balance													$ 0		8,558
Accrued expenses															7,271
Short term debt borrowing capacity																						$ 42,832
Senior Promissory Notes [Member]
Gain on extinguishment of debt					$ 787,544
Aggregate amount of senior promissory notes					9,000,000										7,000,000
Fee payment					506,087
New debt amount fair value					$ 7,706,369
Senior Promissory Notes [Member] \| Unaffiliated Third Party [Member]
Description of loan repayment										CAD $2 million cash received noted in (b) above, the Company accounted for its obligation to issue a variable number of the Company’s Common Shares as Share-settled debt obligation in accordance with ASC 480 measured at fair value or the settlement amount of $1,554,590 (CAD $2 million	CAD $2 million cash received noted in (b) above, the Company accounted for its obligation to issue a variable number of the Company’s Common Shares as Share-settled debt obligation in accordance with ASC 480 measured at fair value or the settlement amount of $1,554,590 (CAD $2 million		CAD $2 million cash received noted in (b) above, the Company accounted for its obligation to issue a variable number of the Company’s Common Shares as Share-settled debt obligation in accordance with ASC 480 measured at fair value or the settlement amount of $1,554,590 (CAD $2 million)	CAD $2 million cash received noted in (b) above, the Company accounted for its obligation to issue a variable number of the Company’s Common Shares as Share-settled debt obligation in accordance with ASC 480 measured at fair value or the settlement amount of $1,554,590 (CAD $2 million)
Promissory Notes [Member] \| August 29, 2022 [Member]
Outstanding principal loan balance													$ 0		0
Accrued interest expenses															5,041
Agreement description													the Company entered into a promissory note for the principal amount of $166,667. The Company received $150,000 in cash and recorded $16,667 as an original issue discount upon issuance. The promissory note matured on the earlier of (a) December 27, 2022, or (b) the date the Company completes a debt or equity financing of at least $1,000,000	the Company entered into a promissory note for the principal amount of $166,667. The Company received $150,000 in cash and recorded $16,667 as an original issue discount upon issuance. The promissory note matured on the earlier of (a) December 27, 2022, or (b) the date the Company completes a debt or equity financing of at least $1,000,000
Interest rate																12%
Promissory Notes [Member] \| July 14, 2023 [Member]
Outstanding principal loan balance													$ 1,081,532		0
Agreement description										the Company entered into an agreement with a third-party lender in the principal amount of €1,000,000 ($1,123,700), the “Note”. The Note matures on July 31, 2028 and bears an annual interest rate of 2.46% plus the 3-month Euribor (3.47% as of September 30, 2024). Pursuant to the agreement, there is a nine-month grace period for interest and principal repayment. The principal is to be repaid in 18 equal quarterly installments of €55,556 commencing on May 2, 2024. During the nine months ended September 30, 2024, the Company repaid €108,633 ($58,179) of the principal. As of September 30, 2024, and December 31, 2023, the Company has accrued interest of €7,845 ($8,743) and €19,820 ($21,925), respectively. As of September 30, 2024, and December 31, 2023 the Company an outstanding balance of €869,067 ($968,575) and €977,700 ($1,081,532), of which $720,908 and $897,165, respectively, is classified as “Notes payable - long term portion” on the accompanying condensed consolidated balance sheets	the Company entered into an agreement with a third-party lender in the principal amount of €1,000,000 ($1,123,700), the “Note”. The Note matures on July 31, 2028 and bears an annual interest rate of 2.46% plus the 3-month Euribor (3.47% as of September 30, 2024). Pursuant to the agreement, there is a nine-month grace period for interest and principal repayment. The principal is to be repaid in 18 equal quarterly installments of €55,556 commencing on May 2, 2024. During the nine months ended September 30, 2024, the Company repaid €108,633 ($58,179) of the principal. As of September 30, 2024, and December 31, 2023, the Company has accrued interest of €7,845 ($8,743) and €19,820 ($21,925), respectively. As of September 30, 2024, and December 31, 2023 the Company an outstanding balance of €869,067 ($968,575) and €977,700 ($1,081,532), of which $720,908 and $897,165, respectively, is classified as “Notes payable - long term portion” on the accompanying condensed consolidated balance sheets		the Company entered into an agreement with a third-party lender in the principal amount of €1,000,000 ($1,123,700), the “Note”. The Note matures on July 31, 2028 and bears an annual interest rate of 2.46% plus the 3-month Euribor (3.96% as of December 31, 2023). Pursuant to the agreement, there is a nine-month grace period for interest and principal repayment. The principal is to be repaid in 18 equal quarterly installments of €55,556 commencing on May 2, 2024	the Company entered into an agreement with a third-party lender in the principal amount of €1,000,000 ($1,123,700), the “Note”. The Note matures on July 31, 2028 and bears an annual interest rate of 2.46% plus the 3-month Euribor (3.96% as of December 31, 2023). Pursuant to the agreement, there is a nine-month grace period for interest and principal repayment. The principal is to be repaid in 18 equal quarterly installments of €55,556 commencing on May 2, 2024
Notes payable long term													$ 897,165		$ 0
Promissory Notes [Member] \| January 23, 2024 [Member]
Outstanding principal loan balance									$ 324,870	$ 324,870
Repayments of debt										$ 10,830
Agreement description										Note matures on March 25, 2025 and is interest free. This Note is being given in connection with the Closing of the Asset Purchase, Sale and Transfer Agreement dated as of October 9, 2023 and as amended from time to time pursuant to which the Company agreed to purchase from the third-party a drug repurposing Artificial Intelligence “AI” powered platform known as “Cloudscreen®” (refer to Note 2, section “Acquisition accounting”). The principal is to be repaid in 15 equal monthly installments of €20,000 commencing on January 25, 2024. During the 9 months ended September 30, 2024, the Company repaid €10,000 ($10,830) of the principal and recorded a foreign currency loss of $16,155. As of September 30, 2024, and December 31, 2023 the Company had an outstanding balance of $323,205 and $317,880 of which $0 and $0, respectively, is classified as “Notes payable - long term portion” on the accompanying condensed consolidated balance sheets	Note matures on March 25, 2025 and is interest free. This Note is being given in connection with the Closing of the Asset Purchase, Sale and Transfer Agreement dated as of October 9, 2023 and as amended from time to time pursuant to which the Company agreed to purchase from the third-party a drug repurposing Artificial Intelligence “AI” powered platform known as “Cloudscreen®” (refer to Note 2, section “Acquisition accounting”). The principal is to be repaid in 15 equal monthly installments of €20,000 commencing on January 25, 2024. During the 9 months ended September 30, 2024, the Company repaid €10,000 ($10,830) of the principal and recorded a foreign currency loss of $16,155. As of September 30, 2024, and December 31, 2023 the Company had an outstanding balance of $323,205 and $317,880 of which $0 and $0, respectively, is classified as “Notes payable - long term portion” on the accompanying condensed consolidated balance sheets
Notes payable long term													$ 317,880
Distribution and Equity Acquisition Agreement [Member] \| Marathon Global Inc [Member]
Cash received upon gross sales											$ 2,750,000			$ 2,750,000
Upfront cash received											$ 2,000,000			$ 2,000,000
Equity interest acquired description										as partial consideration for the Company’s distribution services	as partial consideration for the Company’s distribution services		a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services	a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services
Distribution and Equity Acquisition Agreement [Member] \| Marathon Global Inc [Member] \| Gross Sales One [Member]
Cash received upon gross sales											$ 2,750,000			$ 2,750,000
Distribution and Equity Acquisition Agreement [Member] \| Marathon Global Inc [Member] \| Gross Sales [Member]
Cash received upon gross sales											2,750,000			2,750,000
Gross sales											$ 13,000,000			$ 13,000,000

LEASES (Details)

LEASES (Details) - Operating Lease [Member] - USD ($)	Sep. 30, 2024	Dec. 31, 2023
2024	$ 82,319	$ 350,428
2025	243,175	264,420
2026	179,151	199,155
2027 and Thereafter	300,301	541,818
Total undiscounted operating lease payments	804,946	1,355,821
Less: Imputed interest	95,366	(225,392)
Present value of operating lease liabilities	709,580	1,130,429
Less: Imputed interest	$ (95,366)	$ 225,392

LEASES (Details 1)

LEASES (Details 1) - Finance Lease [Member] - USD ($)	Sep. 30, 2024	Dec. 31, 2023
2024	$ 9,039	$ 28,420
2025	12,892	5,337
2026	3,712
Total undiscounted finance lease payments	25,643	33,757
Less: Imputed interest	(910)	(1,274)
Present value of finance lease liabilities	$ 24,733	$ 32,483

LEASES (Details Narrative)

LEASES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
LEASES (Details Narrative) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Operating lease, term of agreements			The Company has various operating and finance lease agreements with terms up to 10 years		The Company has various operating and finance lease agreements with terms up to ten years, for various types of property and equipment (such as office space and vehicles) etc. Some leases include options to purchase, terminate or extend for one or more years. These options are included in the lease term when it is reasonably certain that the option will be exercised. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term
Operating lease expense					$ 364,968	$ 210,463
Operating lease cash flows used in finance lease	$ 9,765	$ 27,118	$ 41,094	$ 118,847	$ 28,420	99,906
Operating lease, weighted average discount rate			6.74%		6.74%
Operating lease Weighted-average remaining lease term			4 years 29 days		5 years 7 months 28 days
Finance lease, weighted average remaining lease term			1 year 2 months 8 days		1 year 1 month 28 days
Finance lease, interest expense			$ 1,765	20,629	$ 2,903	16,467
Finance lease, weighted average discount rate			6.74%		6.74%
Finance lease, amortization expense	7,589	22,507	$ 35,452	102,549	$ 23,685	85,696
Amortization of right-of-use assets			22,507	102,549	$ 23,686	$ 85,696
General and administrative expenses [Member]
Amortization of right-of-use assets	76,229	235,659	50,690	158,407
Interest expense [Member]
Finance lease, interest expense	$ 457	$ 1,765	$ 6,920	$ 20,629

OTHER LIABILITIES (Details Narr

OTHER LIABILITIES (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
OTHER LIABILITIES (Details Narrative) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
OTHER LIABILITIES
Tax liabilities payable	$ 1,812,919	$ 2,430,517
Payroll tax related current liabilities	1,799,431	1,046,507
Unaudited tax	644,779	591,547
Provision for staff leaving compensation	411,732	408,665
Received prepayments from customers	451,575	$ 207,204
Accrued sales discounts	$ 407,725

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrativec) - USD ($)	1 Months Ended			3 Months Ended		9 Months Ended		12 Months Ended
	Nov. 21, 2023	Jun. 26, 2022	Jul. 31, 2021	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Stock based compensation				$ 109,636	$ 109,636	$ 326,525	$ 214,505	$ 323,957
Payment of additional tax						99,644		99,644
Description for advisory agreement			the Company paid $100,000. The $100,000 bonus was incurred and settled within 2022. Finally, the Consultant received a total of 10,000 shares of the Company’s common stock, 2,000 of such shares that have been previously issued pursuant to previous agreements and additional 15,258 shares that were issued on February 2, 2023, based on the amendment signed on February 1, 2023
Additional stock consideration						$ 264,000
Complementary compensation Shares						440,000
Stocked based compensation						$ 1,103,200	214,505	577,931	$ 24,401
Compensation for non-pecuniary damage amounting								21,744
General and administrative expenses								164,859
Four Third Party Consultants [Member]
Awarded shares	970,000
Awarded share value	$ 999,100
Phase 1 [Member]
Project cost		$ 838,450
Phase 2 [Member]
Project cost		$ 907,084
National Medicines Agency [Member] \| General and administrative expenses [Member]
Stock based compensation				$ 264,750	$ 0	728,250	$ 0	77,250
Imposed fine						$ 16,214		16,214
Stocked based compensation								$ 77,250

EARNINGS PER SHARE (Details)

EARNINGS PER SHARE (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
EARNINGS PER SHARE (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Numerator for Basic and Diluted Earnings Per Share:
Net loss attributable to common stockholders					$ (25,783,834)	$ (63,945,285)
Denominator for Basic Earnings Per Share:
Weighted average number of common shares outstanding Basic	18,418,287	12,585,479	17,724,305	11,346,071	11,968,665	1,928,172
Adjusted Weighted Average Shares					11,968,665	1,928,172
Basic and Diluted Net (Loss) Income per Share					$ (2.15)	$ (33.16)

EARNINGS PER SHARE (Details 1)

EARNINGS PER SHARE (Details 1) - shares	12 Months Ended
EARNINGS PER SHARE (Details 1) - shares	Dec. 31, 2023	Dec. 31, 2022
EARNINGS PER SHARE
Excluded from computation of diluted net loss per share	8,561,476	4,203,063
Warrants [Member]
EARNINGS PER SHARE
Excluded from computation of diluted net loss per share	8,561,476	4,194,236
Convertible Debt [Member]
EARNINGS PER SHARE
Excluded from computation of diluted net loss per share		8,827

STOCK OPTIONS AND WARRANTS (Det

STOCK OPTIONS AND WARRANTS (Details 1) - USD ($)	12 Months Ended
STOCK OPTIONS AND WARRANTS (Details 1) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Number of Shares Outstanding, Beginning balance
Number of Shares Outstanding, Ending balance	0
Number of Shares Exercisable	0
Stock Option [Member]
Number of Shares Outstanding, Beginning balance		37,000
Number of Shares Outstanding, Expired		(37,000)
Weighted Average Exercise Price Outstanding, Beginning balance		$ 1.32
Weighted Average Exercise Price Exercisable	$ 0
Weighted Average Remaining Contractual Term Outstanding, Beginning		3 days
Aggregate Intrinsic Value Outstanding, Beginning balance		$ 75,850
Aggregate Intrinsic Value Exercisable	$ 0

STOCK OPTIONS AND WARRANTS (D_2

STOCK OPTIONS AND WARRANTS (Details) - USD ($)	9 Months Ended	12 Months Ended
STOCK OPTIONS AND WARRANTS (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Number of Shares Outstanding, Beginning balance	0
Number of Shares Outstanding, Ending balance		0
Number of Shares Exercisable		0
Warrants [Member]
Number of Shares Outstanding, Beginning balance	8,561,476	4,194,236	147,930
Number of Shares Outstanding, Granted	9,748,252	7,524,933	9,030,301
Number of Shares Outstanding, Forfeited	0		424,767
Number of Shares Outstanding, Exercised	(4,874,126)	(3,152,386)	(4,559,228)
Number of Shares Outstanding, Expired	(3,096)	(5,307)
Number of Shares Outstanding, Ending balance	13,432,506	8,561,476	4,194,236
Number of Shares Outstanding, Exercisable	13,432,506
Weighted Average Exercise Price, Granted	$ 0.95	$ 1.65	$ 5.96
Number of Shares Exercisable		8,548,142
Weighted Average Exercise Price Outstanding, Beginning balance	3.91	$ 8.31	50.50
Weighted Average Exercise Price Outstanding, Ending balance	2.64	3.91	$ 8.31
Weighted Average Exercise Price, Exercisable	$ 2.64
Weighted Average Exercise Price Exercisable		$ 3.91
Weighted Average Remaining Contractual Term Outstanding, Beginning	4 years 7 months 21 days	5 years 14 days	2 years 14 days
Weighted Average Remaining Contractual Term, Granted	3 years 2 months 26 days	4 years 2 months 4 days	5 years 1 month 17 days
Weighted Average Remaining Contractual Term Outstanding, Ending	3 years 3 months 10 days	4 years 7 months 20 days	5 years 14 days
Weighted Average Remaining Contractual Term Exercisable	3 years 3 months 10 days	4 years 7 months 20 days
Aggregate Intrinsic Value Outstanding, Beginning balance	$ 18,801	$ 2,562,600	$ 4,992,621
Aggregate Intrinsic Value Outstanding, Ending balance	11,681	18,801	$ 2,562,600
Aggregate Intrinsic Value Outstanding, Exercisable	$ 11,681
Aggregate Intrinsic Value Exercisable		$ 18,801

STOCK OPTIONS AND WARRANTS (D_3

STOCK OPTIONS AND WARRANTS (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
STOCK OPTIONS AND WARRANTS (Details Narrative) - USD ($)	Apr. 03, 2023	Sep. 26, 2024	Dec. 29, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Aug. 21, 2023	Sep. 19, 2022	May 25, 2022	Dec. 31, 2021	Dec. 21, 2021
Share-based compensation expense				$ 109,636	$ 109,636	$ 326,525	$ 214,505	$ 323,957
Discription of incentive stock awards						The awards are in the form of restricted stock and will vest in two parts: 50% on October 2, 2023 and 50% on October 2, 2024		The awards are in the form of restricted stock and will vest in two parts: 50% on October 2, 2023 and 50% on October 2, 2024
Number of Warrants Outstanding								0
Option Exercisable								0
Total shares of awarded	185,000
Divined rate								0%	0%
Debt issuance price												$ 15.54
Common stock share issued				23,346,023		23,346,023		15,982,472	10,605,412
Gross cash proceeds from warrants exercised						$ 4,240,977	$ 0	$ 3,533,741	$ 10,826,000
Shares held in escrow		2,532,126
Board of Directors [Member]
Share-based compensation expense				$ 48,425		$ 48,425
Share reserv for issuance										2,500,000
2023 Plan [Member]
Share reserv for issuance										2,500,000
2022 Plan [Member]
Share reserv for issuance											200,000
Minimum [Member]
Risk free interest rate									1.46%
Term									1 year 3 months
Maximum [Member]
Risk free interest rate									3.75%
Term									9 months
Maximum [Member] \| 2023 Plan [Member]
Share reserv for issuance										2,500,000
Warrant Exchange [Member]
Number of Exercised Shares Outstanding			(4,874,126)			(9,748,252)		(3,152,386)
Fair value of warrants immediately before the re-pricing		$ 4,197,280	$ 3,603,183
Fair value of warrants immediately after re-pricing		4,207,073	3,610,825
Deemed dividend		$ 6,185,321	$ 7,218,485					$ 7,642
Warrant exercise price			$ 1.45
Warrant with no expiration		4,874,126	2,437,063	2,332,000		2,332,000
Common stock share issued		2,332,000	1,487,000	2,332,000		2,332,000
Gross cash proceeds from warrants exercised		$ 4,240,977	$ 3,533,741
Shares held in escrow		2,532,126	950,063
Term		5 years	5 years
Warrant Exchange [Member] \| Minimum [Member]
Warrant exercise price		$ 0.8701	$ 2.75
Warrants exercise price		1.45	2.75
Warrant Exchange [Member] \| Maximum [Member]
Warrant exercise price		1.45	1.45
Warrants exercise price		$ 0.8701	$ 1.45
Warrants [Member]
Fair value of exercise prices before re-pricing			fair value of common stock of $1.49, b) exercise price of $1.45 before re-pricing, c) exercise price of $2.75 after re-pricing			exercise price of $1.45 before re-pricing, c) exercise price of $0.8701 after re-pricing		exercise prices of $125.00, $150.00 and $187.50 before re-pricing
Fair value of terms re-pricing			terms of 5.07 years and 5.02 years			term of 4.26 years		terms of 1.40 years, 1.97 years, 2.20 years and 2.26 years
Number of Warrants Outstanding				13,432,506		13,432,506		8,561,476	4,194,236				147,930
Option Exercisable								8,548,142
Fair value of warrants immediately before the re-pricing								$ 1,915,077
Fair value of warrants immediately after re-pricing								9,548,110
Deemed dividend			$ 7,642			$ 9,793		$ 7,633,033
Fair value of common stock				$ 1.49		$ 1.49		$ 93.75
Divined rate		0%				0%		0%
Debt issuance price														$ 50.50
Weighted average contractual term								2 years 14 days
Warrant to purchase share								101,343
Warrant exercise price								$ 50.50
Risk free interest rate		3.83%				3.55%		0.41%
Number of Warrants Exercisable				8,558,380		8,558,380		8,548,142
Warrant issued				13,432,506		13,432,506		8,548,142
Warrant expiration date						expiration dates from October 2024 through October 2029 and 13,334 warrants with no expiration date		expiration dates from March 2024 through October 2029
Warrant with no expiration				13,419,172		13,419,172		13,334

DISAGGREGATION OF REVENUE (Deta

DISAGGREGATION OF REVENUE (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
DISAGGREGATION OF REVENUE (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Revenue	$ 12,411,048	$ 12,823,797	$ 40,202,238	$ 37,537,003	$ 53,376,874	$ 50,347,652
Greece [Member]
Revenue	12,247,597	12,544,643	39,385,730	36,041,012	50,526,307	49,812,839
United States [Member]
Revenue	0	210	0	504	504	0
UK [Member]
Revenue	121,318	190,614	664,225	1,338,509	2,418,373	403,532
Croatia [Member]
Revenue	107	14,159	19,370	14,159	26,985	38,596
Cyprus [Member]
Revenue	16,519	72,754	89,064	141,402	180,404	92,685
Bulgaria [Member]
Revenue	25,507	0	43,849	0	210,033	0
Ireland [Member]
Revenue	$ 0	$ 1,417	$ 0	$ 1,417	1,636	0
Cayman Islands [Member]
Revenue					$ 12,632	$ 0

SEGMENT REPORTING (Details)

SEGMENT REPORTING (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
SEGMENT REPORTING (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Total assets	$ 64,519,982		$ 64,519,982		$ 66,014,811	$ 68,038,621
Total assets					75,724,599
Segment profit / (loss)					(9,439,727)
Revenue	$ 12,411,048	$ 12,823,797	$ 40,202,238	$ 37,537,003	53,376,874	$ 50,347,652
Wholesale [Member]
Total assets					28,193,797
Segment profit / (loss)					(1,661,252)
Revenue					50,744,468
Pharma manufacturing [Member]
Total assets					15,605,459
Segment profit / (loss)					(1,232,732)
Revenue					344,708
Nutraceuticals and Pharmaceuticals [Member]
Total assets					28,054,242
Segment profit / (loss)					(3,552,718)
Revenue					2,287,698
Other [Member]
Total assets					3,871,101
Segment profit / (loss)					(2,993,026)
Revenue					$ 0

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)			1 Months Ended				9 Months Ended		12 Months Ended
SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Nov. 06, 2024	Mar. 21, 2024	Jul. 30, 2024	Jul. 19, 2024	Jun. 27, 2024	Jan. 23, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Apr. 22, 2024
Common stock share sold							901,488
Gross proceeds from share sold							$ 649,039	$ 9,950,037	$ 10,000,017	$ 35,275,573
Common stock, par value							$ 0.001		$ 0.001	$ 0.001
Subsequent Events [Member]
Purchase price for the acquisition amounted						$ 637,080,000,000
Consideration share						280,000
Fair value of shares						$ 319,200
Settelment amount						317,880
Intangible asset						$ 637,080
Common stock share sold		901,488
Gross proceeds from share sold		$ 648,893
Common stock, par value											$ 0.001
Bid price	the closing bid price of the Company’s common stock being at least $1.00 per share for ten consecutive business days
Minimum bid price	$ 1
Deadline report			Nasdaq further extended the filing deadline through October 14, 2024
Closing bid of shares of common stock	$ 1
Subsequent Events [Member] \| Pharmalink [Member]
First purchase order					130,000
First year purchase order					500,000
Over year five purchase order					3,000,000
Subsequent Events [Member] \| Notification Letter [Member]
Bid price				closing bid price of $1.00 or greater per common share for ten consecutive business days from July 5, 2024 to July 18, 2024
Minimum bid price				$ 1
Subsequent Events [Member] \| Placement Agent [Member]
Fees and other commissions		23,153
Net proceeds		$ 625,740